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Flaviviridae are a family of enveloped, positive-stranded RNA viruses
responsible for a variety of diseases including encephalitis, hemorrhagic fever and
hepatocellular carcinoma. The envelope (E) proteins that coat the outer surface of these
viruses provide the molecular machinery that drives receptor interaction and membrane
fusion. The assignment of biological functions to specific structural elements of these E
proteins has proven crucial to the understanding of viral entry into host cells. Clearance is
dependent upon the presence of neutralizing antibodies that are able to disrupt several
stages of this process. Given their fundamental role in the viral life cycle, we sought to
determine the structural basis for envelope protein interaction with antibodies and
receptors for human pathogens of the Flaviviridae family Japanese Encephalitis Virus,
Hepatitis C Virus and St. Louis Encephalitis Virus.
Viruses of the Flavivirus genus within Flaviviridae are grouped into
serocomplexes with similar clinical manifestations that are defined by crossneutralization tests with polysera from heterologous infections. Japanese Encephalitis
Virus (JEV) is the leading cause of viral encephalitis and prototypical member of the JEV
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serocomplex. We determined the 2.1Å resolution crystal structure of the JEV E protein
ectodomain to investigate whether structural features could contribute to our
understanding of serocomplex-specific pathogenesis. JEV E possesses the three domains
characteristic of flavivirus envelopes and epitope mapping of neutralizing antibodies
revealed residues localized to the domain I lateral ridge, fusion loop, domain III lateral
ridge and domain I-II hinge. The dimer interface, however, is remarkably small and lacks
several contacts present in other flavivirus E homodimers. Uniquely conserved histidines
of the JEV serocomplex suggest that pH-mediated structural transitions may be assisted
by lateral interactions outside the dimer interface in the icosahedral virion. Our results
suggest that variation of dimer structure and stability may influence the assembly,
receptor interaction and uncoating of virions.
St. Louis Encephalitis Virus (SLEV) is another member of the JEV serocomplex
with similar pathogenesis to JEV. We determined the 4.0 Å structure of the SLEV E
protein in the post-fusion trimer conformation to compare it with E trimer structures from
other serocomplexes. SLEV E crystallized as a trimer in the absence of lipids or
detergents, requiring only low pH. However, its domain arrangement was nearly identical
to other post-fusion structures. This suggests that viruses can alter dimer assembly but the
structure of the activated, fusogenic conformation may be more strictly conserved.
The only member of Flaviviridae known to chronically infect humans is
Hepatitits C Virus (HCV). HCV is blood borne and carried by roughly 3 percent of the
world’s population. Clinical manifestations include hepatitis, cirrhosis and hepatocellular
carcinoma. HCV envelope protein E2 mediates interaction with host receptors CD81 and
scavenger receptor BI (SR-BI) and is the primary target of neutralizing antibodies. To
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elucidate detailed biochemical roles for these receptors’ interactions with E2, we
determined that the E2 ectodomain (sE2) interacts with soluble CD81 large extracellular
loop (CD81-LEL) with 2:2 stoichiometry, and that this interaction inhibits subsequent
engagement of SR-BI. We then evaluated the affinity and kinetics of sE2:CD81-LEL
binding. Interaction between these proteins was enhanced by deletion of hypervariable
region 1 (HVR1) of E2 and modulated by the genotype from which sE2 was generated.
Furthermore, neutralization of HVR1-deleted HCV by a cross-reactive antibody was
enhanced in a genotype-specific manner that correlated with sE2:CD81-LEL affinity
measurements. Our results suggest that E2 cannot engage CD81 and SR-BI
simultaneously, that HVR1 obscures conserved CD81 and antibody binding sites, and
that genotypic variation influences HCV host receptor preference.
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Chapter 1:
Introduction to Japanese Encephalitis Virus

1	
  

1.1 Abstract
Japanese Encephalitis Virus (JEV) is a mosquito borne pathogen that causes
30,000 to 50,000 cases of encephalitis and 10,000 deaths annually in Asia. There is no
specific treatment for JEV infection and while multiple vaccines have been developed,
licensing issues and safety concerns have restricted their availability in Asia.
Consequently, generation of additional therapies and cost-effective cell culture vaccines
is imperative. JEV belongs to the Flavivirus genus of the Flaviviridae family along with
many other deadly human viruses including Dengue (DV), Yellow Fever (YFV) and
West Nile (WNV). JEV is an enveloped virus with ~11kb positive-stranded genome that
encodes a single polyprotein that is cleaved into 3 structural proteins and 7 non-structural
proteins. Structural protein E is responsible for receptor interaction and membrane fusion.
An icosahedral arrangement of E homodimers decorates the surface of the mature virion.
However, a specific host receptor required for infection by JEV or any other flavivirus
has not yet been identified. The humoral immune response, in particular the generation of
neutralizing antibodies, is vital to clearance of JEV. Several studies have demonstrated
that neutralization of flaviviruses is epitope-specific, with the most potent antibodies
recognizing the lateral ridge of domain III of E. Further delineation of the molecular
mechanisms of JEV interaction with antibodies and host receptors will therefore prove
crucial to the control of this important human pathogen.
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1.2 Transmission and clinical manifestations
JEV was first identified in 1934 as the causative agent of “summertime
encephalitis” in Japan when it was isolated from the brain of a fatal human case1,2. The
primary vector, the Culex tritaeniorhynchus mosquito3, transmits the virus to pigs or wild
birds that serve as amplifying hosts4. Humans may also become infected as dead-end
hosts when bitten by carrier mosquitoes. The majority of infections are asymptomatic, but
more severe clinical manifestations include flu-like symptoms, febrile illness and
meningomyeloencephalitis5. While fewer than 2% of infections result in encephalitic
illness6, the fatality rate of these cases ranges from 20%-67%, with children and the
elderly representing the most susceptible groups7–9. Approximately 30,000 to 50,000
cases of Japanese encephalitis are reported annually, although actual incidence has been
estimated to be 175,000 due to substandard medical facilities and data reporting in
affected regions10.

1.3 Treatment and prevention
Therapy. Treatment of symptomatic infection with JEV is supportive. In more
severe cases, this entails assisted feeding or breathing, anticonvulsants for seizure control,
and osmotherapy for regulation of intracranial pressure. Currently, there is no specific
antiviral therapy for JEV infection. Directed development of such an agent is unlikely
given the relatively poor countries most severely affected by JEV, but it is possible that
broad-spectrum antivirals designed to treat a more widespread, related virus such as
Hepatitis C may be of greater interest to pharmaceutical companies11.

3	
  

Vaccines. Control of JEV and related encephalitic viruses such as West Nile
Virus (WNV) and St. Louis Encephalitis Virus (SLEV) is most likely to be achieved by
preventative approaches such as vaccination and regulation of vectors and amplifying
hosts2. The first JEV vaccine was developed in Japan from the Nakayama reference strain
and consisted of formalin-inactived virus isolated from mouse brains12. More recently,
inactived cell culture derived and live attenuated vaccines from the SA-14-14-2 strain of
JEV have been developed and utilized successfully in China13, Nepal14 and India15.
However, despite the existence of these vaccines, they are not universally available in
Asia due to cost, licensing issues and safety concerns16–19.

1.4 JEV virology
Genome organization of Flaviviridae. JEV is a member of the Flaviviridae
family enveloped, positive-stranded RNA viruses. This family contains three genera,
Flavivirus, Hepacivirus, and Pestivirus. A common feature of all members of
Flaviviridae is the translation of the RNA genome into a single polyprotein that is
cleaved into a series of structural and non-structural proteins by both host and viral
proteases. However, the major differences between these viruses lie in the structural
proteins located within the 5’ region of the genome20 (Fig 1A-C). Flaviviruses encode
one envelope protein: E (Fig 1A), Hepaciviruses encode two: E1 and E2 (Fig 1B), and
pestiviruses encode three: Erms, E1 and E2 (Fig 1C).
Polyprotein processing. The Flavivirus genus of Flaviviridae contains JEV as
well as related viruses WNV, Yellow Fever Virus (YFV) and Dengue Virus (DV). The
genomes of these viruses encode a single polyprotein that is cleaved into 3 structural
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proteins and 7 non-structural proteins21. The structural proteins are capsid (C), premembrane (prM) and envelope (E). C binds to viral RNA to form a nucleocapsid, prM
prevents premature fusion with host membranes and E mediates cellular attachment and
fusion22. The non-structural proteins are NS1, NS2A, NS2B, NS3, NS4A, NS4B and
NS521 (Fig 1A, 1D). The NS1 protein is unique to flaviviruses and represents the only
secreted protein encoded by any member of the Flaviviridae family. NS1 has multiple
functions in the viral life cycle, serving as an inhibitor of complement activation23 and a
co-factor to the viral replication machinery24,25. NS2A contributes to viral assembly26,27
and inhibits interferon-driven transcription28. NS3 is a dual-function protease/RNAhelicase27,29, and NS2B is a co-factor for NS3 protease activity30. NS4A and NS4B both
influence the interferon response31,32 and NS5 is a methyltransferase25 and RNApolymerase33.

1.5 Viral fusion proteins
Fusion protein overview. The major structural component of the JEV virion is the
E protein. Flavivirus E proteins belong to a larger category of transmembrane viral fusion
proteins that coat the outer surface of enveloped viruses. Viral fusion proteins serve as
molecular machines that facilitate cellular attachment and fusion with the host membrane.
While they vary dramatically in structure and sequence, the conserved mechanism by
which they catalyze membrane fusion represents a remarkable example of convergent
evolution34. The basic process by which this occurs involves a chemical or enzymatic
activation event that triggers the formation of a trimer with exposed fusion peptides. The
fusion peptides then insert into the host membrane and drag it together with the viral
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membrane. Common examples of such an event are the acidic pH encountered in the
endosome or cleavage by a host protease upon receptor binding or internalization.
Differences in activation mechanism and three-dimensional structure, however, have led
to the categorization of these proteins as class I34–36, class II36–38 or class III39.
Class I fusion proteins. Defining features of class I fusion proteins include a
predominantly helical structure and proteolytic cleavage of a precursor protein into a
receptor-binding and fusion protein. Activation of class I proteins leads to formation of a
trimeric, helical hairpin fusion structure that folds around a central coiled-coil36. The
prototypical class I fusion protein is influenza hemagglutinin (HA). HA is first translated
as a trimeric precursor HA0 that is cleaved during viral maturation by host proteases into
receptor binding protein HA1 and fusion protein HA240–42 (Fig 2A). This cleavage event
allows the resultant trimer of HA1:HA2 heterodimers to undergo a dramatic
conformational change upon encountering acidic pH, leading to formation of helical
hairpins43 (Fig 2B). The hairpins with newly exposed fusion peptides are able to
penetrate the host lipid bilayer and fuse it with the viral membrane, releasing its contents
into the cytoplasm. Other notable human pathogen class I fusion glycoproteins include
HIV gp4144,45 and Ebola gp246,47.
Class II fusion proteins. Flavivirus E and alphavirus E1 proteins represent the
class II fusion proteins37. Features that distinguish class II from class I proteins are a
requisite dimer to trimer structural rearrangement prior to fusion and a distinct betastrand rich, 3-domain architecture34,36,37 (Fig 2C). Despite substantial differences in
amino acid sequence, cellular processing and arrangement on the viral particle, structures
of E and E1 are strikingly similar43,48–52. The conservation of these domains (the
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structural details of which are described in 1.6 below) has been well established in crystal
structures of flavivirus E ectodomains from Tick Borne Encephalitis Virus (TBEV)48,
DV53 and WNV54,55 as well as alphavirus E1 from Semliki Forest Virus (SFV)49 and
Chikungunya Virus (CV)56. E and E1 fusion loops are shielded by proteins prM and E2
respectively to prevent insertion into lipid bilayers during transport to the cell surface.
prM and E2 are each cleaved by furin57,58 prior to viral budding which generates an
activated, mature virion capable of fusion after cellular uptake59,60. CryoEM
reconstructions of mature WNV61, DV52 and SFV51 revealed that E assembles into
homodimers in flavivirus cryoEM models while SFV E1 and furin-cleaved E2 form
trimers of heterodimers (Fig 2C). In both cases, this assembly results in burial of the
fusion loop at the dimer interface, serving a protective role akin to uncleaved prM and E2
in immature particles. Upon endocytosis and subsequent exposure to the low pH
environment of the endosome, E/E1 proteins on mature virions dissociate from their
dimeric partners, undergo a conformational change and rearrange into a homotrimeric
spike43,50,62 (Fig 2D). This rearrangement brings three fusion loops together at the tip of
the spike, allowing it to penetrate the endocytic membrane and drive the fusion process.
Class III fusion proteins. A third class of fusion protein was first identified upon
determination of crystal structures of the Vesicular Stomatitis Virus (VSV) fusogenic G
protein63,64 and Herpes Simplex Virus 1 (HSV1) glycoprotein B (gB)65. G and gB have
no detectable sequence similarity but adopted structurally homologous 5-domain folds
previously unseen in viral fusion proteins, leading to their distinction as class III39 (Fig
2E). Three of these domains, domain II, IV and the fusion-loop containing domain I, are
primarily composed of beta-strands. However, domain III and V are helical, and domain
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III possesses a helix that forms a trimeric coiled-coil characteristic of class I fusion
proteins. Class III fusion proteins do not require proteolytic cleavage for activation or a
capping protein for their fusion loop and remain trimeric in both the pre- and post-fusion
conformations. Extensive structural reorganization accompanies the class III post-fusion
transition. The most substantial motion involves the repositioning of domain I nearly
180° opposite its pre-fusion orientation, exposing its fusion loop63,65 (Fig 2F).

1.6 JEV envelope glycoprotein structure
E domain architecture. JEV E possesses the three canonical domains
characteristic of class II viral fusion proteins (Fig 2C). E proteins share ~35% amino acid
sequence identity amongst flaviviruses66 and are stabilized by 6 conserved disulfide
bonds67. Domain I (DI) is a central beta-barrel flanked on opposite sides by domains II
(DII) and III (DIII). An N-linked glycosylation site at ectodomain amino acid position
154 within DI is largely conserved and has been suggested to influence receptor
interaction68, neuroinvasion69 and particle secretion70. Domain II is discontinuous, formed
by two extended loops that protrude from domain I, and contains the hydrophobic fusion
peptide at its apex71,72. C-terminal domain III is immunoglobulin-like and connected to
DI by a flexible linker.
Structural rearrangements. Crystal structures of E bound to prM in the immature
conformation73, the pre-fusion dimer,48,53,74 and post-fusion trimer43,62 highlight its many
structural rearrangements during the viral life cycle (Fig 3A-C). These changes are
driven by movements around two hinge regions that connect DI-DII and DI-DIII.
Initially, the fusion loop of the immature E protein is capped by prM, with DI and DII
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roughly in line with one another (Fig 3A). In this immature conformation, 3 E proteins
assemble as trimeric spikes with a prM capping each fusion loop. When the virion
encounters the low pH of the golgi, these trimers become E homodimers on the viral
particle but are still associated with prM. Once prM is cleaved and released, DII kinks
towards an opposing E subunit (Fig 3B), burying its fusion loop and facilitating the
formation of a flat, antiparallel homodimer (Fig 3B). Upon encountering the acidic pH of
the endosome, DIII undergoes a dramatic reorientation by swinging 70° toward domain
II43,59 (Fig 3C). The angle between DI and DII also shifts 30°, returning to a position
similar to that observed in the prM-bound immature state43. This post-fusion trimeric
“spike” brings the three fusion loops in close proximity at its tip, allowing for insertion
into membranes.
Receptor interactions. Flaviviruses have been proposed to interact with a number
of prospective cellular receptors, but there is little evidence that supports direct proteinprotein binding or requirement for infection. αVβ3-integrin has been identified as a
putative WNV and JEV receptor since antibodies raised against it are able to effectively
inhibit infection in cell culture75. However, cell types lacking detectable expression of
this integrin are still infectible76–78. Another tentative JEV receptor, heat shock protein 70
(Hsp70), was proposed based on inhibition of infection by anti-Hsp70 polyclonal
antibodies but has only been evaluated for a single neuronal cell line (Neuro2a)79.
Furthermore, lectins DC-SIGN and DC-SIGNR are considered attachment factors for
DV80 and WNV77. This attachment is mediated by N-linked glycans on the E protein and
has been confirmed by the cryoEM structure of DV bound to the carbohydrate
recognition domain of DC-SIGNR81. Despite the identification and characterization of
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these many candidates, none are required for infection, leaving the nature of a “true”
flavivirus receptor elusive.
Stem and transmembrane regions. The E ectodomain possesses a ~50aa Cterminal hydrophobic “stem” and transmembrane domain that contribute to membrane
fusion82,83. The stem region lies flat along the viral membrane and is composed of two
amphipathic helices. It is truncated from soluble E constructs so it is not present in
available crystal structures84. However, modeling studies have suggested that it forms a
“zipper” with a groove along the outer edge of domain II and to stabilize the post-fusion
trimer85. Mutational analysis of the stem region has since confirmed that hydrophobic
residues of the stem indeed interact with DII and affect trimer stability as well as fusion
efficiency83. Flavivirus E is anchored to the viral membrane by a two-pass trasmembrane
helix that is unique amongst viral fusion proteins. The two helices of this transmembrane
hairpin have been demonstrated to interact with each other, promoting maximum
trimerization and fusion efficiency82.

1.7 Virion structure
Immature virion structure. There is currently no available JEV cryoEM structure.
However, a series of elegant cryoEM studies have delineated the structures of both
immature and mature structures of related viruses WNV and DV52,60,86,86–88. The cryoEM
structure of immature DV particles at the neutral pH of the ER revealed a spiky
decoration of irregular prM-E trimers on its surface. 180 copies of E and prM form these
~600Å diameter particles, which lack the T=3 quasi-symmetry expected of an icosahedral
virion86,87 (Fig 4A). An additional DV cryoEM structure has illuminated the structural
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changes subviral particles undergo when they encounter the acidic (~6) pH of the golgi
prior to maturation60. Pre-incubation of virus at pH 6.0 reduced DV particle diameter to
~530Å and arrangement of prM-E complexes shifted from trimeric spikes to flat
dimers.60 These dimers resembled those found in crystal structures22,48,53,74 and mature
virions52,61 (Fig 4B). This reversible conformational change exposes regions of prM that
allow for efficient furin cleavage prior to viral budding out of the cell60.
Structure of mature virions After particles are trafficked out of the cell and prM
is released, they undergo yet another conformational change. CryoEM structures of WNV
and DV identified a herringbone-like assembly of E dimers52,61. Mature particles are
~500Å in diameter (Fig 4C), smaller than either immature form. These virions are
geometrically unusual in that they display icosahedral symmetry but lack traditional T=3
symmetry52. The monomeric subunits that comprise the 90 E protein homodimers
observed in cryoEM models are identical at 2, 3 and 5-fold axes of symmetry and thus do
not have quasiequivalent environments (Fig 4C)89. The E proteins that lie at these axes
do, however, differ in chemical and stoichiometric environments and can differentially
interact with antibodies and receptors90,91. For instance, therapeutic monoclonal antibody
(mAb) E16 neutralizes West Nile Virus by binding the putative receptor-binding DIII92 at
only the 2-and 3-fold axes but not at the 5-fold axis91. However, E16 neutralizes at a postattachment stage of infection and allows for internalization of viral particles93,94,
suggesting that binding of a surface receptor could occur specifically at the 5-fold axis.
While the reconstructed models of mature flaviviruses display uniform surfaces, it has
been reported that a large population of infectious, partially mature “hybrid” particles are
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released from cells95,96. Determination of the structure and geometry of these partially
mature species presents a challenging problem due to their heterogeneous composition.

1.8 Antibody neutralization
Antibody neutralization models. Two models have been proposed to explain
antibody-mediated neutralization of viruses. The maximum coating model suggests that
neutralization is dependent only upon the number of antibodies binding to any site on a
virus, with neutralization occurring when a critical number of sites become occupied97,98.
This would imply that antibodies with the highest affinity for antigens would neutralize
most potently. Alternatively, the functional inhibition model states that effective
neutralization occurs through specific antibody-antigen interaction98. In this case, epitope
specificity is of utmost importance: antibodies binding to locations on the virion that
prevent distinct stages of the viral life cycle such as receptor interaction or membrane
fusion will be more effective than high affinity antibodies binding to irrelevant regions.
There is evidence to support both theories, and it is possible that antibody neutralization
is virus-specific and can be a consequence of both mechanisms97,98.
Serocomplex classification. Flavivirus infection elicits broadly cross-reactive
antibodies, but polyclonal sera from infection with one virus only neutralize a subset of
other viruses. The serocomplex system of classification for flaviviruses is based on this
observation: membership in each serocomplex is defined by an ability to be crossneutralized by polysera from heterologous infections99. Pathogenesis, tropism and clinical
symptoms are generally conserved within serocomplexes. JEV is the prototypical
member of the Japanese Encephalitis Virus serocomplex which includes SLEV and
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WNV, viruses that all cause febrile illness, flu-like symptoms, acute or encephalitis5,99.
DV, TBEV and YFV also represent three additional serocomplexes, each with distinct
pathogeneses and tropisms.
Neutralization of flaviviruses. The humoral immune response plays a vital role in
the control of flavivirus infection100–102. Understanding the precise molecular
determinants of neutralization will provide new targets for therapeutic antibody and
vaccine development such as proteins, domains or peptides. The majority of antibodies
generated during infection with JEV or other flaviviruses recognize the E protein and
neutralization is epitope-specific91,93,103–105. Identification of antibodies that bind
neutralizing and non-neutralizing epitopes on E as well as mechanisms associated with
recognition of these sites has allowed for the determination of structure-function
relationships of domains, regions or individual residues. The most widely accepted
neutralizing epitopes are the fusion loop of DII and the lateral ridge of DIII. However,
antibody binding at the DI-DII hinge, DI-DIII linker, DI lateral ridge, DII lateral ridge,
DII dimer interface and DII central interface have been associated with neutralization of
JEV, DV and WNV

103,105–107

(Fig 5). The most potent neutralizing antibodies typically

bind DIII and have been associated with blocking attachment and membrane fusion.
Indirect evidence has implicated DIII in receptor interaction: an anti-DIII antibody, 3H5,
prevents flavivirus binding to Vero cells108,109. However, WNV therapeutic antibody E16
allows for internalization of the virion but neutralizes by subsequently preventing fusion
with the endosome91,93,94. Another class of broadly cross-reactive antibodies recognizes
the conserved fusion loop epitope. These antibodies also prevent fusion and are generally
less potent anti-DIII mAbs, potentially because the fusion loop is believed to be
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inaccessible in mature virions. This so-called cryptic epitope may transiently become
exposed as a result of E protein motions on the surface of the virion. Indeed, a cryoEM
structure of an antibody bound to the fusion loop of mature WNV has been solved and
captured a distorted viral particle, implying that these antibodies are able to access this
obscured site in some capacity110.
Antibody dependent enhancement of infection. An important concern in the
design of therapeutic vaccines or antibodies for control of flaviviruses is the phenomenon
of antibody dependent enhancement of infection (ADE). A neutralizing mAb will
effectively prevent infection only upon occupying a critical number of sites on the virion.
Sub-neutralizing concentrations of these antibodies111,112 or coating by non-neutralizing
antibodies113 can promote uptake into cells by host Fc-receptors, leading to ADE. While
JEV, TBEV, YFV and WNV are all susceptible to this phenomenon

114–117

it is most

pronounced when DV infection of one serotype is followed by heterologous infection
with a different DV serotype. The more severe symptoms associated with this second
infection (such as a greater risk for hemorrhagic fever) are believed to be linked to ADE
resulting from the circulation of antibodies generated against the previous serotype. It is
postulated that these antibodies would be of lower affinity for the new virus and thus be
present at sub-neutralizing concentrations capable of enhancing infection. The more
severe clinical manifestations of DV linked to ADE along with the co-circulation of DV
and JEV in Asia warrant serious consideration in future vaccine development.
1.9 Summary
JEV E is responsible for receptor interaction and membrane fusion, and antibodymediated neutralization of the virus is dependent upon successful inhibition of these
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functions. Given the presumed relationship between tropism and receptor interaction, I
sought to investigate whether structural features of the JEV E protein could contribute to
serocomplex-specific pathogenesis. No structure of a JEV serocomplex E protein has
been determined in the dimeric or post-fusion trimeric conformation. Therefore, I solved
the structure of the dimeric JEV E ectodomain. The results have revealed flavivirus
evolutionary mechanisms for differential recognition of host ligands and highlight
important differences in dimeric structures from several serocomplexes.
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Figure 1: Flavivirus polyprotein processing and protein functions. Family
Flaviviridae contains three genera with different structural proteins. A) Hepaciviruses
have a core and two envelope proteins E1 and E2. B) Pestiviruses have capsid, Erms, E1
and E2 proteins. C) Flaviviruses have a capsid, prM and E protein as well as 7 nonstructural proteins. D) Summarized functional roles and localizations of the 10 flavivirus
proteins.
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Figure 2 Viral fusion protein structures.
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Figure 2 legend: Viral fusion protein structures. Structures of the pre-fusion (A) and
post-fusion (B) conformations of class I Influenza HA2. The helical domain that
elongates to expose the fusion peptide is colored yellow, fusion peptide green and Nterminal domains in red and blue. Other HA2 trimer subunits are colored grey. C)
Structures of the pre-fusion class II flavivirus E homodimer and alphavirus E1-E2
heterodimer (C), and post fusion E/E1 trimers (D) DI is red, DII yellow and DIII blue.
The opposing dimeric subunit of the E dimer and E2 of the E1-E2 heterodimer are
colored grey, and the alphavirus E3 protein cyan. The post-fusion trimers (D) of E/E1
have a single subunit with colored domains and remaining subunits in grey. The exposed
fusion loop at the tip of the spike is green. Structures of the pre-fusion (E) and postfusion (F) class III VSV G protein. The DI lateral domain is red, DII trimerization
domain blue, DIII PH domain orange, DIV fusion domain yellow, DV magenta and
fusion peptide green. Only 1 of 3 trimeric subunits is colored in each panel.
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Figure 3. Conformational changes of the Flavivirus E protein. A) E protein in the
immature conformation with fusion-loop (green) capped by prM (grey, space-filled).
Domains I, II & III are colored red, yellow and blue respectively. The arrow and
accompanying angle describe the movement of DII about the DI-DII hinge as E adopts
the mature conformation. B) Mature E homodimer, with one protein colored as described
in A) and the other in grey. The fusion loop is now capped by the DI/DIII cavity of the
opposing subunit. The arrow in B) describes the movement of DIII about the DI-DIII
hinge that accompanies formation of the post-fusion trimer. C) The fusion loop is
exposed at the tip of the trimeric post-fusion spike. One subunit is colored while the other
two are grey.
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Figure 4: Flavivirus virion structures. The top panels display cryoEM densities of
particles described, central panels are cartoons describing the conformation of E and
bottom panels are atomic models generated by fitting E and prM into the cryoEM
densities. A) Immature flavivirus particles assemble in the ER and are comprised of an
icosahedral arrangement of E trimeric spikes with fusion loops capped by prM. B) As
particles pass through the trans-golgi network prM is cleaved by furin and the lower pH
causes them to settle into a dimeric arrangement. C) As the virus matures, the higher pH
encountered upon secretion promotes the release of prM. In all reconstructions, axes of
symmetry are labeled. Adapted from refs 22, 60 & 88.

20	
  

Figure 5: Neutralizing epitopes identified on the flavivirus E protein. Epitopes bound
by antibodies neutralizing JEV, WNV or DV are highlighted in green and displayed on
the surface of a JEV E protein. DI, DII and DIII are colored faded red, yellow and blue
respectively.
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Chapter 2:
Crystal structure of Japanese Encephalitis Virus
envelope protein

The research within this chapter consists of data that are published in the Journal of
Virology.
Luca, VC, AbiMansour, JA, Nelson, CA, Fremont, DH. 2011. Crystal
structure of the Japanese Encephalitis virus envelope protein. (In press).
This manuscript was written entirely by me. I carried out the crystal optimization,
structure solution, model building, structural analysis, and multi-angle light scattering.
Jad Abimansour purified the JEV E protein and assisted with crystallography, and Chris
Nelson designed the JEV E DNA construct and established the protocol for refolding
related E proteins.
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2.1 Abstract
Japanese Encephalitis Virus (JEV) is the leading global cause of viral
encephalitis. The JEV envelope protein (E) facilitates cellular attachment and membrane
fusion and is the primary target of neutralizing antibodies. Herein, we have determined
the 2.1Å resolution crystal structure of the JEV E ectodomain refolded from bacterial
inclusion bodies. The E protein possesses the three domains characteristic of flavivirus
envelopes and epitope mapping of neutralizing antibodies onto the structure reveals
determinants that correspond to the domain I lateral ridge, fusion loop, domain III lateral
ridge and domain I-II hinge. While monomeric in solution, JEV E assembles as an
antiparallel dimer in the crystal lattice organized in a highly similar fashion as seen in
cryoEM models of mature flavivirus virions. The dimer interface, however, is remarkably
small and lacks many of the domain II contacts observed in other flavivirus E
homodimers. Additionally, uniquely conserved histidines within the JEV serocomplex
suggest that pH mediated structural transitions may be aided by lateral interactions
outside the dimer interface in the icosahedral virion. Our results suggest that variation of
dimer structure and stability may significantly influence the assembly, receptor
interaction and uncoating of virions.
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2.3 Introduction
Japanese Encephalitis Virus (JEV) is the leading cause of viral encephalitis
worldwide, responsible for 30,000-50,000 cases and 10,000 deaths annually in eastern
Asia. The virus is arthropod borne and naturally cycles between mosquitoes and pigs or
wild birds but may also be transmitted to humans and horses1. There are multiple
vaccines for JEV but they are not universally available in Asia due to cost, licensing
issues and safety concerns2–5. JEV is a member of the Flavivirus genus along with several
other viruses including West Nile Virus (WNV), Tick Borne Encephalitis Virus (TBEV)
and Dengue Virus (DV).
Flaviviruses are positive-stranded RNA viruses with a 9-12kb genome that is
translated as a single polyprotein that is cleaved by host and viral proteases into structural
proteins capsid (C), pre-membrane (prM) and envelope (E) and 7 non-structural proteins.
Capsid binds to viral RNA and forms a nucleocapsid that is enveloped by an ER derived
membrane containing E and prM. E proteins are responsible for cellular attachment and
possess a hydrophobic loop that mediates fusion of viral and host membranes6–11.
During its life cycle, the JEV virion undergoes a maturation process that
continuously shields the fusion peptide from premature insertion into the host cell
membrane. In an immature virion, E forms irregular trimers with fusion loops capped by
prM until it is cleaved in the trans Golgi prior to viral secretion12–14. E then rearranges
into an icosahedral network of flat antiparallel homodimers that bury the loop at their
interface15,16. Mature virions attach to cells and are taken up into the endosome where the
acidic environment triggers an irreversible change from dimer to trimeric spikes17–20. This
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process exposes the fusion loops that penetrate the endosome and drags together host and
viral membranes, thereby releasing the nucleocapsid into the cell.
The majority of flavivirus neutralizing antibodies bind E and can inhibit several
stages of the entry process including attachment and fusion21–26. Infection with a
flavivirus results in the generation of broadly cross-reactive antibodies, but the polysera
from a given infection will only neutralize a subset of other viruses. This phenomenon is
the basis for the serocomplex system of classification in which flaviviruses are placed
into groups defined by cross-neutralization tests with polysera from heterologous
infections27. Clinical manifestations of infection are retained within a given serocomplex
and range from febrile illness to hemorrhagic fever. The Japanese Encephalitis Virus
serocomplex includes St. Louis Encephalitis Virus (SLEV), WNV and prototypical
member JEV, all of which are known to cause flu-like symptoms, acute or fatal
encephalitis27,28. The remaining serocomplexes also exhibit specific tropisms and
pathogeneses, the most notable of which are represented by Tick Borne Encephalitis
Virus, Yellow Fever Virus, and Dengue Virus.
Herein we have determined the crystal structure of the Japanese Encephalitis
Virus E protein to investigate whether structural features could contribute to our
understanding of serocomplex-specific pathogenesis. The E protein crystallized as the
canonical head-to-tail flavivirus E protein dimer but with a notably small interface. The
JEV E dimer has roughly half the buried surface area of any known flavivirus E structure
and the majority of its contacts are between the fusion loop and Domain I-III pocket, not
at the central dimerization region. We suggest that this smaller dimer interface may be

39	
  

the preferred organization of E proteins from viruses in the JEV serocomplex and that it
provides an effective atomic model for JEV E within mature virions.
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2.4 Results
Bacterial expression and refolding of Japanese Encephalitis Virus E protein.
Recombinant Japanese Encephalitis Virus E protein spanning residues 1-406 of the
ectodomain was produced in E. coli as inclusion bodies and refolded by methods
previously described for WNV E29. Briefly, inclusion bodies were solubilized in
guanidine-HCl and β-mercaptoethanol and refolded by dilution into a buffer containing a
10:1 ratio of reduced to oxidized glutathione to allow for proper formation of disulfide
bonds. Soluble E was then purified by size exclusion chromatography and anion
exchange chromatography. Envelope proteins from JEV, WNV and SLEV were purified
by this method, proving its effectiveness as a low-cost alternative for production of
recombinant flavivirus E proteins.
Structure of Japanese Encephalitis Virus E protein. Crystals of the JEV
ectodomain diffracted to 2.1Å and the structure was solved with an Rwork of 22% and an
Rfree of 18% (data collection and refinement statistics in Table 1). Although it was
refolded from bacterial inclusion bodies, JEV E retained the three-domain organization
and all five disulfide bonds previously observed in other flavivirus E proteins (Fig 1)16,30–
34

. The central domain I is composed of a 9-stranded β-barrel located between the

extended domain II and the globular domain III. Domain II is formed out of two extended
loops that protrude from DI, the larger of which is stabilized by three disulfide bonds and
contains the conserved fusion peptide at its tip. Domain III possesses an Ig-like fold and
is found at the C-terminus of the ectodomain, connected to DI by a short peptide linker.
The crystals only contained one molecule in the asymmetric unit, but application of the
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orthorhombic symmetry operators allowed for the generation of the archetypal flavivirus
envelope dimer.
N-linked glycosylation site. The location and presentation of the glycan linked to
N154 has been linked to particle infectivity and interaction with putative cellular receptors
DC-SIGN or DC-SIGNR8,35,36. Recombinant JEV E ectodomain was purified from
bacterial inclusion bodies by oxidative refolding and therefore lacks this modification. In
order to evaluate whether the Eo-F0 loop region of JEV E is affected by glycosylation at
N154, it was was superimposed onto the glycosylated loop of the closely related West Nile
Virus E structure. The main chain traces in this region overlay residues 144-164 with an
overall RMSD of only 0.45, suggesting that glycosylation does not significantly affect the
presentation of this region.
The Dimer Interface. The most unusual feature of the JEV E structure is its
curiously small dimer interface. On the surface of the mature virion, flavivirus E proteins
exist as an antiparallel dimer with the fusion peptide of DII nestled into a cavity formed
by DI and DIII on the opposing subunit15. In the DV and TBEV E structures, there are
extensive contacts across the DII-DII that stabilize this assembly. Several properties of
the dimer from JEV, DV2, DV3 and TBEV envelope proteins were analyzed using the
Protein Interfaces, Surfaces and Assemblies (PISA) server (Table 2)37. While the
secondary and tertiary structure of JEV E is similar to those of other E proteins, it has
only 44-56% of the buried surface area observed in other flavivirus E dimers (Fig 2).
Additionally, it is not stabilized by any salt bridges and has far fewer hydrogen bonds
across the assembly. The JEV E dimer has 843Å2 of total buried surface area, while the
lowest of any other structure is TBEV E with 1496Å2. Further analysis revealed that the
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largest disparity lies at the DII-DII interface. At this site JEV E only has 150Å2 buried
surface area, compared to 534Å2 or greater for all of the other E proteins. The DI-DIII
pocket that houses the fusion loop has relatively less buried surface area as well, but the
difference at this surface is at most 0.4-fold, as compared to greater than 3-fold for the
DII-DII interface. These values reinforce the conclusion that DII-DII contacts are
deficient in the JEV dimer. The Sc across domain II of JEV E was only 0.372, a value
below what is believed to signify a relevant protein-protein interaction. The other E
proteins were found to have an Sc greater than 0.6, in line with other biologically
significant interfaces. Interestingly, in all E structures the Sc of the fusion loop pocket
was greater than the DII-DII region, suggesting that the precise fit of this peptide is of
functional importance.
Domain I-II hinge angle. The angle between DI and DII varies substantially
throughout the viral life cycle. The relative change in hinge angle between JEV E and
that all other available pre-fusion E protein structures was calculated using Dyndom by
individually superimposing JEV DI and DII onto those of WNV, DV2, DV3 and TBEV E
proteins (Fig 3)38. The most closely related E protein, that of WNV (~75% identity),
exhibited the largest difference at 16.0º, but this structure is monomeric and likely
represents a pre-fusion conformation or intermediate that occurs during the trimer
transition. Of the remaining E proteins, the JEV hinge most closely resembled that of
TBEV, with a difference of only 3.4º. This was surprising since the two viruses are only
38% identical and that JEV E has only about 50% of the buried surface area relative to
TBEV E. The differences in hinge for DV2 and DV3 E were found to be 8.7º and 9.6º
respectively. While E molecules require flexibility to drive structural changes essential
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for infection, it appears they also adjust to accommodate species-specific dimer
arrangements.
Structural Contributions to the Interface. Several loops of the JEV E dimer
subunits are devoid of contacts present in those of DV2, DV3 and TBEV (Fig 4). Three
of these segments are specific to DV2 and DV3 E proteins. The first links strands Bo and
Co of DI and the second is the ‘k-l’ loop of DII (Fig 4A). In the DV2 and DV3 E
structures, these peptides stretch across the assembly to pack against the ‘i-j’ loop from
DII of the opposing subunit (Fig 4A). No residue in any of these regions contributes a
dimer contact in JEV E and its ‘k-l’ loop actually angles up and away from the interface,
in stark contrast to the conformation in DV2 E (Fig 4C). TBEV E, on the other hand,
lacks the contacts found in the DV E proteins but possesses a 6-amino acid insertion
between the f and g strands of DII (Fig 4B). Five of these six residues were identified as
contacts in the TBEV E dimer. This insertion lies atop the ‘b’ and ‘j’ strands of the
antiparallel proteins, so while TBEV has a similar hinge angle to that of JEV it buries
additional surface area via this insertion. Sequence alignments of these regions of E
proteins with known structures highlight their respective dimer contacts (Fig 4D).
JEV E Protein Stoichiometry. To assess the oligomeric state of the JEV E protein
we utilized multi-angle light scattering. This technique directly determines absolute
molecular weight from intrinsic scattering properties of proteins so it is advantageous
over methods such as dynamic light scattering or SEC that extrapolate from
hydrodynamic radius alone. Purified JEV E was loaded onto a SEC column at a
concentration of 20µM and refractive index change and MALS were observed over the
elution profile. JEV E eluted as a single peak with an experimentally determined
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molecular weight of 45.3kD (Fig 5A). JEV E has a predicted molecular weight of
43.6kD, so while the soluble JEV E ectodomain packed as a crystallographic dimer, our
observations demonstrate that it is predominantly monomeric in solution. The molecular
weight of E proteins from WNV and SLEV were also determined in the same fashion.
WNV E yielded a weight of 44.3kD (predicted 43.4kD) and SLEV yielded a weight of
39.6kD (predicted 44.2kD), both of which correspond to that of a monomer (Fig 5B-C).
It has been previously reported that DV2, DV3 and TBEV were solution dimers, so we
evaluated the oligomeric state of DV2 E to validate our assay (Fig 5D)16,31,32,34. Insect
cell expressed DV2 E was utilized in these experiments as we have not been able to
successfully refold DV E proteins from bacterial inclusion bodies. However, previous
studies have indicated that insect cell expressed WNV E is monomeric in solution,
suggesting that the single N-linked glycan does not play a significant role in the
oligomeric state of the soluble ectodomain33. DV2 E indeed had a molecular weight of
90.3kD (predicted 45.4kD) corresponding to that of a dimer. Thus, E ectodomains from
the Japanese Encephalitis Virus antigenic complex (JEV, SLEV, WNV) were all found to
have monomeric molecular weights (Fig 5A-C), while the DV2 E protein exists
predominantly as a dimer in solution (Fig 5D). The propensity of JEV E to remain as a
solution monomer is consistent with the smaller dimer interface we observe relative to
DV2 E.
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Superimposition onto the Dengue Cryo-EM model. Determination of the
cryoEM structures of DV and WNV revealed a framework of E protein dimers within the
context of virion icosahedral symmetry15,39. In order to determine whether the
conformation of JEV E found in our structure could, effectively reconstruct a mature
icosahedral virion, we superimposed E subunits onto the main chain coordinates of DV2
E dimers from the cryoEM model. The JEV E crystal structure fits adequately into the
arrangement with the only clash between main chains occurring in the b-c and h-i loops
at the lateral edge of domain II at the two-fold axis (Fig 6A). This was unexpected given
that fitting of other structures required the disassembly of E into domains and rigid body
refinement34. Further analysis of the JEV model revealed the buried surface area between
predicted dimers of the virion to be 469Å2, yielding a difference of 364Å2 when
compared to the crystallographic dimer (Fig 6C). The buried dimer surface areas of other
unliganded E proteins assembled into the virion were 404Å2 for DV2 (pdb 1TG8), 424Å2
for DV3 (pdb 1UZG) and 975Å2 for TBEV (pdb 1SVB) (Fig 6C). Additionally, aligning
entire dimers from the crystal structures onto the corresponding cryoEM dimers yielded
RMSDs of 2.16 for JEV E, 2.43 for TBEV E, 3.35 for DV2E and 2.83 for DV3 E (Fig
6B). In conjunction with the BSA calculations, this RMSD suggests the JEV E structure
provides an effective model for its assembly in the mature virion.
Localization of histidines. It has been suggested that protonation of histidines at
acidic pH plays an important role in the flavivirus life cycle, especially during the
structural transition that leads to membrane fusion. Proposed functions of these residues
include homodimer dissociation, conformational changes of DIII and trimerization40.
Mutation of broadly conserved H323 of TBEV E was shown to decrease infectivity but
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substitution of each of the individual histidines of WNV E did not have an effect,
suggesting that for some viruses they may act in concert40,41. In JEV E, most are found at
the dimer interface, DI-III hinge and DI-II hinges, locations relevant to their proposed
roles.

Others, however, are situated along the lateral ridge on DII and DIII. Four

histidines: His144, His246, His284 and His319, are entirely conserved in flaviviruses and
found at the dimer interface and inter-domain hinges. Three others: His81, His395 and
His397 are poorly represented in most flaviviruses but conserved within the JEV
serocomplex and positioned at surfaces distal to the dimer interface (Fig 7). Protonation
of the three serocomplex-specific histidines at this lateral edge would likely have an
effect on the quaternary arrangement of adjacent subunits based on the modeling of JEV
E into the DV cryo-EM reconstruction. The conservation at these positions may provide
additional energy to stabilize JEV E within the icosahedral framework at neutral pH,
possibly compensating for lost contributions at the dimer interface. At acidic pH, the
protonation of these His residues outside the dimer interface may be an important
mechanism for the regulation of viral uncoating.
Neutralizing epitopes. Mapping of antibodies onto the three-dimensional
structures of the West Nile Virus and Dengue Virus E proteins has revealed the
localization of dominant neutralizing epitopes24. Antibodies that neutralize flaviviruses
localize to specific regions of the protein that span all three E protein domains, with the
observation that many of the most potently neutralizing mAbs recognize the lateral ridge
and ‘A’ strand of DIII22,24,42–45. Several studies have identified individual residues
essential to recognition of JEV by neutralizing antibodies A3, B2, E3, NARMA3, 503,
4G2 and E3.326,46–50. We have compiled and highlighted these residues on the crystal
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structure and mature virion model of JEV E. These fall into four distinct regions: the DIDII hinge, DI lateral ridge and DIII lateral ridge, which are exposed in the cryoEM
structure, and the buried fusion loop (Fig 8A)23,24. Antibodies B2 (I126), NARMA3 (Q52)
and 503 (Q52, I126, K136, S275) all bind exposed residues in the DI-DII hinge region (Fig
8C). Antibody A3 (K179) maps to the DI lateral ridge (Fig 8D) and antibodies E3 (G302)
and E3.3 (I337, F360, R387) recognize the DIII lateral ridge (Fig 8E). Broadly cross-reactive
antibody 4G2 has been shown to weakly neutralize JEV and interacts with residues 104,
106 and 107 at the tip of the fusion loop (Fig 8B). The DI-DII hinge, DI and DIII lateral
ridge epitopes are all largely exposed on the JEV mature virion, the exception being
epitopes located where DIII packs at the at the inner 5-fold axis. It has been previously
reported that antibodies binding WNV E at a similar epitope are also inaccessible51. The
fusion loop epitope is commonly recognized by broadly cross-reactive antibodies and is
partially buried in the JEV E model virion. This epitope is likely only transiently exposed
due to motions of E proteins in the virion or in particles that contain E in the immature
conformation.
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2.5 Discussion
The structure of the JEV E ectodomain was determined to identify unique
characteristics of this important pathogen. A notable feature of our high-resolution
structure is the unusual dimeric interface of the E subunits. Measurements of homodimer
buried surface area, shape complementarity, hydrogen bonds and salt bridges each
indicate a less substantial interface relative to those of TBEV, DV2 and DV3. We
determined the oligomeric state of JEV, SLEV and WNV E proteins and found that all
were solution monomers consistent with our JEV structure as well as two independent
crystal structures of monomeric WNV E30,33. Our results suggest that flavivirus evolution
has modulated the E homodimer interface and dimeric affinity, which may substantially
affect recognition by antibodies and cellular receptors.
Cryo-EM structures of mature WNV and DV have revealed a tightly packed
“herringbone” arrangement of E proteins in which the dimer interface as well as lateral
ridges of all three domains support a stable icosahedral framework15,39. E protein
homodimerization has been thought to be a primary building block of the mature
flavivirus virion, so it was surprising to find that JEV E and related serocomplex proteins
were solution monomers. An explanation for the disparate dimer properties of the JEV
envelope could be that it relies upon quaternary contacts among dimers rather than the
dimer interface per se as principal load-bearing points in the viral chassis. Consistent with
this hypothesis is the location of the JEV serocomplex’s uniquely conserved histidines at
the outer edges of the E protein where quaternary contacts would be made with other E
dimer rafts. While mutation of individual histidine residues does not have a significant
effect on West Nile Virus infectivity, it has been proposed that protonation of multiple
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histidines in concert may drive E homodimer dissociation as an essential step in the series
of conformational changes that lead to membrane fusion40,41. Strikingly, three of nine
histidines conserved in the JEV serocomplex (Fig 7) are found on the lateral edge of E
rather than at hinge regions or the dimer interface, suggesting that these viruses may
utilize pH to regulate structural transitions by breaking non-dimer interfaces.
Analysis of contact residues across E proteins revealed specific structural
differences between the JEV homodimer and that of DV or TBEV. Two DII loops, ‘k-l’
of DV2/3 and ‘f-g’ of TBEV, make contributions to the interface that are entirely absent
in JEV E. The ‘k-l’ loop angles forward in one structure of DV2 E (1OKE) and creates a
pocket that the hydrophobic ligand n-octyl-β-D-glucoside was observed to bind
crystallographically31. In the JEV E structure, this loop is splayed away from the interface
but opens a channel ~15Å in diameter where these contacts would be made in DV2 E
(Fig 2). These channels are large enough to accommodate the insertion of a host ligand,
raising the possibility that their presence or absence could influence viral tropism by
modulating receptor interaction. Alternatively, the major contributor of E dimer contacts
present in TBEV but not JEV is the ‘f-g’ loop of DII. In TBEV, ‘f-g’ contains a 6-amino
acid insertion that positions itself atop ‘b’ and ‘j’ strands from the opposing DII and
appears to latch the subunits together. Other TBEV E serocomplex members Powassan
Virus and Langat Virus also share this insertion. Notably, a histidine residue H208 is
conserved at the apex of the loop so protonation at low pH could provide energy to repel
the molecules apart.
While our comparison of E proteins has highlighted differences between the
crystal structures, serological data suggests that E may adopt a continuum of distinct
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conformations on the surface of the virion. Structural proteins from flaviviruses,
picornaviruses, nodaviruses and rhinoviruses are all believed to exhibit flexibility within
their icosahedral organization43,52–55. Evidence that has arisen from the study of both DIII
and fusion loop-specific neutralizing antibodies strongly suggests that the cage of
flavivirus E proteins ratchet through conformations specific to the virus that encodes
them. It has been reported that high temperature pre-incubation of Dengue Virus with an
anti-DIII Fab resulted in an unusual, distorted cryo-EM structure in which E was locked
into a previously unobserved icosahedral assembly55. The antibody recognizes an epitope
of DIII that is partially masked in mature virions, yet the Fab managed to bind the virion
and capture this unusual conformation. The West Nile specific antibody E16, on the other
hand, binds a similar epitope and does not cause any significant changes in the mature
arrangement upon binding22. The range of motion of E proteins within a mature virion
could thus be influenced by the packing of the dimer. Another class of antibodies bind the
fusion loop epitope that is buried in the cryo-EM model of the mature virus particle,
implying that it must be at least transiently exposed during its life-cycle24,46.
Unexpectedly, many of these fusion loop antibodies are broadly cross-reactive but do not
cross-neutralize. JEV and TBEV in particular were found to have a poor correlation
between the antibody affinity for their recombinant E proteins and neutralization titer,
strongly suggesting that exposure of this conserved epitope differs from one viral species
to the next56. One fusion-loop antibody, E53, has even been reported to preferentially
recognize the E protein spikes that occur in immature virions29. Indeed, partially mature
virions would be predicted to have the propensity for unique assembly based on the
number and location of uncleaved prM29,57,58. The resulting permuted distortions of the E
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protein network likely results in arrangements not represented by the icosahedral
geometry of reported cryo-EM models.
It is becoming increasingly clear that the distinct arrangement of flavivirus E
protein subunits can affect antibody recognition and neutralization. Recent evidence has
described a neutralizing Fab with a paratope that cross-links two independent E proteins
on the surface of the virion.59. While this antibody bound icosahedral axes outside of the
dimer interface, its discovery supports the notion that specific organization of JEV, DV
and TBEV E proteins can influence molecular recognition events of the virion.
Additional factors that may influence E presentation on the particle surface are the
transmembrane and stem-loop regions not present in the crystal structures60. However,
their influence does not oppose the hypothesis that quaternary organization or flexibility
could be distinct for individual flaviviruses.
In conclusion, the structure of the JEV E ectodomain has revealed a uniquely
small dimer interface that may play a role in flavivirus stabilization, immunorecogntion
and pathogenesis. Features of the protein including its monomeric solution state,
relatively low buried surface area and location of serocomplex-conserved histidines
suggest that it is representative of its native state in the virion. Superimposition of JEV E
onto the DV cryoEM structure of the mature virion results in only a single clash and did
not require the separation of domains to effectively reconstruct a JEV particle. This
model also highlights the residues recognized by several classes of neutralizing antibody,
indicating both surface exposed and buried epitopes. As both clearance and enhancement
of flavivirus infections strongly depend on antibody recognition of complex E protein
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epitopes, continued evaluation of intricate structural features of these proteins is essential
to the design of future therapeutics and vaccines.
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2.6 Materials and Methods
Cloning, Expression and Purification of soluble JEV E, SLEV E and WNV E.
A cDNA encoding ectodomain residues 1-406 of the JEV E from the SA-14-14-2 strain
protein and those of WNV and SLEV E were cloned into the bacterial expression vector
Pet21a (+). This vector was transformed into BL21-DE3 (RIL) cells (Stratagene), grown
in a large-scale 4L culture and induced at an optical density 400nm of 0.8 with 1mM
isopropyl β-D-1-thiogalactopyranoside (IPTG). After 4 hours the cells were centrifuged
and pellets were suspended in 50mL solution buffer (50mM Tris pH 8.0, 25% sucrose,
10mM DTT) and then an equal amount of lysis buffer (50mM Tris pH 8.0, 1% TritonX100, 100mM NaCl, 10mM DTT) was added. The mixture was treated with 0.8mg/mL
lysozyme and sonicated three times for 15 seconds to disrupt cell membranes. Next, the
lysate was centrifuged at 10,000xg and the pellet containing the protein inclusion bodies
was washed 3x with 50mL wash buffer (50mM Tris pH 8.0, 0.5% TritonX-100, 100mM
NaCl, 1mM DTT) and then once in wash buffer without TritonX-100. Purified inclusion
body pellets were resuspended in 20mL TE buffer (10mM Tris pH 8.0, 1mM EDTA) and
2mL aliquots of this slurry were each solubilized in 10mL of 6M guanidine-HCl, 10mM
Tris pH 8.0 and 20mM β-mercaptoethanol. These aliquots were rapidly diluted by adding
1mL every 30 minutes drop-wise into a rapidly stirring 1L reservoir of oxidative
refolding buffer (400mM non-detergent sulfobetaine-201 (NDSB-201), 100mM Tris pH
8.0, 0.5mM oxidized glutathione and 5mM reduced glutathione) for overnight refolding.
The refolded protein was concentrated to a volume of 10mL using an Amicon 400
concentrator with 30kD cutoff membrane and purified on a S200 size exclusion
chromatography (SEC) column. It was isolated from eluted fractions corresponding to a

54	
  

predicted molecular weight of 20kD, suggesting it interacts with the sephadex beads of
the column since the purified protein was full-length. This material was further purified
on a MonoQ anion exchange column.
Expression and Purification of DV2 E. Residues 1-394 of Dengue Virus 2 E
ectodomain with an N-terminal honeybee melittin signal sequence were cloned into the
baculovirus transfer vector pAcUW51. The DV2 E encoding transfer vector was then cotransfected into SF9 cells grown in serum free Sf-900 II media (Invitrogen) with the
Flashbac Gold bacmid (Oxford Expression Technologies) to allow homologous
recombination to generate recombinant baculoviruses. The virus was then amplified by
passaging the supernatant at ratios of 1:10 into fresh SF9 cultures until titer was sufficient
for large-scale expression. 5 liters of hi-five cells grown in Express Five (Invitrogen)
serum free media were then infected with recombinant virus to drive expression of
secreted DV2 E. The supernatant from the large-scale infection was then filtered with a
0.2µm cutoff bottle-top filter, concentrated and buffer exchanged into nickel binding
buffer (300mM sodium citrate, 150mM NaCl and 50mM NaPO4 pH 8.0) using a
Cetramate tangential flow concentrator with 30kD cutoff membrane. This supernatant
was then purified by nickel and size-exclusion chromatography.
Crystallization of JEV E. Soluble JEV E protein was crystallized at 20°C by
hanging drop vapor diffusion. Drops containing 0.5µL of protein at a concentration of
10mg/mL were combined with 0.5µL of mother liquor containing 0.1M Tris pH 8.0, 16%
polyethylene glycol (PEG) 3350 and 0.2M sodium citrate and diffraction-quality crystals
grew in 3 days. The crystals were cryoprotected by transferring them briefly into a drop
containing 10% PEG 3350, 25% glycerol, 0.2M sodium citrate, 0.1M Tris pH 8.0 and
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then cooling them in liquid nitrogen. Data were collected at the Advanced Photon Source
(APS) beamline 21-ID-F. The data set was processed, integrated, scaled and merged
using HKL200061. JEV E crystallized in space group I222 with unit cell dimensions
a=61.1 Å, b=62.4Å, c=243.0Å and contains one molecule per asymmetric unit.
Structure Determination. The structure of JEV E was solved using molecular
replacement. The West Nile Virus E protein (pdb ID 2HG0/2I69) was used as a model in
Phaser via the PHENIX graphical user interface62. Mutation of amino acid side chains
and model building was done in Coot63. The model was refined to 2.1Å resolution in
several steps using PHENIX refine. Initially rigid body refinement of each of the three
domains was performed followed by atomic refinement and automated addition of
waters. Coordinates were then uploaded to the TLSID server to obtain domain
predictions for translation liberation screw (TLS) refinement64,65. The resultant structure
has a final Rwork of 18.0% and an Rfree of 22.1% and a total of 214 waters. The N-terminal
403 of 406 amino acids of the E protein construct were built into the model.
Multi-Angle Light Scattering. JEV, WNV, SLEV and DV2 E proteins (200µg)
were loaded in sizing buffer (150mM sodium chloride, 20mM HEPES pH 7.4, 0.01%
sodium azide) onto a size exclusion chromatography column set up in series with a Dawn
Helios II multi-angle light scattering detector (Wyatt), Optilab rEX (Wyatt) differential
refractive index detector and photodiode array detector 996 (Waters). The light
scattering, refractive index change and UV absorbance were each observed over the
elution profile.

The data was then analyzed with the Astra V macromolecular

characterization software package (Wyatt) to calculate the molecular weight of each
protein from the light scattering and refractive index change.
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2.6.6 Protein structure accession number.
The coordinates for JEV E have been deposited in the RCSB Protein Data Bank
(accession code 3P54).
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Table 1: X-ray data collection and refinement statistics for JEV E protein
ectodomain
Data collection
Space group
Cell dimensions
Resolution (high res shell)
Completeness
Redundancy
I/σ
R-merge (I)

I222
a=61.11 Å, b=62.40 Å, c=243.04 Å
50.0-2.10 Å (2.18-2.10 Å)
99.24% (99.8%)a
4.3 (4.4)
12.1 (2.0)
0.07 (0.427)

Refinement
Resolution (high res shell)
R-work reflectionsb (F>0)
R-free reflections
R-work
R-free
JEV E residues (atoms)
Solvent atoms
Estimated coordinate error
Wilson B-factor
R.m.s.d. bond lengths
R.m.s.d. bond angles

30.2-2.10 Å (2.17–2.10 Å)
25663 (2470)a
1284 (136)
0.1811 (0.2037)
0.2242 (.2294)
403 (3045)
210
0.230
27.62 Å2
0.009 Å
1.098°

a
b

Values in parentheses are for data in the highest resolution shell
Statistics as defined in Phenix

Table 2: Analysis of E protein dimer interfaces
E
JEV
(3P54)
DV2βOG
(1OKE)
DV2
(1TG8)
DV3
(1UZG)
TBE
(1SVB)

BSA
(Å2)
843.1

BSA D13D2 (Å2)
346.8

BSA DIIDII (Å2)
149.4

S C:
total
0.786

S C:
D13-D2
0.799

SC D2D2
0.372

Interface
residues
38

Hbonds
2

Salt
Bridges
0

1929.2

577.5

825.2

0.719

0.766

0.655

62

17

4

1703.0

557.5

613.9

0.735

0.790

0.612

57

20

5

1593.2

533.6

534.6

0.654

0.629

0.602

51

12

2

1496.2

412.8

672.1

0.702

0.754

0.633

49

8

2
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Figure 1: Crystal structure of JEV E ectodomain. JEV E possesses the three domains
characteristic of flavivirus E with symmetry operators that allow for generation of the
canonical E dimer. JEV E cartoon representation crystal structure with domain I
highlighted in red, domain II in yellow, domain III in blue and crystallographic dimer
generated from orthorhombic symmetry in grey. The structure is also shown rotated 90°
into the page. The fusion loop is colored green and the ‘k-l’ loop and glycosylation site
are indicated in both structures.

59	
  

Figure 2: Relative buried surface area of dimeric flavivirus E protein structures.
JEV E has a small dimer interface relative to other E crystal structures. Surface
representations of known dimeric E protein crystal structures are displayed arranged in
ascending order of buried surface area. Note the that JEV E and TBEV E have visible
solvent channels between subunits at the dimer interface, and that these channels are
absent in DV E dimers with greater buried surface area.shrinking channels between the
subunits as buried surface area decreases.
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Figure 3: Comparison of E protein DI-DII hinge angles. The DI-DII hinge angle of
JEV E is most similar to that of TBEV E. Various crystal structures of E were
superimposed onto DI of JEV E and the relative angle between DI and DII was
determined using Dyndom. Proteins are colored according to virus of origin and the
numbers on the left indicate the difference in angle between DI and DII of each E protein
and JEV E. The DV3 E protein was omitted for clarity and because it varies by less than
1 degree from that of DV2 E.
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Figure 4: Dimeric contact residues in E proteins from DV, TBEV and JEV
serocomplexes. Multiple loops of domains I and II have dimer contacts in TBEV and DV
E that are lacking in JEV E. A. Loops colored green contribute to dimer contacts in the
Dengue Virus and B. Tick Borne Encephalitis E proteins but not in JEV E. C. The
equivalent loops are colored red in the JEV E structure. D. The sequences corresponding
to the numbered loops are aligned for all known dimeric E protein structures, with dimer
contact residues highlighted in green. The parent virus of the E protein its pdb id are
shown left to the left of each sequence.
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Figure 5: Multi-angle light scattering evaluation of E protein solution oligomeric
state. E proteins from viruses of the JEV E serocomplex favor a monomeric solution
state. Multi-angle light scattering was utilized to calculate the solution molecular weight
(MW) of JEV E (A), SLEV E (B), WNV E (C) and DV2 E (D) over their elution profile
on a S200 sizing column. JEV E, SLEV E and WNV E had MW corresponding to that of
monomers while DV2 E was that of a dimer. The UV absorbance trace is colored black,
molar mass calculation in blue and fitted molar mass in red.
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Figure 6: Comparison of E protein crystal structures to DV2 cryo-EM model. A.
JEV E monomers were superimposed onto E proteins from the DV2 cryoEM
reconstruction. The enlarged window of E proteins at the 2-fold axis shows the only
clashing main-chain loops, ‘b-c’ and ‘h-i’, in cyan and magenta respectively. B. JEV E
and DV2 E crystal structure backbones (green) are overlaid onto artificially generated
dimers created by superimposing monomers from the crystal structure onto Dengue E
dimers of the cryoEM model (grey). C. The table describes the buried surface areas from
the crystal structures, the cryoEM model dimers and the RMSD obtained by aligning the
crystal structure dimers onto the cryoEM models.
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Figure 7: Conservation and localization of histidines of E proteins from the JEV and
DV serocomplexes. Histidines on the lateral edge of DII and DIII are poorly represented
in flaviviruses but conserved in the JEV serocomplex. Histidines of the DV2 E and JEV
E proteins are shown in stick representation on one dimer subunit and labeled with their
residue number for the given virus. Those colored green represent those conserved in all
flaviviruses, orange are conserved in only the DV2 (top) or JEV serocomplex (bottom)
and grey are not broadly conserved. Histidines fully conserved in the JEV serocomplex
but not in other flaviviruses are found on the outer edge of the dimer and marked with an
asterisk.
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Figure 8: Mapping of neutralizing epitopes onto the JEV E protein and
reconstructed virion. JEV E neutralizing epitopes are found at the DI-DII hinge, DI
lateral ridge, DIII lateral ridge and fusion loop. A. Side chains of residues critical for
binding by previously identified JEV neutralizing antibodies are colored green and in
spherical representation. B. 4G2 (G104, G106, L107) maps to the fusion loop. C. B2 (I126),
NARMA3 (Q52) and 503 (Q52, I126, K136, S275) map to the DI-DII hinge. D. A3 (K179)
maps to the DI lateral ridge (panel D). E. E3 (G302) and E3.3 (I337, F360, R387) map to the
DIII lateral ridge. The regions described above have also been mapped onto the model of
the JEV virion to reveal their arrangement and accessibility in the icosahedral assembly.
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Chapter 3:
The St. Louis Encephalitis Virus envelope fusogenic trimer
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3.1 Abstract
St. Louis Encephalitis Virus (SLEV) is a member of the JEV serocomplex of
flaviviruses and can cause febrile illness, nausea and encephalitis. We determined the 4.0
Å structure of its E protein in the post-fusion trimer conformation to compare it with E
trimer structures from other serocomplexes. SLEV E crystallized as a trimer in the
absence of lipids or detergents, requiring only low pH. However, its domain arrangement
was nearly identical to other post-fusion structures. This suggests that viruses can alter
dimer assembly but the structure of the activated, fusogenic conformation may be more
strictly conserved.
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3.2 Cloning, purification and crystallization of SLEV E
Cloning and purification of SLEV E was carried out as described in 2.5.1. After
successful refolding, SLEV E was buffer exchanged into 50mM sodium acetate pH 5.5
and concentrated to ~5mg/mL. SLEV E protein was crystallized at 20°C by hanging drop
vapor diffusion. Drops containing 0.5µL of protein at a were combined with 0.5µL of
mother liquor containing 0.1M sodium acetate pH 5.5, 3% polyethylene glycol (PEG)
8000 and 2% ethylene glycol. Diffraction-quality crystals grew in 3-7 days (Fig 1A).
Crystals were cryoprotected by transferring them briefly into a drop containing 10% PEG
8000, 25% ethylene glycol and 0.1M sodium acetate pH 5.5 and then cooling them in
liquid nitrogen. Data were collected at the Advanced Photon Source (APS) beamline
ID19. The data set was processed, integrated, scaled and merged using HKL20001. SLEV
E crystallized in space group I23 with unit cell dimensions a = b = c = 177.34 Å and
contains one molecule per asymmetric unit.

3.3 Structure determination
The structure of SLEV E was solved using molecular replacement. The sequence
of SLEV E was threaded onto the structure of the post-fusion E trimer from Dengue 22
(pdb ID 1OK8) using Phyre23. This model was then used for molecular replacement
using Phaser within the PHENIX graphical interface4. An additional model of SLEV E
was generated by threading SLEV E onto the JEV E crystal structure (pdb ID 3P54) and
manually superimposing domains I, II and III onto those molecular replacement solution.
SLEV has greater sequence identity with JEV E than DV E, so this model was used as a
reference model during refinement. The structure was refined to 4.0Å resolution in
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PHENIX by rigid body refinement followed by several rounds of atomic refinement with
reference model and secondary structure restraints was performed and yielded an Rwork of
32% and Rfree of 34% (Table 1).

3.4 SLEV E post-fusion trimer
The preliminary crystal structure of SLEV E was determined at refined to 4.0Å
resolution. The Rwork and Rfree were 32 and 34% respectively, and 383 out of 406 residues
were built into the model. The loops spanning residues 146-164 was not visible in the
density. The residues of this loop are also disordered in both post-fusion structures of DV
E proteins, so this is not unusual2,5. SLEV E adopted the 3-domain architecture
previously observed in E proteins6. DI is an 8-stranded β-barrel, DII is formed out of two
extended loops protruding from DI and DIII is a 6-stranded Ig-like domain (Fig 1A).
Crystals were grown at pH 5.5 and E was found in the post-fusion conformation. There
was a single E protein in the asymmetric unit, but application of cubic symmetry allowed
for generation of the trimer (Fig 1A). When DI of SLEV E was superimposed onto DI of
the DV2 E trimer, the most significant differences were visible in DII, while DIII from
SLEV E did not vary substantially in orientation relative to DV2 DIII (Fig 1B). Further
analysis will be carried out upon further refinement, as we do not wish to over-interpret
our results given the low resolution of the structure.

3.5 Discussion and future directions
We have solved the first structure of a post-fusion E protein from the JEV
serocomplex. It was originally believed that E protein trimerization required both acidic
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pH and the presence of membranes7. However, the post-fusion structure of DV1 E was
recently solved in the absence of detergent5. Interestingly, DV2 E2 and TBEV E8 crystals
grown in presence of lipids or detergents diffracted to high resolution (2.0 and 2.7 Å).
DV1 E5 and SLEV E structures, on the other hand, are relatively low-resolution (3.5 Å
and 4.0 Å), implying insertion into membranes provides additional stabilization.
Attempts to improve the resolution of the SLEV E crystals have been
unsuccessful. The crystals have a high solvent content (~80%) that was apparent upon
inspection of the large solvent channels that permeate the lattice (Fig 2). The fusion loops
are completely buried within a pocket formed by DI-DIII from 3 different E proteins that
each belong to a separate trimer (Fig 3). Attempts to dehydrate crystals have failed thus
far. Our next attempt to improve diffraction will be to pursue crystallization of SLEV E
in the presence of stabilizing lipids or detergents. We obtained a 4.0 Å resolution SAD
data set with selenomethionine-derived SLEV E and the additional phase information
will be utilized to improve our model. Future efforts will focus on the comparison of a
fully refined SLEV E structure to the structures of other class II fusion proteins in the
post-fusion conformation.
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Table 1: Data collection and refinement statistics
Data collection
Space group
Cell dimensions
Resolution (high res shell)
Completeness
Redundancy
I/σ
R-merge (I)

I23
a=b=c=177.34Å
50.0-4.00 Å (4.07-4.00 Å)
99.56% (99.5%)a
11.7 (11.7)
30.5 (7.0)
0.07 (0.488)

Refinement
Resolution (high res shell)
R-work reflectionsb (F>0)
R-free reflections
R-work
R-free
SLEV E residues (atoms)
Wilson B-factor
R.m.s.d. bond lengths
R.m.s.d. bond angles

37.8-4.03 Å (4.17–4.03 Å)
7383 (698)a
388 (36)
0.3254 (0.3503)
0.3433 (.4021)
381 (2917)
131.70 Å2
0.009 Å
1.544°

a

Values in parentheses are for data in
the highest resolution shell
b
Statistics as defined in Phenix
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Figure 1: Crystal structure of SLEV E. A) Cubic crystals grew in 3% PEG 8000, 2%
ethylene glycol, 0.1M sodium acetate pH 5.5 after 3-7 days. B) SLEV E trimer. DI is
colored red, DII yellow, DIII blue and fusion loop green. Application of cubic symmetry
allowed generation of the trimer, with additional subunits colored grey and wheat. C)
Least-squares superimposition of DI of SLEV E onto DI of DV2 E (grey). Slight
differences in the angles of DII and DIII relative to DI are visible.
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Figure 2: SLEV E packing and solvent channels. The SLEV E trimer was formed by
application of cubic symmetry and packed into a lattice with large solvent channels
between trimers. A single E subunit is displayed below (outlined box, red ribbon
structure). The top left panel shows only the E packing arrangement, the right panel
shows the density and the center panel is the two merged.
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Figure 3: Fusion loop burial. A) In the absence of detergent, the fusion loops of SLEV
E packed into a pocket formed by DI and DIII of three E monomers that each belong to a
separate trimer assembly. DI is shown in red, DII in yellow and DIII in blue. The trimer
with inserted fusion loop (green) is shown in cartoon representation. DIII is omitted from
the cartoon representation for clarity. B) The stick representation of the 3 fusion loops is
displayed.
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Chapter 4:
Introduction to Hepatitis C Virus
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4.1 Abstract
Hepatitis C virus (HCV) is a blood borne pathogen that chronically infects
roughly 3% of the global population. Clinical manifestations include hepatitis, cirrhosis
and hepatocellular carcinoma. HCV is a member of the Flaviviridae family, a group of
enveloped, positive-stranded RNA viruses. The current therapy for HCV is a combination
of interferon-α and ribavirin. This treatment only succeeds in ~50% of cases and often
leads to more detrimental side effects than those of the disease. The inability to develop a
preventative vaccine has been linked to many features that shield the virus from antibody
recognition, including extensive glycosylation and sequence variability of envelope
proteins E1 and E2. Entry is mediated by direct interaction between E2 and receptors
CD81 and scaveng3er receptor BI. However, virions also associate with lipoproteins that
allow for hijacking of the lipoprotein transport machinery to facilitate infection. There is
no crystal structure for E1 or E2 and their organization on mature virions is unknown.
Determination of the structural and biophysical basis for HCV receptor interaction should
illuminate new targets for the rational design of antivirals and antibodies that can inhibit
HCV at vulnerable stages of the entry process.
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4.2 Discovery and epidemiology
Hepatitis C was first isolated as the causative agent of non-A, non-B viral
hepatitis in 19891, but genetic “molecular clock” approaches estimate the virus first
appeared in humans as many as 1,000 years ago2. Transmission of HCV occurs from
contact with infected blood. The majority of cases have resulted from needle sharing
during injected drug use or blood transfusions that occurred prior to screening for the
virus in 19903. Sexual transmission of HCV is possible but rare4. Up to 75% of those
infected proceed to chronic infection, although the virus has been deemed the “silent
epidemic” because a high percentage these individuals clinical symptoms may be delayed
for several years5,6. There are 8,000-10,000 annual deaths7 linked to HCV infection, a
relatively small number relative to the 1.5 to 3 million deaths caused by HIV8. However,
it has been estimated that 170 million people are chronically infected with HCV9, which
is ~5 times that of those carrying HIV. Therefore, progression of liver disease HCVpositive individuals poses a massive public health problem.

4.3 Clinical manifestations and treatment
Symptoms of chronic infection. Many chronic HCV infections are asymptomatic,
and in some cases their manifestation of clinical symptoms does not occur for 20 or more
years10. The most common symptoms that do occur include jaundice, fatigue, cirrhosis,
hepatitis, and hepatocellular carcinoma11. However, even those with asymptomatic
infection are at risk for progressive liver damage. HCV is currently the leading cause of
adult liver transplantation in the U.S., but if the antiviral therapy is not able to clear the
virus prior to the transplant, re-infection will occur.
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Antiviral therapy. The current treatment for HCV is a combination of pegylated
interferon-α and ribavirin12. Viral clearance as a result of this combination therapy is
~50%, but depends upon the HCV genotype being treated13. Genotype 1 is most
prevalent in the U.S. and is the most resistant14. Side effects of this lengthy 48-week
regimen occur in 50% or more patients and range from flu-like symptoms to depression.
The severity of these side effects relative to the typically mild short-term symptoms of
HCV infection results in a large degree of patient non-compliance and thus
discontinuation of treatment15. Promising results have been achieved with an antiviral
that specifically inhibits the HCV NS2-3A viral protease. In clinical trials, combination
therapy that included this protease, interferon-α and ribavirin inhibitor resulted in a
sustained virologic response in 72% of patients16. Several other drugs that specifically
target other non-structural proteins are also in clinical trials, forecasting a promising
future for control of HCV17.
Vaccine development. Development of a prophylactic or therapeutic HCV
vaccine has been unsuccessful to date. This is largely because of the extensive sequence
diversity amongst strains or generation of quasispecies within a single host18–20. The only
preventative vaccine to be evaluated in clinical trials consisted of recombinant HCV E1
and E2 envelope proteins21. This vaccine was well tolerated and generated neutralizing
antibodies against HCV. However, this approach is unlikely to succeed given the results
of several previous studies. For example, it has been established that chronically infected
individuals often possess high titers of neutralizing antibodies,22 and that E1-E2 vaccines
tested on chimpanzees do not prevent infection with heterologous strains23. Future
prophylactic approaches are likely to focus on the use of virus-like particles (VLPs) or
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inactivated virus, but immunization with these agents still does not address the issue of
sequence variability. A potentially more promising approach involves complementation
of the antiviral regimen with a therapeutic vaccine. Augmentation of the immune system
by recombinant interferon-α is essential to this treatment, so it is apparent that boosting
the host response can be a successful strategy24. Therapeutic vaccines utilizing
recombinant HCV E125, core26,27 or non-structural proteins28,29 have been developed with
and administered with several different delivery systems but none are particularly
effective30.

4.4 Virology
HCV is a member of the Flaviviridae family and is the lone representative of
genus Hepacivirus. There are six major genotypes of HCV, each of which differ by 3035% in sequence at the nucleotide level31. HCV is an enveloped, positive-stranded RNA
virus that possesses a ~9.6kb genome. The genome encodes for a single polyprotein is
cleaved by viral and host proteases into 3 structural and 7 non-structural (NS) proteins32
(Fig 1). Core binds to viral RNA and forms the nucleocapsid and been implicated in the
inhibition of interferon signalling33. Envelope protein 1 and 2 (E1/E2) are transmembrane
proteins that coat the surface of the HCV virion. These proteins are primarily involved in
functions that mediate cellular entry such as attachment, receptor interaction and
membrane fusion34. The p7 non-structural protein is a dual-pass transmembrane protein
that exhibits ion-channel activity in vitro35,36. NS2 is a membrane protein involved in the
replication complex and is essential for cleavage at the NS2/3 junction in the
polyprotein37. NS3 is a multi-function protein with an N-terminal cysteine protease
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domain and a C-terminal RNA-helicase38. NS4A is co-factor for NS3 and associates with
the ER through its transmembrane domain39. NS4B is a 4-pass transmembrane protein
that induces a membranous web involved in formation and budding of HCV virions40–42.
NS5A is a membrane-associated phosphoprotein that binds to viral RNA43 and NS5B and
is essential for replication. NS5B is also membrane associated and serves as a low fidelity
RNA polymerase44,45.

4.5 HCV envelope glycoproteins
The surface of the mature HCV virion is decorated with transmembrane envelope
glycoproteins E1 and E2 that facilitate attachment and membrane fusion. E1 and E2 have
been proposed to operate as class II fusion proteins (refer to 1.5.3) based on predictions
that their secondary structure consists primarily of β-strands, and has similar genomic
organization to flaviviruses. However, their sequences are divergent from any known
class II protein, and a group of class III fusion proteins rich in β-strand content have also
been recently discovered46, so this presumption is highly speculative. The majority of
host neutralizing antibodies recognize E2, however neutralizing anti-E1 antibodies have
been reported. While E1 and E2 have been studied extensively, several basic features
including their oligomeric state and assembly in the native virion, membrane topology
and localization of a fusion peptide remain unclear.
E1 biochemistry, membrane topology and putative functions. E1 is a 162aa
(polyprotein aa 192-353) transmembrane protein with poorly understood function. The
ectodomain of E1 contains 4 N-linked glycosylation sites and the protein has 6 cysteine
residues that form disulfide bonds (Fig 2A). A proposed function of E1 is to serve as a
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chaperone for folding of E247, but several studies have verified that soluble E2 constructs
adopt a functional fold in the absence of E1 co-expression48,49. Several regions of E1
have been suggested to contain the HCV fusion peptide. Perhaps most intriguing is the
hydrophobic central region of E1 that spans polyprotein residues 272-298. This region
has been proposed by some to serve as a fusion peptide50 and by others a central
transmembrane domain51. Indeed, there is conflicting evidence that supports both a twopass and single-pass transmembrane topology model of E1. Antibodies that bind residues
313-327 can neutralize HCV, suggesting the region immediately C-terminal to 272-298 is
exposed on the virion and argues that E1 has a lone transmembrane domain at its Cterminus52. On the other hand, the same C-terminal region recognized by these antibodies
also binds the HCV core protein, which is enveloped by the viral membrane and
inaccessible to host antibodies51. This second finding implies that E1 possesses a
transmembrane helix at 272-298 as well as its C-terminus. It is possible, especially given
that HCV envelope protein organization in viral particles is unclear, that these conflicting
data may be reconciled by the existence of two distinct forms of E1 with one or two
transmembrane domains. E1 also can potentially mediate HCV entry by associating with
apolipoproteins B and E (ApoB, ApoE) to direct interaction with the low-density
lipoprotein receptor (LDL-R)53.
E2 biochemistry. E2 is a 363aa transmembrane protein (polyprotein aa 384-743)
responsible for direct interaction with HCV receptors CD8154,55 and SR-BI56,57 and is the
primary target of neutralizing antibodies. E2 contains 11 N-linked glycosylation sites, all
of which have been confirmed to be modified by host cells58, and 18 conserved cysteines
that stabilize its structure by forming disulfide bonds59 (Fig 2B). Lines of evidence
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supporting the hypothesis that E2 is a class II viral fusion protein are anecdotal and based
entirely on its localization in the genome and secondary structure content. E2 has no
significant sequence similarity to any known protein, making structural prediction
difficult. Regardless of these limitations, a computational model of E2 generated through
the threading of its sequence onto domains I and II of a flavivirus E protein has been
published60. Mutation of polyprotein residues 416-430 and 600-620 led to defects in
HCV pseudoparticle fusion61 and are thus considered candidates for the viral fusion
peptide. However, in the absence of structural information it is difficult to differentiate
peptides that physically penetrate host membranes from those that assist in
conformational changes prior to fusion.
E2 soluble ectodomain. C-terminal truncation of E2 prior to its hydrophobic stem
and transmembrane regions results in the secretion of a soluble form of its ectodomain48.
This recombinant, soluble E2 (sE2), spanning polyprotein residues 384-660, has been
critical to the discovery of HCV receptors CD8155 and SR-BI57, monoclonal antibody
generation56 and biochemical studies of envelope protein function. Production of sE2
leads to the secretion of a monomeric form along with disulfide-linked aggregates48. I
have reproduced this expression pattern by generating sE2 through recombinant
baculovirus infection of Hi-Five cells and it is the main protein reagent used in the HCV
portion of my thesis. Methods described for this purification can be found in 4.7.1.
Briefly, sE2 secreted into insect cell supernatants was purified by nickel and size
exclusion chromatography (SEC), and the monomeric fraction obtained from the SEC
purification was collected and utilized for subsequent experiments (Fig 3). Monomeric
sE2 is believed to resemble the native E2 ectodomain based on its ability to directly bind
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host receptors CD8162 and SR-BI57 and inhibit HCV infection when bound to
hepatocytes49. There is also evidence that HCV particles contain disulfide-linked E2
aggregates, but soluble forms of these aggregates do not bind CD8163 and few studies
have investigated their relevance otherwise.
Hypervariable region 1. The most genetically diverse region of the HCV genome
is located at the N-terminus of E2 and deemed hypervariable region 164 (HVR1). Despite
its sequence variability, the length and physiochemical properties of HVR1 are
conserved65, suggesting it retains structural elements or functional utility (Fig 4). Indeed,
HVR1 has been implicated in binding to hepatocytes and evasion of the humoral immune
response. HVR1 binds to heparin sulfate through electrostatic interaction with basic
residues and this binding may be competitively inhibited by the heparin-binding V3
variable loop of HIV66,67. Furthermore, deletion mutants of E2 lacking HVR1 lose the
ability to bind SR-BI57, highlighting its importance for interaction with at least two
attachment factors. HVR1 was one of the first identified neutralizing epitopes on the
HCV structural proteins68. Based on this discovery, it was demonstrated that treatment of
chimpanzees with anti-HVR1 polysera was able to prevent infection with homologous
strains23. This protection reinforced the biological importance of HVR1 but its variability
makes it an inherently poor vaccine candidate. HCV lacking HVR1 has increased
susceptibility to neutralizing antibodies and captures increased amounts of soluble CD81
in pull-down assays, suggesting it may also play a role in concealing conserved protein
surfaces from antibodies69.
Oligomeric

state

and

disulfide

connectivity

in

recombinant

E1/E2.

Understanding of envelope protein arrangement in native HCV virions has been
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complicated because of substantial differences in the properties of recombinant versus
virus-incorporated envelope proteins. While there is little structural information available
for these proteins, the connectivity of the disulfide bonds formed in both E1 and E2 has
been established. Those formed by E1 were sequential70, with each cysteine forming an
intramolecular bond with an adjacent cysteine (Fig 2A). The E2 disulfides contained
sequential and non-sequential linkages, implying they play a role in stabilization of
tertiary structure59 (Fig 2B). Early assessments of the oligomeric state of transiently
expressed E1 and E2 observed the formation of a non-covalent heterodimer71. However,
the story grew more complex upon evaluation of E1 and E2 association in infectious
particles. These studies revealed a barely detectable fraction of monomeric E1 and E2
and large quantities of disulfide-linked oligomers, suggesting a web of cross-linked E1
and E2 proteins encase the native virion72. Furthermore, cell-culture derived virus
requires reduced (unpaired) cysteine residues in E1 and E2 for infection73. These data
indicate the disulfide mapping of recombinant E1 and E2 does not recapitulate what is
present in infectious virus. The poor comprehension of HCV envelope protein assembly
presents a major concern for the selection of effective immunogens for vaccination.

4.6 The HCV virion
The HCV virion is composed of C, the RNA genome and a host derived lipid
membrane containing E1 and E2. These particles are roughly spherical and measure
~50nm across74. The association of HCV with lipoproteins such as ApoB, ApoE or HDL
results in a low particle buoyant density relative to other small RNA viruses75. These
lipoprotein-associated forms of HCV are referred to as lipoviroparticles. Infection of
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hepatocytes by lipoviroparticles may be mediated by direct interaction between E1 and
E2 with a variety host entry factors, or by indirect interaction between lipoproteins and
cellular lipoprotein receptors76–79.

4.7 Host entry factors
A multitude of candidate receptors and attachment factors important for HCV
infection have been identified (Fig 5). Most of these host factors may be assigned to three
categories: 4 transmembrane tetraspanins (CD81) and tight-junction proteins (claudins
1/6/9,

occludin),

lipoprotein

receptors

(SR-BI,

LDL-receptor),

and

carbohydrates/carbohydrate recognition proteins (heparin sulfate, DC-SIGN, L-SIGN).
While direct interaction with HCV has only been demonstrated for a subset of these
molecules, many are still required for productive infection of hepatocytes.
CD81. The first identified HCV receptor was tetraspanin CD8162. Tetraspanins
are a family of 4 transmembrane domain proteins that interact with one another to
stabilize membranes and participate in signaling. CD81 is also a member of the B-cell
receptor complex, and HCV can infect B-cells along with hepatocytes80,81. There are two
extracellular loops in between the transmembrane helices of CD81, the second of which
is deemed the large-extracellular loop (LEL). The crystal structure of this loop revealed a
5-helix arrangement and two molecules in the asymmetric unit forming what is presumed
to be a homodimer82. The interaction of E2 and CD81 has been mapped to the LEL,
specifically to residue F185 situated on opposite ends of the homodimer83 (Fig 6). Protein
determinants of E2:CD81 binding have also been mapped to discontinuous regions of E2
including W420, G436-Y443, Y527, W529, G530 and D53584,85 (Fig 2B). CD81 likely
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serves as a post-attachment receptor since anti-CD81 mAbs neutralize HCV regardless of
whether they are applied before or after virus is bound to hepatocytes55. Interaction of
HCV with CD81 also serves to prime the virus for membrane fusion86.
Scavenger receptor BI. Scavenger receptor BI is required for HCV infection and
directly interacts with E257. SR-BI is a two-pass transmembrane protein with N- and Ctermini oriented towards the cytosol. It has a single, ~400aa glycosylated extracellular
loop and is involved in lipid and cholesterol transport through binding of lipoproteins and
uptake of foreign substances or organisms. Ligands that interact with the extracellular
loop are typically negatively charged and include high-density lipoprotein (HDL)87,
ApoB and ApoE87,88. HCV is often found in serum as a “lipoviroparticle” associated with
ApoB and ApoE. Therefore, it has been proposed that HCV hijacks the SR-BI transport
machinery to gain entry into cells, either by engaging SR-BI with E257 or associated
ApoE76,78. HCV infection is also enhanced by the presence of HDL89,77,90, providing
further evidence for this mechanism. Unlike what is observed for interaction with CD81,
binding of HCV to SR-BI occurs at an early stage of infection and specifically involves
amino acids 70-87 and E210 in the N-terminal half of the extracellular loop91. Deletion of
HVR1 from E2 ablates SR-BI binding57, indicating it contains at least part of the
molecular determinants for this interaction. Interestingly, both SR-BI and CD81 are also
involved in Plasmodium falciparum (causative agent of malaria) infection of
hepatocytes92, suggesting they may be part of a conserved portal for pathogen entry.
Tight junction proteins. Claudins 1, 6 and 9 (CLN1, CLN6, CLN9)93,94 and
occludin (OCLN)95 are tight junction proteins necessary for HCV infection. These
proteins function as cellular adhesion molecules and each has a 4-transmembrane
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topology similar to CD81. CLN1/6/9 and OCLN do not directly bind HCV, but appear to
co-localize with other receptors96 and can facilitate direct cell-to-cell transmission97.
Antibodies that bind CLN1 block HCV infection98, implying it is in proximity to the
virus during entry. Indeed, complexes of CD81 and CLN1 have been identified and
appear to associate with HCV96. OCLN may also indirectly associate with HCV, as it coprecipitates with E2 from infected cells99. The specific determinants within CLN1 and
OCLN required for HCV infection have been identified and include the first extracellular
loop of CLN193 and second extracellular loop of OCLN95. While the exact role of tight
junction molecules in HCV infection is unclear, discovery of OCLN as an entry factor led
to the development of the first immunocompetent HCV mouse model. Transgenic mice
expressing human CD81 and OCLN are susceptible to a single cycle of HCV infection100,
reinforcing the importance of OCLN for HCV infection despite its inability to directly
bind virus.
Other candidate attachment and entry factors. Additional molecules implicated
in HCV infection are the LDL-receptor76,101, heparin sulfate66,67 and mannose-binding
lectins DC-SIGN and L-SIGN102. The LDL-receptor likely interacts with HCV in a
manner similar to SR-BI in which indirect interactions with virion-associated lipoproteins
facilitates entry76. Binding of HCV to heparin sulfate occurs through interactions with
HVR1 and enhances viral attachment to hepatocytes67. DC-SIGN and L-SIGN bind
carbohydrates on E2, allowing HCV to disseminate to proximal hepatocytes upon
infection of a cell102. However, several different viruses attach to cells through nonspecific interactions with heparin sulfate and mannose-binding lectins, so these are
typically considered attachment factors and not true receptors.
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4.8 Role of antibodies in chronic infection
The role of neutralizing antibodies in acute and chronic HCV infection is unclear.
Early experiments were met with paradoxical results: most individuals chronically
infected with HCV had high titers of neutralizing antibodies but acute infections were
associated with low titers22. More recent studies, however, reported that spontaneous
clearance of HCV is consistently linked to rapid induction of neutralizing antibodies
during the acute phase of infection while those with a delayed response progress to
chronic infection103,104. It is therefore likely that once a poor initial response allows HCV
to establish infection, its many immune evasion strategies allow it to persist in the
presence of neutralizing antibodies.

4.9 Antibody evasion mechanisms
Genetic variation and hypervariable region 1. HCV employs a variety of
strategies to evade recognition and clearance by antibodies. Perhaps the most effective is
the ability of HCV to rapidly vary its sequence due to the low fidelity of RNA
polymerase NS5B45. In infected patients, a population of quasispecies will emerge18–20
and a high degree of diversity amongst these species during early infection is predictive
of a chronic infection105. The most diverse region of HCV is HVR1, a variable region that
serves a role in cellular attachment67 as well as antibody evasion69. Antibodies that bind
HVR1 neutralize HCV but do not lead to clearance, presumably due to its frequent
mutation106. Furthermore, HVR1 is able to obscure conserved neutralizing epitopes from
recognition69.
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Glycosylation of E2. Viral N-linked glycans are believed to be flexible and
structurally indistinguishable from host carbohydrates, so they are rarely targeted
exclusively by neutralizing antibodies. The presence of several glycans on the surface of
a virion could therefore sterically inhibit antibody access to protein epitopes. Mutation of
N-linked glycans at sites N417, N423, N448, N532 and N645 of E2 (Fig 2C) each leads
to increased neutralization sensitivity107, indicating they are able to shield protein
surfaces from recognition. All E2 glycans also exhibit microheterogeneity58, meaning
modification at a single site may is not consistent. This implies that even neutralizing
antibodies able to recognize carbohydrate epitopes would not effectively bind all
available sites on viral particles.
Cell to cell transmission. HCV is able to spread directly from cell to cell upon
infection of hepatoma and B-cell lines108,109. This means of transmission is independent
of CD81109 but still requires CLN1 and OCLN109,108, suggesting the virus may pass
through tight junctions. Cell-to-cell transfer from infected cell lines to uninfected cells
occurs despite the presence of neutralizing antibodies, representing yet another
mechanism utilized by HCV to evade the humoral immune response.

4.10 Neutralizing epitopes
Several neutralizing antibodies have been mapped to specific sites on E1 and E2.
Some of the first identified were found to recognize the C-terminal half of HVR1 and
functioned by blocking cellular attachment. In our own studies, we isolated neutralizing
antibodies that bind C-terminal residues of HVR1 G397, F403, G406 as well as residue
R572 within the intergenotypic variable region (igVR)110 and block infection at a post-
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attachment step56. This mapping suggests these two variable regions are within close
spatial proximity in the structure of E2 (Fig 2C). Additional conserved linear and
discontinuous neutralizing epitopes have been determined for several antibodies, and are
most commonly located within E2 polyprotein residue ranges 412-424 or 523-550111–114.
Binding determinants for CD81 are also located within these regions85, implying that
HCV cross-neutralization may be achieved through generation of antibodies that
recognize this site. For unclear reasons, no neutralizing antibodies that bind residues of
E2 C-terminal to the igVR have been isolated. The epitopes of two anti-E1 monoclonals
that neutralize HCV have been identified (Fig 2A). The first is located at the nonconserved N-terminus of E1. This epitope is recognized by antibody H-111, which
neutralized HCV pseudoparticles by preventing attachment115. The other spans conserved
residues 313-327 near the C-terminus of E1116. Antibodies that recognize this region are
able to cross-neutralize several HCV genotypes, which warrants consideration of E1 for
future vaccine or therapeutic development.

4.11 Generation and characterization of a panel of anti-E2 antibodies
In order to study the structural basis for antibody neutralization of HCV, I took
part in a collaborative effort that led to production of a large panel anti-E2 monoclonal
antibodies56. I played a significant role in the generation and characterization of these
antibodies, so the associated publication containing detailed methods and my specific
contributions is attached (Appendix 1). However, the neutralization mechanisms defined
in this work guided subsequent experiments in my thesis so they are summarized below.

100	
  

The goal of our work was to generate neutralizing monoclonal antibodies, map
them to specific regions of E2 and correlate structural features with neutralization
mechanism. To initiate this study, I produced sE2 from genotype 1 and 2 for
immunization of mice (Fig 3). I then generated yeast-displayed E2 constructs for
screening of hybridoma supernatants. By this method, we isolated a total of 79
monoclonal antibodies that reacted with E2. I also generated yeast display constructs
expressing E2 from genotypes 1-6 as well as two C-terminal truncations of E2117. The
yeast were utilized to evaluate cross-reactivity and map antibodies to one of three regions
of E2 (Fig 7). Experiments performed by collaborators identified 7 neutralizing
antibodies, mapped them to individual residues of E2 and determined their ability to
inhibit E2 interaction with CD81 and SR-BI.
Our results revealed that the most potent neutralizing antibodies bound region 1 of
E2 and recognized broadly conserved epitopes or HVR1 (Table 1). One antibody,
H77.39, blocked interaction with both CD81 and SR-BI. These findings suggested CD81
and SR-BI could share an overlapping binding site on E2. My subsequent investigation of
this possibility and the role of HVR1 were inspired by these findings and became a major
focus of this thesis (Chapter 4).

4.12 Summary
Despite the identification of a wide array of HCV receptors and entry factors,
many essential structural and biophysical details accompanying these interactions have
not been determined. Therefore, I sought to clarify several aspects of the interplay
between E2, CD81 and SR-BI. I elucidated the stoichiometry of sE2 and CD81-LEL
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alone and in complex. I was able to determine the kinetics and affinity of this interaction
as well as the ability of HVR1 to modulate E2 binding to CD81 and SR-BI. Perhaps most
interestingly, I established that sE2:CD81-LEL complexes are unable able to engage SRBI, suggesting they share a binding site on E2. Future directions will focus on the
crystallization of E2 in hopes of understanding the structural basis for HCV attachment,
entry and fusion.
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Table 1: Summary of neutralizing anti-E2 mAbs. Adapted from ref. 56, Sabo et al.
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Figure 1: The HCV polyprotein. Structural proteins are colored blue in the schematic,
non-structural proteins are colored red. Protease cleavage sites are indicated by arrows
and the host or viral protease that cleaves a given site is listed above each site.
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Figure 2: HCV E1 and E2. A) A schematic of E1 indicating disulfide linkages (green
bars connected by black lines), glycans (black Y-shaped protrusions), conserved
neutralizing epitope (blue, spans 412-424 and 523-550), non-conserved neutralizing
epitope (red) and hydrophobic region (orange with phi). Polyprotein residues
corresponding to the termini, disulfides and N-linked sites are labeled. B) Schematic of
E2 that indicates disulfide linkages (green bars connected by black lines), CD81 binding
regions (magenta bars) and variable regions (light grey). C) Schematic indicating
conserved (blue, spans 412-424 and 523-550) and non-conserved (red, spans 384-410 and
570-580) neutralizing epitopes believed to be within spatial proximity on the E2 surface.
Glycans are shown as black Y-shaped protrusions . Polyprotein residues corresponding to
the N-linked sites, cysteines and termini are displayed in B) and C).
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Figure 3: Purification of soluble E2. The steps of sE2 purification including
transfection, recombinant baculovirus amplification, affinity chromatography and size
exclusion chromatography are described. Each arrow indicates a purification or purity
assessment step. Infected insect cells were tracked and titered by GFP fluorescence given
the transfer vector utilized encoded a GFP on a second promoter. The SEC profile is
displayed in the bottom right corner, and fractions corresponding to the numbering across
the profile were loaded in non-reducing buffer on an SDS-PAGE gel. Disulfide linked
aggregates are found in fractions 1-3 and therefore only the monomeric sE2 found in
peak labeled 4 was collected.
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Figure 4: Conservation of physiochemical properties within HVR1. Several residues
of HVR1 have specific chemical characteristics65, indicated by the coloring above.
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Figure 5: HCV receptors. A cartoon representation of HCV entry, HCV
lipoviroparticles are green with blue spikes. HCV binds attachment factors GAGs, DCSIGN or L-SIGN prior to directly or indirectly interacting with lipoprotein receptors
LDL-R or SR-BI. E2 directly binds to CD81. Tight-junction proteins CLN1/6/9 and
OCLN are required for infection but their exact role is unclear. Upon some combination
of associations with these receptors, the HCV virion is taken into cells by clathrinmediated endocytosis.
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Figure 6: Crystal structure and E2 binding determinants of CD81-LEL. Subunits of
the CD81-LEL dimer are colored magenta and light pink. Helices containing E2 binding
determinants are colored yellow and green respectively. The plasma membrane is
approximately oriented along the plane of the page.

109	
  

Figure 7: Yeast surface display constructs of E2. Yeast displayed E2 is linked at the Nterminus to cell wall protein Aga2, tethering it to the surface. Yeast expressing region I
(E2 residues 384-520), regions I and II (E2 residues 384-605) or regions I-III (E2
residues 384-660) were used to map antibody recognition regions by exclusion. An
example is displayed for antibody H77.28. Dot plots indicate a shift in the yeast
population when an antibody is able to bind; in this case it requires regions I and II. E2
(residues 384-660) from genotypes 1-6 were also successfully displayed.

110	
  

4.13 References
1. Choo, Q.L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, nonB viral hepatitis genome. Science 244, 359-362 (1989).
2. Pybus, O.G. et al. Genetic history of hepatitis C virus in East Asia. J. Virol. 83, 10711082 (2009).
3. Heintges, T. & Wands, J.R. Hepatitis C virus: epidemiology and transmission.
Hepatology 26, 521-526 (1997).
4. Cavalheiro, N. de P. Sexual transmission of hepatitis C. Rev. Inst. Med. Trop. Sao
Paulo 49, 271-277 (2007).
5. Lauer, G.M. & Walker, B.D. Hepatitis C virus infection. N. Engl. J. Med. 345, 41-52
(2001).
6. Hoofnagle, J.H. Course and outcome of hepatitis C. Hepatology 36, S21-29 (2002).
7. Alter, M.J. Epidemiology of hepatitis C. Hepatology 26, 62S-65S (1997).
8.

UNAIDS report for 2003: most deaths and new infections ever; some good news.
AIDS Treat News 3 (2003).

9.

Hepatitis C: global prevalence. Wkly. Epidemiol. Rec. 72, 341-344 (1997).

10. Pellicano, R. et al. The epidemiology of hepatitis C virus infection. An update for
clinicians. Minerva Gastroenterol Dietol 50, 1-7 (2004).
11. Marcellin, P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol. 31 Suppl
1, 9-16 (1999).
12. Ferguson, M.C. Current therapies for chronic hepatitis C. Pharmacotherapy 31, 92111 (2011).

111	
  

13. Soriano, V., Peters, M.G. & Zeuzem, S. New therapies for hepatitis C virus infection.
Clin. Infect. Dis. 48, 313-320 (2009).
14. Manns, M.P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet 358, 958-965 (2001).
15. Kraus, M.R. et al. Compliance with therapy in patients with chronic hepatitis C:
associations with psychiatric symptoms, interpersonal problems, and mode of
acquisition. Dig. Dis. Sci. 46, 2060-2065 (2001).
16. Sherman, K.E. et al. Response-guided telaprevir combination treatment for hepatitis
C virus infection. N. Engl. J. Med. 365, 1014-1024 (2011).
17. Lin, K. Development of novel antiviral therapies for hepatitis C virus. Virologica
Sinica 25, 246-266 (2010).
18. Martell, M. et al. Hepatitis C virus (HCV) circulates as a population of different but
closely related genomes: quasispecies nature of HCV genome distribution. J. Virol.
66, 3225-3229 (1992).
19. Fishman, S.L. & Branch, A.D. The Quasispecies Nature and Biological Implications
of the Hepatitis C Virus. Infect Genet Evol 9, 1158-1167 (2009).
20. Bukh, J., Miller, R.H. & Purcell, R.H. Genetic heterogeneity of hepatitis C virus:
quasispecies and genotypes. Semin. Liver Dis. 15, 41-63 (1995).
21. Frey, S.E. et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with
MF59 administered to healthy adults. Vaccine 28, 6367-6373 (2010).
22. Logvinoff, C. et al. Neutralizing antibody response during acute and chronic hepatitis
C virus infection. Proc. Natl. Acad. Sci. U.S.A. 101, 10149-10154 (2004).

112	
  

23. Choo, Q.L. et al. Vaccination of chimpanzees against infection by the hepatitis C
virus. Proceedings of the National Academy of Sciences 91, 1294 -1298 (1994).
24. Bailly, F., Si, N., Si, A. & Trepo, C. Treatment of HCV liver disease by recombinant
interferon alpha. Nephrol. Dial. Transplant. 11 Suppl 4, 56-57 (1996).
25. Leroux-Roels, G. et al. A candidate vaccine based on the hepatitis C E1 protein:
tolerability and immunogenicity in healthy volunteers. Vaccine 22, 3080-3086
(2004).
26. Alvarez-Lajonchere, L. et al. Immunogenicity of CIGB-230, a therapeutic DNA
vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical
trial. J. Viral Hepat. 16, 156-167 (2009).
27. Drane, D. et al. Priming of CD4+ and CD8+ T cell responses using a HCV core
ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 5, 151157 (2009).
28. El-Gogo, S., Staib, C., Lasarte, J.J., Sutter, G. & Adler, H. Protective vaccination
with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J
Gene Med 10, 177-186 (2008).
29. Jirmo, A.C. et al. Monocytes transduced with lentiviral vectors expressing hepatitis C
virus non-structural proteins and differentiated into dendritic cells stimulate multiantigenic CD8(+) T cell responses. Vaccine 28, 922-933 (2010).
30. Halliday, J., Klenerman, P. & Barnes, E. Vaccination for hepatitis C virus: closing in
on an evasive target. Expert Rev Vaccines 10, 659-672 (2011).
31. Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of
hepatitis C virus genotypes. Hepatology 42, 962-973 (2005).

113	
  

32. Grakoui, A., Wychowski, C., Lin, C., Feinstone, S.M. & Rice, C.M. Expression and
identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67, 13851395 (1993).
33. Lin, W. et al. Hepatitis C virus core protein blocks interferon signaling by interaction
with the STAT1 SH2 domain. J. Virol. 80, 9226-9235 (2006).
34. Voisset, C. & Dubuisson, J. Functional hepatitis C virus envelope glycoproteins. Biol.
Cell 96, 413-420 (2004).
35. Pavlović, D. et al. The hepatitis C virus p7 protein forms an ion channel that is
inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl. Acad. Sci. U.S.A.
100, 6104-6108 (2003).
36. Griffin, S.D.C. et al. The p7 protein of hepatitis C virus forms an ion channel that is
blocked by the antiviral drug, Amantadine. FEBS Lett. 535, 34-38 (2003).
37. Reed, K.E., Grakoui, A. & Rice, C.M. Hepatitis C virus-encoded NS2-3 protease:
cleavage-site mutagenesis and requirements for bimolecular cleavage. J. Virol. 69,
4127-4136 (1995).
38. Kim, D.W., Gwack, Y., Han, J.H. & Choe, J. C-terminal domain of the hepatitis C
virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res.
Commun. 215, 160-166 (1995).
39. Wölk, B. et al. Subcellular localization, stability, and trans-cleavage competence of
the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell
lines. J. Virol. 74, 2293-2304 (2000).

114	
  

40. Egger, D. et al. Expression of hepatitis C virus proteins induces distinct membrane
alterations including a candidate viral replication complex. J. Virol. 76, 5974-5984
(2002).
41. Hügle, T. et al. The hepatitis C virus nonstructural protein 4B is an integral
endoplasmic reticulum membrane protein. Virology 284, 70-81 (2001).
42. Lundin, M., Monné, M., Widell, A., Von Heijne, G. & Persson, M.A.A. Topology of
the membrane-associated hepatitis C virus protein NS4B. J. Virol. 77, 5428-5438
(2003).
43. Pawlotsky, J.M. & Germanidis, G. The non-structural 5A protein of hepatitis C virus.
J. Viral Hepat. 6, 343-356 (1999).
44. Behrens, S.E., Tomei, L. & De Francesco, R. Identification and properties of the
RNA-dependent RNA polymerase of hepatitis C virus. EMBO J. 15, 12-22 (1996).
45. Argentini, C., Genovese, D., Dettori, S. & Rapicetta, M. HCV genetic variability:
from quasispecies evolution to genotype classification. Future Microbiol 4, 359-373
(2009).
46. Backovic, M. & Jardetzky, T.S. Class III viral membrane fusion proteins. Curr. Opin.
Struct. Biol. 19, 189-196 (2009).
47. Brazzoli, M. et al. Folding and dimerization of hepatitis C virus E1 and E2
glycoproteins in stably transfected CHO cells. Virology 332, 438-453 (2005).
48. Michalak, J.P. et al. Characterization of truncated forms of hepatitis C virus
glycoproteins. J. Gen. Virol. 78 ( Pt 9), 2299-2306 (1997).
49. Whidby, J. et al. Blocking Hepatitis C Virus Infection with Recombinant Form of
Envelope Protein 2 Ectodomain. J Virol 83, 11078-11089 (2009).

115	
  

50. Bruni, R. et al. A computational approach identifies two regions of Hepatitis C Virus
E1 protein as interacting domains involved in viral fusion process. BMC Struct Biol
9, 48 (2009).
51. Nakai, K. et al. Oligomerization of hepatitis C virus core protein is crucial for
interaction with the cytoplasmic domain of E1 envelope protein. J. Virol. 80, 1126511273 (2006).
52. Meunier, J.-C. et al. Isolation and characterization of broadly neutralizing human
monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82, 966973 (2008).
53. Mazumdar, B., Banerjee, A., Meyer, K. & Ray, R. Hepatitis C virus E1 envelope
glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.
Hepatology 54, 1149-1156 (2011).
54. Nakajima, H., Cocquerel, L., Kiyokawa, N., Fujimoto, J. & Levy, S. Kinetics of HCV
envelope proteins’ interaction with CD81 large extracellular loop. Biochem. Biophys.
Res. Commun. 328, 1091-1100 (2005).
55. Cormier, E.G. et al. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl.
Acad. Sci. U.S.A. 101, 7270-7274 (2004).
56. Sabo, M.C. et al. Neutralizing monoclonal antibodies against hepatitis C virus E2
protein bind discontinuous epitopes and inhibit infection at a postattachment step. J.
Virol. 85, 7005-7019 (2011).
57. Scarselli, E. et al. The human scavenger receptor class B type I is a novel candidate
receptor for the hepatitis C virus. EMBO J. 21, 5017-5025 (2002).

116	
  

58. Iacob, R.E., Perdivara, I., Przybylski, M. & Tomer, K.B. Mass spectrometric
characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein
reveals extended microheterogeneity of N-glycans. J. Am. Soc. Mass Spectrom. 19,
428-444 (2008).
59. Krey, T. et al. The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal
the Tertiary Organization of the Molecule. PLoS Pathog 6, (2010).
60. Yagnik, A.T. et al. A model for the hepatitis C virus envelope glycoprotein E2.
Proteins 40, 355-366 (2000).
61. Lavillette, D. et al. Characterization of Fusion Determinants Points to the
Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the
Membrane Fusion Process of Hepatitis C Virus. J Virol 81, 8752-8765 (2007).
62. Pileri, P. et al. Binding of hepatitis C virus to CD81. Science 282, 938-941 (1998).
63. Patel, A.H., Wood, J., Penin, F., Dubuisson, J. & McKeating, J.A. Construction and
characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions
critical for glycoprotein aggregation and CD81 binding. J. Gen. Virol. 81, 2873-2883
(2000).
64. Bukh, J., Miller, R.H. & Purcell, R.H. Genetic heterogeneity of hepatitis C virus:
quasispecies and genotypes. Semin. Liver Dis. 15, 41-63 (1995).
65. Penin, F. et al. Conservation of the conformation and positive charges of hepatitis C
virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell
attachment. J. Virol. 75, 5703-5710 (2001).
66. Barth, H. et al. Cellular binding of hepatitis C virus envelope glycoprotein E2
requires cell surface heparan sulfate. J. Biol. Chem. 278, 41003-41012 (2003).

117	
  

67. Basu, A., Beyene, A., Meyer, K. & Ray, R. The hypervariable region 1 of the E2
glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does
not lead to infection in a pseudotype system. J. Virol. 78, 4478-4486 (2004).
68. Kato, N. et al. Humoral immune response to hypervariable region 1 of the putative
envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67, 3923-3930 (1993).
69. Bankwitz, D. et al. Hepatitis C virus hypervariable region 1 modulates receptor
interactions, conceals the CD81 binding site, and protects conserved neutralizing
epitopes. J. Virol. 84, 5751-5763 (2010).
70. Depraetere, S., Depla, E., Verheyden, G. & Bosman, A. HCV E1 comprising specific
disulfide bridges. (2008).at
<http://www.google.com/patents/about/7413741_HCV_E1_comprising_specific_dis
ul.html?id=s8msAAAAEBAJ>
71. Dubuisson, J. et al. Formation and intracellular localization of hepatitis C virus
envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis
viruses. J. Virol. 68, 6147-6160 (1994).
72. Vieyres, G. et al. Characterization of the envelope glycoproteins associated with
infectious hepatitis C virus. J. Virol. 84, 10159-10168 (2010).
73. Fraser, J., Boo, I., Poumbourios, P. & Drummer, H.E. Hepatitis C virus (HCV)
envelope glycoproteins E1 and E2 contain reduced cysteine residues essential for
virus entry. J. Biol. Chem. 286, 31984-31992 (2011).
74. Yu, X. et al. Cryo-electron microscopy and three-dimensional reconstructions of
hepatitis C virus particles. Virology 367, 126-134 (2007).

118	
  

75. Bradley, D. et al. Hepatitis C virus: buoyant density of the factor VIII-derived isolate
in sucrose. J. Med. Virol. 34, 206-208 (1991).
76. Owen, D.M., Huang, H., Ye, J. & Gale, M., Jr Apolipoprotein E on hepatitis C virion
facilitates infection through interaction with low-density lipoprotein receptor.
Virology 394, 99-108 (2009).
77. Voisset, C. et al. High density lipoproteins facilitate hepatitis C virus entry through
the scavenger receptor class B type I. J. Biol. Chem. 280, 7793-7799 (2005).
78. Hishiki, T. et al. Infectivity of hepatitis C virus is influenced by association with
apolipoprotein E isoforms. J. Virol. 84, 12048-12057 (2010).
79. Maillard, P. et al. The interaction of natural hepatitis C virus with human scavenger
receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J. 20,
735-737 (2006).
80. Fornasieri, A. et al. Hepatitis C virus (HCV) in lymphocyte subsets and in B
lymphocytes expressing rheumatoid factor cross-reacting idiotype in type II mixed
cryoglobulinaemia. Clin. Exp. Immunol. 122, 400-403 (2000).
81. Machida, K. et al. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation
reduces the affinity and neutralizing activities of antibodies against HCV envelope
protein. J. Virol. 82, 6711-6720 (2008).
82. Kitadokoro, K. et al. CD81 extracellular domain 3D structure: insight into the
tetraspanin superfamily structural motifs. EMBO J. 20, 12-18 (2001).
83. Higginbottom, A. et al. Identification of amino acid residues in CD81 critical for
interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 74, 3642-3649
(2000).

119	
  

84. Drummer, H.E., Boo, I., Maerz, A.L. & Poumbourios, P. A conserved Gly436-TrpLeu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant
of CD81 binding and viral entry. J. Virol. 80, 7844-7853 (2006).
85. Owsianka, A.M. et al. Identification of conserved residues in the E2 envelope
glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80,
8695-8704 (2006).
86. Sharma, N.R. et al. Hepatitis C virus is primed by CD81 protein for low pHdependent fusion. J. Biol. Chem. 286, 30361-30376 (2011).
87. Hoekstra, M., Berkel, T.J.V. & Eck, M.V. Scavenger receptor BI: A multi-purpose
player in cholesterol and steroid metabolism. World J Gastroenterol 16, 5916-5924
(2010).
88. Li, X., Kan, H.-Y., Lavrentiadou, S., Krieger, M. & Zannis, V. Reconstituted
discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The
amino-terminal 1-165 domain of ApoE suffices for receptor binding. J. Biol. Chem.
277, 21149-21157 (2002).
89. Bartosch, B. et al. An interplay between hypervariable region 1 of the hepatitis C
virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein
promotes both enhancement of infection and protection against neutralizing
antibodies. J. Virol. 79, 8217-8229 (2005).
90. Dreux, M. et al. High density lipoprotein inhibits hepatitis C virus-neutralizing
antibodies by stimulating cell entry via activation of the scavenger receptor BI. J.
Biol. Chem. 281, 18285-18295 (2006).

120	
  

91. Catanese, M.T. et al. Role of scavenger receptor class B type I in hepatitis C virus
entry: kinetics and molecular determinants. J. Virol. 84, 34-43 (2010).
92. Yalaoui, S. et al. Scavenger receptor BI boosts hepatocyte permissiveness to
Plasmodium infection. Cell Host Microbe 4, 283-292 (2008).
93. Evans, M.J. et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step
in entry. Nature 446, 801-805 (2007).
94. Zheng, A. et al. Claudin-6 and claudin-9 function as additional coreceptors for
hepatitis C virus. J. Virol. 81, 12465-12471 (2007).
95. Ploss, A. et al. Human occludin is a hepatitis C virus entry factor required for
infection of mouse cells. Nature 457, 882-886 (2009).
96. Bonander, N. et al. Structural characterization of CD81-Claudin-1 hepatitis C virus
receptor complexes. Biochem. Soc. Trans. 39, 537-540 (2011).
97. Brimacombe, C.L. et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell
transmission. J. Virol. 85, 596-605 (2011).
98. Krieger, S.E. et al. Inhibition of hepatitis C virus infection by anti-claudin-1
antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
Hepatology 51, 1144-1157 (2010).
99. Liu, S. et al. Tight junction proteins claudin-1 and occludin control hepatitis C virus
entry and are downregulated during infection to prevent superinfection. J. Virol. 83,
2011-2014 (2009).
100.

Dorner, M. et al. A genetically humanized mouse model for hepatitis C virus

infection. Nature 474, 208-211 (2011).

121	
  

101.

Monazahian, M. et al. Low density lipoprotein receptor as a candidate receptor

for hepatitis C virus. J. Med. Virol. 57, 223-229 (1999).
102.

Cormier, E.G. et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate

transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 101,
14067-14072 (2004).
103.

Pestka, J.M. et al. Rapid induction of virus-neutralizing antibodies and viral

clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. U.S.A.
104, 6025-6030 (2007).
104.

Dowd, K.A., Netski, D.M., Wang, X.-H., Cox, A.L. & Ray, S.C. Selection

pressure from neutralizing antibodies drives sequence evolution during acute
infection with hepatitis C virus. Gastroenterology 136, 2377-2386 (2009).
105.

Farci, P. et al. The outcome of acute hepatitis C predicted by the evolution of the

viral quasispecies. Science 288, 339-344 (2000).
106.

Kurosaki, M., Enomoto, N., Marumo, F. & Sato, C. Rapid sequence variation of

the hypervariable region of hepatitis C virus during the course of chronic infection.
Hepatology 18, 1293-1299 (1993).
107.

Helle, F. et al. The neutralizing activity of anti-hepatitis C virus antibodies is

modulated by specific glycans on the E2 envelope protein. J. Virol. 81, 8101-8111
(2007).
108.

Valli, M.B. et al. Transmission in vitro of hepatitis C virus from persistently

infected human B-cells to hepatoma cells by cell-to-cell contact. J. Med. Virol. 78,
192-201 (2006).

122	
  

109.

Witteveldt, J. et al. CD81 is dispensable for hepatitis C virus cell-to-cell

transmission in hepatoma cells. J. Gen. Virol. 90, 48-58 (2009).
110.

McCaffrey, K., Boo, I., Poumbourios, P. & Drummer, H.E. Expression and

characterization of a minimal hepatitis C virus glycoprotein E2 core domain that
retains CD81 binding. J. Virol. 81, 9584-9590 (2007).
111.

Law, M. et al. Broadly neutralizing antibodies protect against hepatitis C virus

quasispecies challenge. Nat. Med. 14, 25-27 (2008).
112.

Owsianka, A. et al. Monoclonal antibody AP33 defines a broadly neutralizing

epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79, 11095-11104
(2005).
113.

Owsianka, A.M. et al. Broadly neutralizing human monoclonal antibodies to the

hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89, 653-659 (2008).
114.

Angus, A.G.N. & Patel, A.H. Immunotherapeutic potential of neutralizing

antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future
Microbiol 6, 279-294 (2011).
115.

Keck, Z.-Y. et al. Human monoczlonal antibody to hepatitis C virus E1

glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78, 72577263 (2004).
116.

Meunier, J.-C. et al. Isolation and characterization of broadly neutralizing human

monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82, 966973 (2008).

123	
  

117.

Martinez-Donato, G. et al. Expression and processing of hepatitis C virus

structural proteins in Pichia pastoris yeast. Biochem. Biophys. Res. Commun. 342,
625-631 (2006).

124	
  

Chapter 5:
Hepatitis C E2 interaction with CD81 inhibits binding to
Scavenger Receptor BI and is modulated by genotype and
hypervariable region 1
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5.1 Abstract
Hepatitis C Virus (HCV) infects roughly 3% of the global population and is the
leading cause of liver disease in adults in the United States. Infection of hepatocytes
requires the presence of several candidate cellular receptors, the most thoroughly
characterized of which are scavenger receptor B1 (SR-BI) and tetraspanin CD81. To
elucidate the detailed biochemical roles of these receptors’ interactions with the HCV
envelope protein E2, we first determined that soluble E2 ectodomain (sE2) interacts with
CD81 large extracellular loop (CD81-LEL) with a 2:2 stoichiometry, and that this
interaction inhibits subsequent engagement of SR-BI. Affinity and kinetics of sE2:CD81LEL binding were then measured by surface plasmon resonance. Affinity of sE2 for
CD81-LEL was enhanced by deletion of hypervariable region 1 (HVR1) of E2 and acidic
pH, and modulated by the HCV genotype from which sE2 was produced. Furthermore,
neutralization of HVR1-deleted HCV by a broadly cross-reactive antibody was enhanced
in

a

genotype-specific

manner

that

correlated

with

sE2:CD81-LEL

affinity

measurements. Taken together, our results suggest that E2 alone cannot simultaneously
engage both CD81 and SR-BI, that HVR1 obscures CD81 and antibody binding sites, and
that genotypic variation substantially influences HCV host receptor preference.
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5.3 Introduction
Hepatitis C Virus (HCV) is a blood borne pathogen carried by roughly 3% of the
global population1. Symptoms associated with chronic infection include cirrhosis,
hepatitis and hepatocellular carcinoma. Currently, there is no vaccine for HCV and
treatment is a combination of pegylated interferon-α2,3 and ribavirin4, which results in a
sustained virologic response in only ~45% of cases5. However, this 48-week regimen is
associated with severe side effects, resulting in a large degree of patient non-compliance
and thus premature discontinuation of therapy. Recent clinical trials that incorporated an
inhibitor of HCV protease NS2/3 have reported an increased rate of viral clearance6,7,
suggesting that development of additional antivirals for a cocktail-based approach is a
promising strategy for future therapies.
HCV is a member of Flaviviridae, a family of enveloped viruses with a singlestranded positive-sense RNA genome. The genome encodes for a polyprotein that is
cleaved into 3 structural and 7 non-structural proteins by host and viral proteases8,9. The
core, envelope 1 (E1), and envelope 2 (E2) proteins represent the HCV structural
proteins. Core binds to the RNA genome and is enveloped by a host lipid membrane that
contains transmembrane proteins E1 and E2 to comprise the infectious virion. E2 has
been implicated in receptor interaction and is the primary target for neutralizing
antibodies10–13, while the function of E1 is poorly understood. The oligomeric state and
disulfide organization of E1 and E2 in the mature virion are also unclear. Initial studies
reported a heterodimeric E1-E2 complex,14 while other more recent work suggests a
complex network of monomers and disulfide linked oligomers15. A recombinant, soluble
form of E2 lacking the transmembrane domain and C-terminal stem region (sE2) is
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believed to adopt a fold similar to full-length E2 and has been a valuable tool in
functional and biochemical studies16,17.
Distinct features of the E1 and E2 are able to complicate HCV recognition by the
adaptive immune system. Extensive glycosylation of both envelope proteins is believed
to reduce accessibility of neutralizing epitopes18–20. E1 and E2 possess 4 and 11 N-linked
glycosylation sites respectively and mutation of several N-linked residues has been linked
to increased susceptibility to neutralizing antibodies18,20. Additionally, E2 encodes for 3
regions that exhibit considerable sequence variability. The inter-genotype variable region
(igVR) diverges across each of the 7 or more HCV genotypes21 while hypervariable
regions 1 and 2 (HVR1, HVR2) display variability between isolates and can even
contribute to the emergence of quasispecies within a single host22–25. HVR1 consists of
the N-terminal 27 amino acids of E2 and is a dominant neutralizing epitope22,25,26.
Despite its high mutation rate, certain features of HVR1 including its length and
physiochemical properties are conserved27, suggesting it may retain structural elements or
biological roles important for the viral life cycle. Such roles include mediating viral
attachment via binding to heparin sulfate28,28 and, along with certain E2 glycans19,20,
concealment of conserved receptor and antibody binding sites26,29.
A series of host factors are implicated in HCV infection, the most thoroughly
characterized of which are tetraspanin CD8111,30 and the HDL-binding scavenger receptor
BI (SR-BI)10. Other candidate receptors are tight-junction molecules claudins 1/6/931,32
and occludin33, mannose-binding lectins DC-SIGN and L-SIGN34, LDL-receptor35 and
heparin sulfate28,36. Direct interaction between E2 with CD8126,37 and SR-BI has been
demonstrated in several assays38,39, and antibodies that bind either receptor potently
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inhibit HCV infection40,41. Conserved discontinuous regions and residues of E2 are
involved in CD81 interaction42,43, while the non-conserved HVR1 represents the putative
SR-BI binding site44,45. Understanding of the specific kinetic and functional contributions
of CD81, SR-BI and other receptors in during infection is currently limited. CD81 is
believed to function at a post-attachment step in the entry process46 and primes the virion
for membrane fusion47. SR-BI, on the other hand, is involved in cellular attachment38 and
is able to facilitate HDL mediated enhancement of infection48.
Herein, we have deconvoluted the relationship between E2 and receptors CD81
and SR-BI. Kinetics and affinity between several E2 constructs and CD81 were
determined to evaluate the impact of genotype, pH and hypervariable region 1 on this
interaction. Deletion of HVR1 resulted in genotype specific enhancement of binding to
CD81-LEL, suggesting that the degree by which it obscures this binding site may vary
substantially between isolates. We also experimentally determined the solution
oligomeric state of sE2, CD81-LEL and the sE2:CD81 complex to further elucidate this
crucial stage of HCV infection. Furthermore, CD81-LEL interaction with sE2 prevented
subsequent engagement to SR-BI, suggesting the presence of a shared binding site for
both receptors.
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5.4 Results
Stoichiometry of sE2:CD81 interaction. Direct biochemical interaction between
sE2 to CD81-LEL has been demonstrated in several studies11,37,42,43, yet the solution
oligomeric state of these molecules alone or in complex have not been resolved. We
utilized multi-angle light scattering (MALS) to determine the molecular weight (MW) of
sE2 and CD81-LEL over individual peaks resolved by a size exclusion column. This
direct measurement of MW is advantageous over methods such as dynamic light
scattering or size-exclusion chromatography that determine molecular weight based on
extrapolation from hydrodynamic radius alone. The predicted MW of sE2 in the absence
of glycosylation is 32.1kD (Fig 1A). We determined that MW of sE2 was 36.1kD,
corresponding to that of a monomer (Fig 1B). This larger value was to be expected given
that sE2 has 11 N-linked glycan sites of unknown or heterogeneous composition that
could not be accounted for in the calculation. The predicted MW of the recombinant
CD81-LEL construct is 13.8kD and the experimental value was that of a dimer (28.5kD).
To obtain the stoichiometry of the sE2:CD81-LEL complex, we mixed CD81-LEL with
5-fold molar excess sE2 and then determined the MW of the two resultant peaks
individually. The MW of the first peak to elute from the column was 34.0kD,
corresponding to monomeric sE2, as it was expected to be in excess, and the MW of the
second peak was calculated at 101.8kD (Fig 1C). This value corresponds to a 2:2
interaction and can be explained by addition of the experimental MW of 2 molecules of
sE2 (72.2kD) and one dimer of CD81-LEL (28.5kD) that would yield a predicted
experimental MW of 100.7kD. Also supporting this stoichiometry is the noncrystallographic homodimeric crystal structure of CD81-LEL49. Residues implicated in
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E2 interaction are located on opposite faces of the dimer50 so it is unlikely that a single
E2 protein could encircle the entire CD81 assembly and contact both sides
simultaneously.
Effects of genotype, HVR1 deletion, pH, and enzymatic deglycosylation on
kinetics & affinity of sE2:CD81 interaction. In order to thoroughly establish the
biochemical relationship between E2 and human CD81, we utilized surface plasmon
resonance (SPR) to measure affinity and kinetics of interaction under a variety of
conditions. Elucidation of the stoichiometry of interaction between the two proteins
allowed for proper orientation on the sensor chip. This entailed immobilization of dimeric
CD81-LEL as opposed to monomeric sE2 to avoid avidity effects that artificially inflate
KD values when passing multimeric proteins over an immobilized ligand. The data were
fitted to a 1:1 kinetic model in accordance with our MALS results that suggested each
subunit of the CD81-LEL dimer interacts with one sE2 molecule.
Since it has been proposed that HVR1 obscures the CD81 binding site of E229, we
evaluated binding of both genotype 1 (H77) and genotype 2 (J6) sE2 and ΔHVR1 sE2
constructs over immobilized CD81-LEL (Fig 2A). The KD of interaction for genotype 1
sE2 was 1.01x10-7 M and for genotype 2 was 1.75 x10-6 M (Fig 2B). In this case,
genotypic variation alone was responsible for a 17-fold difference in affinity. Deletion of
HVR1 from genotype 1 sE2 resulted in a 2.2-fold increase in KD while deletion of HVR1
from genotype 2 sE2 yielded a more substantial 8.8-fold enhancement (Fig 2B). This
difference implies that the extent that HVR1 obscures recognition is modulated by viral
genotype. The kinetic basis for this change was an increase in on-rate (ka), supporting the
notion that deletion of HVR1 exposes the CD81 binding site and allows for more rapid
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engagement by E2. Fitting individual curves corresponding to each sE2 concentration
revealed no significant increase or decrease in kd (data not shown), indicating that while
CD81-LEL has two sE2 binding sites there was no evidence for cooperativity.
Binding experiments were performed as a function of pH in an attempt to observe
affinity changes that may result as HCV passes through the endosome during its life
cycle. At pH 6.4 (early endosome) the KD of genotype 1 sE2 for CD81-LEL increased by
2.9-fold relative to pH 7.4 (Fig 2B). The relative affinity increased further at pH 5.4 (late
endosome) to 4.4-fold (Fig 2B). At pH 5.4, the enhancement in KD resulted from an
increase in on-rate but also was accompanied by a more rapid off-rate and therefore a
decrease in half-life. The biological relevance of this more rapid dissociation could be
attributed to the consideration that HCV virions likely require disengagement from CD81
prior to initiating fusion events with the host membrane.
Enzymatically deglycosylated sE2 was also evaluated for kinetics and affinity of
interaction with CD81-LEL relative to untreated sE2. A series of three enzymes, Endo
F1/F3 and PngaseF were used to deglycosylate native sE2. First, sE2 was treated with
Endo F1/F3, then buffer exchanged into optimal conditions for PngaseF treatment prior
to addition of this third enzyme. The untreated sE2 construct has a predicted MW of
~31kD but runs as a diffuse band at ~54kD on a 4-12% SDS gel due to the extensive
glycosylation (Fig 2C). Upon treatment with these enzymes, sE2 runs at ~38kD,
indicating a reduction of approximately 60% (16kD) of the glycosylation MW (Fig 2C).
To control for possible effects of the pH 5.5 buffer required for Endo F1/F3 cleavage,
sE2 used for comparison in kinetics and affinity measurements was treated with the
equivalent buffers in the absence of EndoF1/F3/PngaseF. Removal of these glycans only
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had a small effect on kinetics of affinity of CD81 interaction, increasing 2.3-fold relative
to the sE2 incubated with buffer alone.
Enhancement of HCVcc neutralization by a cross-reactive mAb upon HVR1
deletion. HCV-neutralizing antibodies are significantly less potent relative to those that
neutralize other members of Flaviviridae39,51–53. This disparity is potentially due to
concealment of neutralizing epitopes by the variable regions and glycans of E2. We have
demonstrated that deletion of HVR1 from sE2 resulted in an enhancement of affinity for
receptor CD81 that was modulated by the genotype from which it was produced. These
results led us to conclude that HVR1 obscures the CD81 binding site and neutralizing
epitopes to different degrees based on properties of the isolate it originated from. To
evaluate the extent in which HVR1 contributes to this inhibition in the context of the
HCV virion, we performed neutralization assays using a broadly cross-neutralizing
antibody H77.39 on both genotype 1 and 2 HCVcc +/- HVR1. This antibody recognizes a
conserved region of E2 and inhibits CD81 and SR-BI binding. The antibody was more
potent in both HVR1 deletion viruses, with EC50 increases of 55-fold for the genotype 1
virus and 253-fold for the genotype 2 virus (Fig 3). This greater enhancement of
neutralization potential for HVR1 deleted genotype 2 HCV relative to genotype 1
correlates with the increase in affinity displayed by genotype 2 ΔHVR1 sE2 binding to
CD81-LEL relative to genotype 1. The fold-change in KD is substantially lower than that
of the EC50 value, but this is expected given there are many copies of E2 per virion and
HVR1 could contribute to lateral quaternary interactions with these additional E2
molecules.
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CD81-LEL inhibition of sE2:SR-BI interaction. We have previously
demonstrated that certain HCV-neutralizing antibodies inhibit sE2 interaction with both
CD81 and SR-BI39. We therefore hypothesized that these receptors may share an
overlapping binding site. To evaluate whether sE2 is able to bind SR-BI and CD81
simultaneously, we incubated sE2 with various concentrations of CD81-LEL and
observed the effect on interaction with CHO cell-expressed SR-BI. Indeed, equimolar or
greater concentrations of CD81-LEL potently inhibited subsequent engagement with SRBI. Bound sE2 was detected by flow cytometry with a fluorescently labeled secondary
antibody specific to a C-terminal 6x His tag and should not interfere with CD81 or SRB1 binding (Fig 4A-B). To control for the possibility that sE2 binding to both receptors
simply caused steric inhibition of the secondary antibody, we stained sE2 to CHO cells in
the presence or absence of excess CD81-LEL, washed away excess protein, lysed the
cells and then performed a western blot to detect the bound sE2. In this experiment, the
proteins are denatured and separated following staining of the cells and unbound sE2 was
detected with a non-conformational antibody, eliminating the possibility that recognition
by the secondary antibody was impeded by the dual engagement of both receptors (Fig
4C). Staining of wild-type CHO cells with sE2+/- CD81-LEL resulted in a small
background E2 band, but sE2 staining of SR-BI expressing CHO cells was reduced in the
presence of CD81-LEL. Our results reinforced the original flow cytometry data and
support the conclusion that a single E2 molecule does not efficiently bind SR-BI while in
complex with CD81.
Neutralizing antibodies J6.36 and J6.103 bind the C-terminus of HVR1.
Previous reports indicate that antibodies that bind the C-terminus of HVR1 are able to
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neutralize HCVpp26,54. While the detailed mechanism for their neutralization is unclear, it
has been reported that they are able to prevent attachment to multiple hepatocyte cell
lines55. We previously characterized antibodies J6.36 and J6.103 for genotype crossreactivity, epitope recognition and inhibition of sE2 interaction with receptors CD81 and
SR-BI39. Each was specific for genotype 2 (J6) E2 and lost binding upon mutation of
residues G397+R572, F403 and G406. Neither mAb cross-reacted with other HCV
genotypes and two of four residues bound lie within HVR1; thus, we anticipated that
their dominant epitope would lie within this region. We evaluated J6.36 and J6.103 for
binding to GST-fusion constructs that spanned the full HVR1 (residues 385-410 of the E2
polyprotein) as well as truncations consisting of residues 385-397, 391-403 and 398-410.
Indeed, both reacted with full length HVR1. Neither bound the N-terminal residues 385397. J6.103 recognized the C-terminal 398-410 segment and central 391-403 peptides
with comparable signal as the full length HVR1. J6.36, on the other hand, gave a robust
signal for the C-terminal 398-410 peptide but yielded a much lower signal for 391-403
(Fig 5).
Deletion of HVR1 ablates sE2 binding to CHO cell expressed SR-BI but not
CD81. Several studies have demonstrated that HVR1 interacts with SR-BI10,45,56. In order
to evaluate whether our ∆HVR1 sE2 was properly folded, CHO cells expressing human
SR-BI or CD81 with E2 from two different genotypes +/- HVR1 (Fig 6). Indeed,
deletion of HVR1 from both H77 and J6 sE2 reduced binding to SR-BI dramatically.
However, we did not observe an increase in binding of ∆HVR1 sE2 to CD81 as was
detected in our SPR experiments. This may be explained by the fact that the enhanced
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affinity of ∆HVR1 sE2 for CD81-LEL was primarily due to an increase in on-rate, while
increased cell staining is attributed to half-life, which is linked to the kinetic off-rate.

5.5 Discussion
In our study, we ascertained the binding stoichiometry, kinetics and affinity of the
soluble E2 ectodomain for the CD81 large extracellular loop. By utilizing a variety of
modified sE2 constructs and solution conditions, we determined that genotype and
deletion of HVR1 had the most substantial effects on E2:CD81 affinity, and that acidic
pH and the enzymatic removal of sE2 glycans played a more modest role. In vitro
experiments with HVR1 deletion viruses resulted in a dramatic increase in the
neutralization potency of a broadly cross-reactive antibody that blocks E2:CD81
interaction, supporting our biochemical results that indicated HVR1 obscures the CD81
binding site. Deletion of HVR1 from also resulted in ablation of sE2 binding to SR-BI.
Additionally, we observed that binding of sE2 to recombinant CD81-LEL potently
inhibits subsequent engagement of SR-BI expressed on the surface of CHO cells,
suggesting the binding site for these receptors may overlap on the E2 protein.
An essential step in HCV infection is direct binding of E2 to receptor CD81.
Several protein determinants that contribute to this interaction have been identified, but
the oligomeric state of the CD81:E2 complex has not been resolved. Using multi-angle
light scattering we were able to determine that sE2 and CD81-LEL interact as a 2:2
complex. A CD81 residue, F185, is critical to E2 interaction50 and maps to opposite ends
of the LEL homodimer49. Two E2 monomers would be able to engage this residue with
little possibility for steric inhibition, and so its location on the CD81-LEL crystal
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structure is supportive of our stoichiometric data. Analysis of the sE2: CD81-LEL
affinity measurements did not indicate cooperative binding, so it is yet to be determined
whether HCV infection requires or is enhanced through bivalent CD81 interaction with
E2. Arenavirus GP1 represents an example of a viral surface protein that recognizes
opposing ends of a dimeric receptor (transferring receptor 1) with 2:2 stoichiometry57 but
kinetic information that would allow for biophysical comparisons of these interactions
has not been determined.
A suggested role for HVR1 is the concealment of the conserved CD81 binding
site of E224,26. However, the specific role of HVR1 in the energetics accompanying the
E2:CD81 interaction remains unclear. Elucidation of the solution oligomeric states of sE2
and CD81-LEL allowed us to properly orient them in SPR experiments in order to
accurately determine their single-site KD. The KD for sE2 from H77 and J6 strains were
101nM and 1750nM respectively. These values fall within the range observed for
envelope protein-receptor interactions from unrelated viruses such as HIV58 and
Measles59. Deletion of HVR1 from sE2 constructs enhanced this affinity, confirming that
the region indeed obscures the CD81 binding site. However, this increase varied
substantially between the H77 (~2-fold increase) and J6 (~9-fold increase) strains
indicating both wild-type affinity for CD81 and the extent to which HVR1 affects this
interaction are genotype-specific. A more pronounced effect was observed in the
neutralization of HVR1-deleted HCV by H77.39, an antibody that blocks CD81-E2
interaction. The EC50 of H77.39 was increased 55-fold and 253-fold for H77 and J6
respectively, suggesting that HVR1 concealment is genotype-specific in HCV virions as
well. This large increase in neutralization potential of H77.39 relative to minor increases
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in sE2:CD81-LEL affinity may be due to amplification resulting from the absence of
several HVR1 peptides or stabilizing effects exerted by HVR1 in the quaternary structure
of the virion.
Both CD81 and SR-BI bind directly to E2 and are necessary for productive HCV
infection10,11. Given this requirement, our finding that sE2 engagement of CD81-LEL
precludes SR-BI binding gives rise to multiple possible models for utilization of these
two receptors. One model would suggest that the virion interacts with both receptors
through coordination of two separate E2 proteins, each of which binds only one receptor.
While this mode of synchronized interaction of viral envelope proteins has not (to our
knowledge) been previously reported, there is no obvious physical limitation that
excludes this option. Alternatively, HCV may require a viral or host co-factor that
mediates interaction of a single E2 protein with CD81 and SR-BI. E1 might fill this role,
however no soluble, properly folded E1 construct has been reported and previous studies
with E1-E2 captured from lysates did not observe a substantial increase in CD81-LEL
binding relative to E2 alone37. Other candidates include host lipoproteins apolipoprotein
E (ApoE), low-density or high-density lipoprotein (LDL or HDL). Infectious HCV may
be found as lipoviroparticles associated with ApoE60 and LDL61, and HCV infectivity is
enhanced in the presence of HDL48. Another feasible scenario is that the acidic pH of the
endosome or receptor-binding triggers a conformational change that enables one E2
protein to interact with CD81 and SR-BI. Several viral envelope proteins are primed in
this fashion, but this mechanism is most notably exemplified by the interaction of HIV
gp120 with host receptor CD4. Attachment of gp120 to CD4 alters the structure of gp120
and potentiates subsequent binding to host chemokine receptors58,62–64. Our affinity
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measurements indicated mild enhancement of sE2:CD81-LEL affinity at low pH so these
molecules do not likely disengage in the endosome. It is possible that E2 releases from
SR-BI at acidic pH but we have not been able to test this due to the lack of a soluble form
of the receptor.
Several determinants of CD81 and SR-BI interaction with E2 have been
identified. Known CD81 binding regions are discontinuous and include residues W420,
Y527, W529, G530, D53542 and a hydrophobic peptide spanning G436-Y44343. Prior
studies, as well as results of our staining SR-BI expressing cells with ∆HVR1 sE2
indicate that HVR1 is necessary for E2 to engage SR-BI. However, pre-incubation of sE2
with CD81-LEL potently inhibited SR-BI interaction, suggesting these two receptors may
partially share a binding site on E2. Indirect evidence for the location of this shared site
may be garnered from the epitope mapping of antibody H77.39 that inhibits E2 binding
to both receptors. This antibody mapped to residues N415 and N417, which lie directly
between the C-terminus of HVR1 (polyprotein residue 410) and CD81 binding residue
W420. Based on the location of the H77.39 epitope, we speculate that the conserved
region of E2 C-terminal to HVR1 may comprise a portion of this overlapping site.
Alanine scanning reports have established that mutation of N41542 or N41719 did not
substantially reduce E2:CD81 binding, but W420 or the 436-433 peptide represent other
candidate residues in this region.
As ongoing studies illuminate the antibody evasion strategies employed by HCV
envelope proteins, it is important to note the many parallels that have emerged to those
utilized by HIV. Unlike large, chronic DNA viruses such as Herpes Simplex Virus-1 that
encode for an array of immunomodulatory proteins, HCV and HIV are small RNA
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viruses with limited genomic space reserved for this purpose. Common features include
modulation of affinity for host receptors through sequence variation58,62,65 and shielding
of important envelope protein interfaces from antibody recognition with variable loops or
glycans20,29,66–68. HIV gp120 can utilize CD4 or either of chemokine receptors
CXCR4/CCR5 for infection58,62. While gp120 from most HIV strains binds CD4,
mutations in the V3 loop have allowed monospecific variants to utilize just a single
chemokine receptor69,70. HCV is believed to require both SR-BI and CD81, but our
results indicate that affinity of the E2-CD81 interaction can differ by at least 17-fold
across genotypes. This divergence may represent an evolutionary response to immune
pressure or a strain-specific fluctuation in HCV preference for receptors akin to what has
been described for HIV. Given the limited number of HCV strains amenable to cellculture production, it is entirely possible that undiscovered strains have distinct receptor
requirements. The HCV HVR1 and HIV V3 variable regions can also bind with heparin
sulfate to augment cellular attachment28,36,71,72 and are targeted by neutralizing
antibodies26,54,65,72. By utilizing variable regions for important functional roles, these
viruses can retain structural integrity while evading antibody recognition.
In conclusion, we have resolved several previously unknown biochemical and
molecular details of the interplay between E2, CD81 and SR-BI. Delineation of the 2:2
binding stoichiometry of the E2:CD81 complex has clarified an important aspect of HCV
attachment and entry. Furthermore, we have resolved the kinetics and affinity of this
interaction and established that concealment of receptor- and antibody-binding sites by
HVR1 is genotype dependent. We have also determined that sE2 engagement of CD81LEL prevents subsequent interaction with SR-BI, suggesting that these receptors share an
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E2 binding site. Alternately, HCV may sequentially engage its receptors in stages as it
becomes internalized. If HCV E2 indeed possesses an overlapping binding site for these
receptors, it presents an intriguing target for inhibitor, therapeutic antibody or vaccine
development. Taken together, our findings raise the question of whether HCV, like HIV,
has strain-specific preferences for receptor interaction. Given the limited number of HCV
isolates that replicate in cell culture, it is possible that undiscovered strains do not require
all of the established receptors. As structural information emerges on the HCV envelope
proteins, it is expected that many of these questions will be resolved and stimulate the
development of novel therapeutics.

5.6 Materials and methods
Cloning expression and purification of sE2 and Δ HVR1 sE2. Residues 384-661
of genotype 1 (H77) or residues 385-661 of genotype 2 (J6) E2 ectodomain with an Nterminal honeybee melittin signal sequence were cloned into the baculovirus transfer
vector pAcUW51. Since the yield of H77 sE2 was initially poor for this construct, a
mutation of unpaired cysteine C652 to serine was introduced to increase secretion from
insect cells (REF). HVR1 deletion constructs (ΔHVR1 sE2) spanning these same regions
of the H77 and J6 isolates but lacking residues 387-410 (H77) or 388-410 (J6) were also
generated. Residues 384-386 and 385-387 of these constructs were retained to allow for
proper cleavage of the signal peptide by signal peptidase. The E2 encoding transfer
vectors were co-transfected into SF9 cells grown in Sf-900 II media (Invitrogen) with the
Flashbac Gold bacmid (Oxford Expression Technologies) to permit homologous
recombination for production of recombinant baculoviruses. The virus was then
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amplified by passaging the supernatant at ratios of 1:10 into fresh SF9 cultures until titer
was sufficient for large-scale expression. 5 liters of Hi-five cells grown in Express Five
(Invitrogen) media were infected with recombinant virus to drive expression of secreted
sE2. The supernatants from the large-scale infections were then filtered with a 0.2µm
cutoff bottle-top filter, concentrated and buffer exchanged into nickel binding buffer
(300mM sodium citrate, 150mM NaCl and 50mM NaPO4 pH 8.0) using a Centramate
tangential flow concentrator with 30kD cutoff membrane. The supernatants were finally
purified by nickel and size-exclusion chromatography.
Cloning expression and purification of CD81-LEL. Residues 114-203 of human
CD81 were cloned from a cDNA into a Pet28a(+) vector modified with a thrombin
cleavable C-terminal BirA biotinylation sequence and 6x His tag. This bacterial
expression vector was transformed into BL21-DE3 (RIL) cells (Stratagene), grown in a
large-scale 6L culture of luria broth (LB) supplemented with 50mg/L kanamycin and
induced at an optical density 400nm of 0.8 with 1mM isopropyl β-D-1thiogalactopyranoside (IPTG). After 4 hours of induction the cells were centrifuged and
pellets suspended in solution buffer (50mM Tris pH 8.0, 25% sucrose, 10mM DTT).
Next, an equal amount of lysis buffer (50mM Tris pH 8.0, 1% TritonX-100, 100mM
NaCl, 10mM DTT) was added. The lysate was supplemented with 0.8mg/mL lysozyme
and sonicated to disrupt cell membranes.

The lysate was then centrifuged; the

supernatant was discarded and the inclusion body pellet was washed 3x with wash buffer
(50mM Tris pH 8.0, 0.5% TritonX-100, 100mM NaCl, 1mM DTT) and once in wash
buffer without TritonX-100. Purified inclusion bodies were solubilized in 6M guanidineHCl, 10mM Tris pH 8.0 and 20mM β-mercaptoethanol. Aliquots of this solution were
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diluted in oxidative refolding buffer containing 400mM L-arginine, 100mM Tris pH 8.0,
0.5mM oxidized glutathione and 5mM reduced glutathione for overnight refolding. The
refolded protein was concentrated using an Amicon 400 concentrator with 10kD cutoff
membrane and purified on a S200 size exclusion column.
Enzymatic deglycosylation of sE2. 1mg of H77 sE2 was buffer exchanged into
Endo F digestion buffer (0.1M acetate pH 5.5) and protease inhibitor cocktail (Sigma)
was added to a final concentration of 1x in a total volume of 100µL. 1 unit of Endo F1
and Endo F3 (Sigma) were each added to the digestion, which was allowed to proceed for
6 hours at room temperature. Next, 20uL of 1M Tris-HCl pH 8.0 was added to the
reaction along with 2500 units of Pngase F and incubated at room temperature overnight.
sE2 was subsequently purified by nickel chromatography to remove the glycosidases.
Cloning expression and purification of GST-HVR1 fusion proteins. HVR1
peptides spanning residues 385-410, 385-397, 391-403 and 398-410 of the J6 isolate were
cloned into the PGEX-4T-1 vector which encodes for an N-terminal GST tag. DNA
inserts were generated by ordering complementary, overalapping primers (IDT) with
BamHI and XhoI sites encoded at the 5’ and 3’ ends (relative to the coding region of the
sequence) respectively. Double-stranded inserts were generated by boiling equimolar
concentrations of each primer mixed together and letting the solution cool to room
temperature. PGEX-4T-1 was cleaved at BamHI and XhoI, restriction sites allowing for
in frame cloning of the HVR1 inserts, gel purified and ligated with the various HVR1
constructs.
GST-HVR1 peptides were expressed as soluble fusion proteins in 1L cultures of
BL21 DE3 (RIL) cells (Stratagene) by inducton with 1mM IPTG upon reaching an OD of
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1.0. Expression was allowed to proceed for 4 hours after induction, after which cells were
lysed in B-PER lysis buffer (Pierce), clarified by centrifugation at 10,000g for 30 minutes
and purified by affinity chromatography with glutathione linked agarose.
Multi-angle light scattering. CD81-LEL or sE2 protein (200µg) was individually
injected onto an HPLC and flowed over a sizing column while multiple parameters were
measured. The light scattering, refractive index change and UV absorbance were
observed over the elution profile via the Dawn Helios II multi-angle light scattering
detector (Wyatt), Optilab rEX (Wyatt) differential refractive index detector and
photodiode array detector 996 (Waters) respectively. These data were analyzed with
Astra V macromolecular characterization software (Wyatt) to calculate the molecular
weight (MW) of each protein from the light scattering and refractive index change. In
order to determine the MW of the sE2:CD81-LEL complex, 100µg CD81-LEL was
mixed with 500µg of sE2 and each of the two resultant peaks in the elution profile
(representative of excess sE2 and complex) was processed as described above.
Surface plasmon resonance. CD81-LEL was coupled to a CM5 sensor chip using
standard amine chemistry to a level of 200 response units (RU). Various concentrations
of sE2 +/- HVR1 from genotypes 1 and 2 were passed over the chip at 60µL/min until
reaching equilibrium. This required 240 seconds for genotype 1 and 60 seconds for
genotype 2. All curves were reference subtracted from a control flow cell containing 200
RU of amine coupled murine anti-Kb antibody to account for non-specific interaction.
The chip was regenerated with 0.1M glycine pH 2.7 after sE2 binding to remove any
protein that remained bound. This regeneration condition did not result in any observable
loss of subsequent binding during the runs. Binding experiments were performed on a
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Biacore T-100 instrument in HBS-EP buffer pH 7.4 (10mM Hepes, 150mM NaCl, 3mM
EDTA, 0.005% Tween-20). When varying pH conditions to measure its effects on
kinetics of genotype 1 sE2:CD81-LEL interaction, HBS-EP was adjusted to pH 6.4 or 5.4
with 1N hydrochloric acid. For each experiment, a minimum of 5 curves were fitted to a
1:1 kinetic binding model in order to determine ka, kd and KD using the Biacore T-100
evaluation software.
Neutralization of HCVcc and Δ HVR1 HCVcc. Neutralization of chimeric
viruses +/- HVR1 with genotype 1a(H77)-2a(J6) specific core-NS2 sequences was
assessed by focus forming unit assay: 50 to 400 TCID50 of HCV were incubated 1 h at
37°C with MAb H77.39 or an isotype control and then incubated with cells for 3 h. After
48 h cells were immunostained for NS5A as previously described [54]. FFU counting
was automated using ImmunoSpot Series 5 UV Analyzer [58]. Percent neutralization was
calculated by relating FFU counts to mean of six-replicates incubated in the absence of
antibody (virus only). Neutralization data were analyzed as variable slope dose-response
curves using GraphPad Prism 4.0 and IC50-values were interpolated by the software.
ELISA for detection of antibody binding to HVR1. 200ng of each GST-HVR1
fusion protein were diluted into 100µL of coating buffer (0.5 M carbonate bicarbonate
buffer, pH 9.6), loaded into a 96-well Maxisorp plate (Nunc) and allowed to incubate
overnight at 4°C. Wells were washed 3x with PBS + 0.05% Tween and blocked for 1
hour at 37°C with PBS + 1% BSA, then washed 3x again. Wells containing a GST-HVR1
protein or BSA alone were then incubated with 500ng of either J36 or J103 antibody in
100µL PBS + 1% BSA for 30 minutes at 4°C. Wells were next washed 3x and treated
with a peroxidase conjugated anti-mouse Fc polyclonal antibody for 30 minutes at 4°C
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for secondary detection. Finally, wells were washed 3x to remove excess secondary
antibody and developed with 150µL of 3, 3′ ,5 ,5′-Tetramethylbenzidine (TMB) substrate
for 5 minutes at room temperature. This experiment was performed in duplicate three
independent days and a representative experiment was reported.
E2 binding to receptor-expressing CHO cells. To assess whether CD81-LEL
could inhibit binding of sE2 to SR-BI, CHO cells expressing SR-BI were detached with
PBS supplemented with 4 mM EDTA and 10% FBS and washed three times in medium.
Cells (105) were pelleted in a V-bottom plate and incubated with 0.5µM of genotype 1
(H77) sE2 pre-mixed with varying concentrations of CD81-LEL (0-16 µM). Cells were
washed, incubated with an Alexa Fluor 647-labeled penta-His antibody (Qiagen) for 20
min on ice, washed again, and binding analyzed on a FACSArray flow cytometer
(Becton-Dickinson) using FloJo software (Tree Star). Binding of 1µM sE2 and ΔHVR1
sE2 was detected using the same staining protocol in the absence of CD81-LEL.
Statistical analysis. All data were analyzed using Graphpad Prism software
(version 4.0) .
Western blot for detection of E2 binding to SRB1 expressing CHO cells. 105
wild type CHO cells as well as those expressing human CD81, SR-BI or no recombinant
receptor were stained with 4µM H77 sE2 alone or pre-mixed with 32 µM human CD81LEL in PBS+1% BSA. Cells were washed three times with PBS, resuspended in 50µL
PBS+1% Tween-20 and 50µL SDS loading buffer + 10mM 2-mercaptoethanol and lysed
by sonication. 30µL samples were loaded onto a 4-15% precast polyacrylamide gel
(Biorad) and then transferred to a PVDF membrane using the iBlot system (Invitrogen).
The membrane was blocked with PBS+0.1% Tween-20 containing 5% non-fat dry milk
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(Biorad) for 30 minutes and then non-conformational murine anti-E2 antibody H77.36
was added to a concentration of 10µg/mL and incubated for 30 minutes. The membrane
was then washed three times in PBS+0.1% Tween-20 and stained with goat anti-mouse
Fc peroxidase-conjugated secondary antibody (Sigma) for 30 minutes at a 1:25,000
dilution. The blot was again washed 3 times, dried and samples were detected using the
ECL western blotting detection reagent (GE Healthcare) after a 30 second exposure on
CL-Xposure film (Pierce).
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Figure 1: Oligomeric state of sE2 and CD81-LEL alone and in complex. Solution
molecular weight of CD81-LEL (A), sE2 (B) and the two proteins in complex (C) were
determined by multi-angle light scattering over their elution profiles from a sizeexclusion column. In panel “C”, each peak was evaluated independently. The molecular
weight of peak 1 corresponded to a 2:2 CD81-LEL:sE2 complex and peak 2 is
corresponded to sE2, which was in excess. The black trace represents UV absorbance, red
and blue represent the molar mass and fitted molar mass across the peaks.
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A

B

Figure 2: Affinity and kinetics of sE2:CD81-LEL interaction. A) Selected sensograms
are displayed, red curves are the raw data and the black curves are 1:1 kinetic fits. CD81LEL was immobilized on a sensor chip and H77 or J6 sE2 +/- HVR1 was flowed over the
surface to evaluate kinetics and affinity. H77 sE2 was also tested at pH 6.4 and 5.4, and
after deglycosylation. The row designated H77 E2 (deglyc ctrl) contains the parameters
for sE2 exposed to the equivalent buffers conditions as the enzymatically treated protein.
B) SDS-page gel analysis of untreated sE2 or sE2 treated by EndoF3 alone, Endo F1 and
F3, or Endo F1, F3 and PngaseF.
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Figure 3: Neutralization of J6 and H77 HCVcc +/- HVR1 by a broadly crossreactive antibody. Broadly cross-reactive antibody H77.39 blocks sE2 interaction with
CD81 and was tested for neutralization of H77 and J6 virus +/- HVR1. Bracketed values
to the right of the chart of EC50 values represent increase fold-increase over the
neutralization of ΔHVR1 virus over wild-type virus.
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B

C

Figure 4: Soluble CD81-LEL inhibits sE2 engagement of SR-BI. A) Inhibition of sE2
binding to CHO cells expressing SR-BI was tested by staining in the presence of various
concentrations of CD81-LEL and detecting by flow cytometry. B) Data from (A) is
expressed as percent inhibition of sE2 binding to SR-BI expressing cells v. concentration
of CD81-LEL. C) Western blot of lysates from WT CHO cells or CHO cells expressing
CD81 or SR-BI stained with sE2 or sE2 + CD81-LEL (designated by +LEL). Bound sE2
was detected with non-conformational anti-E2 antibody H77.36.
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Figure 5: Neutralizing antibody recognition of HVR1. HVR1 or truncations of HVR1
were fused to GST was detected by monoclonal antibodies J6.36 or J6.103. BSA alone
served as a negative control.
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Figure 6: Binding of sE2 and ∆HVR1 sE2 to CD81 and SR-BI. CHO cells expressing
SR-BI or CD81 were stained with sE2 or ΔHVR1 sE2 from H77 or J6 strains. Bound sE2
was detected with an anti-6x His antibody.
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Chapter 6:
Conclusions and future directions
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6.1 Abstract
The focus of this thesis was the establishment of a structural basis for antibody
and receptor interactions with Flaviviridae Japanese Encephalitis Virus and Hepatitis C
Virus. To this end, I determined the high-resolution dimeric crystal structure of JEV E,
which provided insight into the mechanisms of serocomplex-specific pathogenesis in
flaviviruses. Additionally, I was able to resolve several biochemical features of the
interplay between HCV envelope protein E2, antibodies and host receptors CD81 and
SR-BI. Studies of these interactions indicated that E2 cannot simultaneously engage both
receptors and that sequence diversity within E2 may contribute to receptor preference.
Future studies will focus on identification of specific residues involved in the putative
shared CD81/SR-BI binding site on E2 and determination of the kinetics and affinity of
E2 interaction and membrane-bound receptors. I speculate that crystallization of E2 will
require generation of new constructs that more closely resemble its conformation in the
native virion. Finally, I have discussed the need for new therapeutics and reviewed
antivirals that have been garnered from advances in the understanding of virus structure
and entry.
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6.2 Conclusions and summary: JEV E structure
JEV is an important human pathogen and the leading global cause of viral
encephalitis. Cross-neutralization tests have allowed for classification of flaviviruses into
serocomplexes1 with specific tropisms and pathogeneses. Our results have illuminated
structural and biophysical features of flavivirus E proteins that may contribute to
serocomplex-specific pathogenesis. The high-resolution crystal structure of JEV E
revealed a dimer interface that is remarkably small relative to those of other known
dimeric E structures. This interface had only ~50% of the buried surface area found
between other E homodimers. JEV E lacks many of the contacts found at the central DIIDII dimerization region of other E structures. The surface area it does bury is almost
exclusively within the DI-DIII pocket that houses the fusion-loop, highlighting the
evolutionary requirement to shield this peptide from prematurely inducing fusion.
Given the sparse JEV E dimer interface and monomeric crystal structure of WNV
E2,3, we hypothesized that reduced dimerization propensity may be serocomplex-specific.
Indeed, we found that JEV E, WNV E and SLEV E were predominantly monomeric in
solution while DV2 E was dimeric. We resolved the oligomeric states of these proteins
by multi-angle light scattering, which allows for direct experimental determination of
molecular weight. Utilization of this technique was of particular importance since
oligomeric state determination by techniques such as SEC and crystallography has
yielded inaccurate results for E proteins. Our own JEV E crystallized as a dimer but
favored monomers in solution, and extrapolations based on molecular weight standards
using SEC have been unreliable3.
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Quaternary interactions between E proteins on the surface of virions can influence
binding of antibodies and cellular receptors. The epitope of WNV-neutralizing antibody
CR4354 is found across two adjacent E proteins, indicating that the specific assembly of
E on the virion can contribute to immune recognition4. DIII is believed to play a role in
flavivirus attachment and entry5,6 and packs in 3 distinct chemical environments on the
mature virion7. However, anti-DIII antibody E16 binds only 2 of these 3 environments
but allows for virion attachment and entry8,9. This implies that only a pentameric
arrangement of DIII at the 5-fold axis is required for receptor interaction at the cell
surface.
It has become increasingly clear that E protein organization plays a significant
role in host recognition of flaviviruses. Our findings therefore implicate the assembly and
dimerization affinity of E proteins in serocomplex-specific pathogenesis.

6.3 Conclusions and summary: HCV receptor interaction
Extensive characterization of a large panel of anti-E2 antibodies has provided
insight towards mechanisms of effective neutralization of HCV. The most potent
neutralizing antibodies bound the N-terminal region I of E2, could be cross-reactive or
strain-specific and were able to inhibit interaction with CD81, SR-BI or both10. These
findings led us to further investigate the specific molecular determinants responsible for
E2 interaction with these two receptors.
Since our H77.39 antibody was able to strongly inhibit sE2 binding to both CD81
and SR-BI, we wanted to investigate whether these receptors may share a binding site on
E2. We pre-bound sE2 to CD81-LEL and were indeed able to block subsequent binding
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to SR-BI. Currently we are only able to speculate as to where on E2 the binding sites of
SR-BI and CD81 may overlap. Our own work and that of several others have identified
HVR1 (E2 residues 384-410) as a requirement for SR-BI interaction11,12. Residues W420
and 529-535 are required for E2:CD81 interaction13, so reasonable prediction is that the
W420 or other conserved residues in close proximity to HVR1 may comprise the shared
site. Another possibility is that an event accompanying HCV entry, such as a receptor- or
acid-induced conformational change, allows E2 to link both receptors or disengages it
from one so it may bind the other. We are in the process of investigating whether the
reverse of our findings, pre-binding of E2 to SR-BI, will block CD81:E2 interaction.
While direct binding of E2 to CD81 has been extensively characterized, some
basic biochemical features of this interaction are unknown. We determined the solution
oligomeric state of sE2, CD81-LEL and the sE2:CD81 complex. CD81-LEL formed a
homodimer that was engaged by 2 monomeric sE2 proteins to form a 2:2 complex. This
stoichiometric information allowed us to properly orient the two proteins in SPR
experiments that measured the kinetics and affinity of this interaction. Binding was noncooperative, and CD81-LEL and sE2 bound with an affinity comparable to that observed
for other viral envelope proteins with cellular receptors. The interaction was strengthened
mildly by low pH (5.4) and enzymatic removal of glycans from sE2, but these increases
are unlikely to be of biological relevance.
Two of our neutralizing antibodies bound HVR1 of E2, a region that plays several
roles in the HCV life cycle. Deletion of HVR1 from sE2 led to enhancement of CD81LEL binding, and this increase in affinity was genotype specific. Additionally,
neutralization of HVR1-deleted virus by our broadly cross-reactive mAb H77.39 was
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enhanced and correlated with the genotype-specific increase in affinity observed in our
SPR experiments. Taken together, these results indicate that the extent that HVR1
conceals the CD81 binding site and conserved neutralizing epitopes varies across HCV
genotypes.

6.4 Future directions: HCV receptor interaction
Kinetics and affinity of sE2 interaction with membrane bound receptors. While
our results have clarified some aspects of E2 interaction with receptors, several questions
remain. The 2:2 complex of sE2 and CD81-LEL formed in solution, but it is unclear
whether bivalent engagement of CD81 by HCV in a cellular system is necessary for
infection. Furthermore, the interaction of E2 with full-length CD81 or SR-BI in cell
membranes may not be identical to what is observed in solution. In the immediate future,
it is realistic to believe we can determine the affinity of sE2 for SR-BI and CD81
captured from cell lysates to better recapitulate the native interaction. This could be
achieved by biolayer interferometry because the technique bypasses the sensitive fluidics
of SPR instruments.
Purification of E1-E2 complexes. A major concern in studies of HCV entry is the
inability to generate a soluble E1-E2 complex with properties similar to E1-E2 in wildtype virus. Little is known about the function of E1, including its influence on E2
receptor binding. Even basic features of E1 such as its membrane topology are unclear.
Unfortunately, the oligomeric state of E1 and E2 virions is also poorly understood so
development of a functional E1-E2 complex will likely require a trial and error approach
with truncations, leucine-zippered heterodimers or linkers. Another potential strategy

169	
  

would be to purify E1 and E2 with trypsin treatment of virus grown in serum-free media
(to eliminate contaminating lipoproteins associated with particles). This approach has
been used successfully in purification of TBEV E14, but the relatively low titer of cellculture produced HCV could hamper such efforts.
Identification of individual E2 residues involved in SR-BI interaction. CHO
cells expressing SR-BI allowed us to test our anti-E2 antibodies for inhibition of E2:SRBI binding, but will also provide us with an excellent tool to identify the molecular
determinants of this interaction in future experiments. While HVR1 has been proposed to
bind SR-BI11, HVR1 peptide alone is not sufficient for E2:SR-BI binding (data not
shown). Staining of these SR-BI expressing CHO cells with mutants of sE2 known to
have null CD81 binding activity may allow us to identify residues involved in an
overlapping binding site. One ideal example is a mutant of the W420 residue only 10aa
upstream of HVR1 in primary sequence and ablates CD81 binding15. The specific SR-BI
binding determinants within HVR1 are also undefined. Our antibodies J6.36 and J6.103
each block this interaction and map to G397, F403 and G406 of E210, providing a series
of candidate residues for mutation.

6.5 Future directions: Flaviviridae and structural biology
Flavivirus structures. The structural biology of flaviviruses has been studied
extensively. Currently, there are available crystal structures of one immature E protein
bound to prM16, 5 in the pre-fusion conformation3,17–19 and 3 in the post-fusion
conformation20–22. Also, cryoEM structures and constructions have been determined for
immature viruses at neutral23,24 and acidic25 pH and mature viruses alone7,26, bound to
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antibodies27,27 and bound to the DC-SIGN attachment factor28. The final frontier in
regards to structure determination of whole flavivirus virions will most likely be the
result of advances in technology that allow for single molecule reconstruction at nearatomic resolution29. A large percentage of particles released by infected cells are partially
mature, meaning they incorporate uncleaved prM proteins30. A single-particle
reconstruction that reveals the structure a partially mature virion, or even the structure of
a single fully mature particle could resolve many unanswered questions in the realm of
flavivirus structural biology. For example, such a reconstruction may finally explain how
neutralizing antibodies recognize buried epitopes such as the fusion loop. The discovery
of a true cellular receptor that interacts with E would also generate new avenues for cocrystallization studies, but the requirement or existence of such a molecule is speculative.
Determination of HCV envelope protein structures. Many of my efforts were
directed toward the crystallization of HCV E1 and E2 but were met with little success.
While crystallization of a given protein is never guaranteed, one can provide several
arguments based on the available literature as to why no group has succeeded in
determining a structure of E1 or E2. The paradigm for envelope glycoprotein
crystallization was established by Kwong et al. and led to successful determination of the
HIV gp12031. The techniques were directed at minimizing the degrees of heterogeneity
and conformational flexibility inherent to viral fusion proteins. Deletion of variable
loops, mutation of N-linked glycosylation sites, enzymatic removal of glyans and
stabilization with Fabs are the main strategies used to accomplish this goal. While
mutation of more than a single N-linked glycosylation site on E2 was found to
dramatically reduce yield, I was able to produce HVR1-deleted sE2, enzymatically
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remove ~70% of its glycan molecular weight and complex it with Fab. Screening sE2
modified or complexed by these methods did not yield protein crystals. These methods
were popularized many years ago, and have utilized in attempts to crystallize E2 by many
groups besides our own; so it would seem there are additional complicating factors that
prevent crystallization.
One hypothesis to explain no group has successfully crystallized E2 is that sE2
may be secreted as a heterogeneous population with varying degrees of unpaired and
paired cysteines. Constructs of E2 span residues 384-660 and have been disulfide mapped
to reveal the connectivity between the cysteines of purified sE2 monomers32. However, it
has been determined that infectious HCV particles contain disulfide-linked E1 and E2
oligomers and require the presence of reduced cysteines33,34. It is also widely reported
that production of sE2 results in secretion of disulfide linked aggregates. Our own
experiments have confirmed this result and have even found that monomeric sE2 can
form disulfide-linked oligomers after extended periods of refrigeration (data not shown).
Future efforts to crystallize E2 will be more likely to succeed once an appropriately
folded conformation of E2 or an E1-E2 complex is isolated.

6.6 The future of antiviral therapy for Flaviviridae
There are intriguing economical and philosophical questions regarding the utility
of antiviral therapies that target specific Flaviviridae proteins. The existence of approved
vaccines for YFV and JEV35 is likely to limit efforts by pharmaceutical companies to
focus efforts on these viruses. Few other arthropod-borne flaviviruses represent global
health threats except for DV, which infects ~50 million people annually36. As there are no
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approved vaccines or specific treatments for DV infection, it is one of the only
flaviviruses likely to be a target for design of specific antivirals.
Hepatitis C chronically infects roughly 170 million people, however the number
of annual incidences has declined by ~90% since 1990 due to screening of donated blood
and organs. The decline in new infections, ~50% success rate of existing therapies and
delayed onset of symptoms make HCV a unique case for pharmaceutical development.
Essentially, there exists a massive population of infected individuals but minimal spread
of the virus, prompting the urgent need for treatments that augment the effectiveness of
the current regimen. If infected individuals may be cured before the onset of damaging
symptoms, a massive public health crisis could be averted. Vaccination against DV and
HCV has been unsuccessful, possibly due to antibody-dependent enhancement linked to
heterologous DV infection37 and extensive genetic variability of HCV38, so future
development of antiviral compounds or therapeutic antibodies remains a priority.
Several recent discoveries, however, may lead to the effective control of
Flaviviridae. Antibodies or compounds that target host receptors and broad-spectrum
antiviral compounds are two promising strategies. Preventing interaction with required
host factors is advantageous in that it circumvents the issue of viral diversity. Extensive
characterization of HCV cellular receptors has provided several potential candidates for
such an approach. Indeed, antibodies that bind CD8139, SR-BI40 and CLN141 and a
compound that targets SR-BI42 each are able to inhibit HCV infection of hepatocytes.
Furthermore, Plasmodium falciparum utilizes both CD81 and SR-BI for invasion of
hepatocytes43,44, suggesting molecules that target this entry pathway may be broadly
applicable. While no required receptor for members of the flavivirus genus has been
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identified, the successful inhibition of HCV infection by these methods should encourage
future searches.
Several broad-spectrum antiviral compounds that neutralize enveloped viruses
have also been identified. One example of such an agent, LJ001, inhibits infection of
cells by flaviviruses, paramyxoviruses and filoviruses amongst others and is believed to
function by binding viral membranes to disrupt fusion45. Another molecule, squalamine,
inhibits DV2 and Hepatitis B Virus infection in vitro and YFV and MCMV in vivo by
neutralizing the negative charge of host membranes in a manner that is believed to inhibit
viral replication46. An especially promising drug, T-705 (Farapirivir) protects mice from
lethal infection with influenza A viruses and is currently in phase II clinical trials47.
The failure to develop several vaccines for many important human viruses
illuminates the need for detailed understanding of the structure and entry of Flaviviridae.
Extensive characterization of these processes has led to the discovery of many new viral
and cellular proteins amenable to targeting by antibodies or pharmacological agents.
Therapies that use a multi-pronged approach to boost the immune response, disrupt
receptor interactions and directly target viral components are foreseeable in the near
future and may help to eradicate these difficult to treat pathogens.
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Appendix 1:
Neutralizing Monoclonal Antibodies against Hepatitis C Virus
E2 Protein Bind Discontinuous Epitopes and Inhibit Infection
at a Post-Attachment Step

The research within this appendix consists of data that are published in the Journal of
Virology.
Sabo, MS, Luca, VC, Prentoe, J, Blight, KJ, Lemon, S, Ball, JK, Bukh, J, Evans, M,
Fremont, DH, Diamond, MS. 2011. Neutralizing Monoclonal Antibodies against
Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a PostAttachment Step.
My personal contributions to this manuscript were: i) Cloning, purification and
expression of soluble E2 ii) Design, cloning and expression of genotype yeast displayed
E2 from genotype 1-6 and C-terminal E2 truncations iii) Preliminary staining of yeast
displayed E2 C-terminal truncations and genotypes 3-6 with the panel of hybridoma
supernatants. Writing of the manuscript and the majority of experiments were carried out
by Michelle Sabo.
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A1.1 Abstract
The E2 glycoprotein of hepatitis C virus (HCV) mediates viral attachment and
entry into target hepatocytes and elicits neutralizing antibodies in infected patients. To
characterize the structural and functional basis of HCV neutralization, we generated a
novel panel of 78 monoclonal antibodies (MAbs) against E2 proteins from genotypes 1a
and 2a HCV strains. Using high-throughput focus-forming reduction or luciferase-based
neutralization assays with chimeric infectious HCV containing structural proteins from
both genotypes, we defined eight MAbs that significantly inhibited infection of the
homologous HCV strain in cell culture. Three of these bound E2 proteins from strains
representative of HCV genotypes 1-6, and one MAb, H77.39, neutralized infection of
strains from five of these genotypes. The two most potent neutralizing MAbs in our
panel, H77.39 and J6.36, inhibited infection at an early post-attachment step. Receptor
binding studies demonstrated that H77.39 inhibited binding of soluble E2 protein to both
CD81 and SR-B1, whereas J6.36 blocked attachment to SR-B1 and modestly reduced
binding to CD81. Using yeast surface display, we localized epitopes for the neutralizing
MAbs on E2. One of the strongly inhibitory MAbs, J6.36, showed markedly reduced
binding when amino acids within the first hypervariable region (HVR1) and at a site
~200 residues away were changed, suggesting binding to a discontinuous epitope.
Collectively, these studies help to define the structural and functional complexity of
antibodies against HCV E2 protein with neutralizing potential.
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A1.3 Introduction
Hepatitis C virus (HCV) is a blood-borne, hepatotropic virus that infects ~170
million people worldwide. Approximately 70% of infected individuals progress to
chronic liver disease, which carries an increased risk of cirrhosis and hepatocellular
carcinoma1. In general, treatment of chronic HCV is complicated by resistance due to
extensive genetic diversity. HCV has been classified into seven major genotypes, which
differ by ~30% at the nucleotide level2, and this positive-sense, single-stranded RNA
virus has a capacity for rapid evolution of variant viruses during persistent infection. The
current treatment, pegylated IFN-a2a and ribavirin, has variable side effects and response
rates depending on the virus and host genotype3. No vaccine is currently available, and
pre-clinical development has been hampered by a lack of understanding of which
conserved epitopes on the HCV structural proteins should be targeted.
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HCV contains a ~9.6kb RNA genome that is translated as a single polyprotein and
then cleaved by viral and host proteases into structural proteins (core, E1, E2), p7, and
nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B)4. Viral attachment
and entry is mediated by the envelope glycoproteins, E1 and E2. Four attachment or entry
receptors that are required for infection of hepatocytes have been identified including
CD815, scavenger-receptor B1 (SR-B1)6, and the tight junction proteins claudin-1
(CLDN1)7, and occludin (OCLN)8. The importance of E2 binding to the large
extracellular loop of CD81 has been established in vitro5,9–12, and interactions between E2
hypervariable region 1 (HVR1) and SR-B1 have been reported6,13,14. The structural basis
of binding of E2 to its cognate cell attachment factors, however, is poorly understood, in
part because high-resolution structures of the HCV glycoproteins or intact virion have not
been solved.
The role of the humoral immune response in controlling HCV infection in patients
remains controversial, as patients with persistent infection develop high-titer antibodies
that do not appear to clear infection1. Nonetheless, there are emerging data that classes of
monoclonal and polyclonal antibodies against HCV have protective activity. Binding to
CD81 by soluble forms of E2 (sE2, truncated proximal to the transmembrane domain) is
inhibited by antibodies that also neutralize infection of pseudotyped HCV particles
(HCVpp) derived from the structural proteins of multiple genotypes15,16. Perhaps more
convincing, experiments in chimpanzees and chimeric mice have shown that passive
transfer of anti-E2 antibodies protects against infection17–19, and immunization with E1E2 virus-like particles and E2 glycoprotein in chimpanzees induces protective
antibodies18,20,21. Moreover, in a comprehensive study of neutralizing MAbs derived from

184	
  

infected patients, MAbs that bound regions comprised of amino acid residues 396–424,
436–447 and 523–540 on E2 neutralized HCVpp derived from multiple genotypes18.
Thus, anti-E2 antibodies apparently can restrict HCV infection, although the exact steps
(attachment, entry, or fusion) in the viral entry process that are inhibited and the
corresponding E2 binding epitopes have not been elucidated.
To gain more insight into the molecular and structural basis of anti-E2 antibody
neutralization of HCV infection, we generated a panel of 78 mouse monoclonal
antibodies (MAbs) against soluble, recombinant E2 proteins derived from genotypes 1a
(H77 strain) and 2a (J6 strain) HCV strains. These MAbs were analyzed for inhibitory
activity against infectious HCV in cell culture and assessed for mechanism of action with
respect to inhibition of ligand binding on the cell surface. By combining this functional
analysis with a high-throughput yeast surface display mapping strategy, we identified
neutralizing MAbs that bound to distinct regions of E2, including MAbs that recognized
determinants with discontinuous epitopes with primary sequences greater than 150 amino
acids apart. These experiments suggest that neutralizing MAbs blocking distinct stages of
the HCV cell entry process recognize discontinuous epitopes on the E2 protein.

A1.4 Results
MAb generation. Previous studies have demonstrated that HCV-specific
monoclonal and polyclonal antibodies, particularly those that recognize the E2 protein,
can control HCV infection in vitro and in vivo17,18,20,37–39. However, only a few of these
antibodies have been characterized for their ability to inhibit at different stages of HCV
infection or mapped to epitopes at the amino acid level. To better define the structural
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basis of antibody neutralization of HCV, we generated a new panel of anti-HCV MAbs
by immunizing BALB/c mice with soluble, recombinant E2 protein that was expressed in
insect cells and derived from either genotype 1a (H77 strain, amino acids 384-664) or
genotype 2a (J6 strain, amino acids 385-664) viruses. After five independent splenocytemyeloma cell fusions, we subcloned 37 MAbs from genotype 1a-immunized mice and 41
MAbs from genotype 2a-immunized mice, all with reactivity against the E2 structural
glycoprotein of HCV.
Neutralizing activity of anti-E2 MAbs. To study the inhibitory capacity of
genotype 1a MAbs in cell culture, we utilized an H77-JFH1 chimeric infectious virus that
contains genotype 1a core-NS2 sequence in the JFH1 background, with a compensatory
Q221L mutation in NS3 (pHJ3-5)23,24. For high-throughput screening, we adapted a
focus-forming unit (FFU) assay with Huh-7.5 cells such that infectious foci were scored
objectively on an ELISPOT reader and the reduction in number of FFU was assessed
after pre-incubation of virus with individual MAbs (Fig 1A). We performed a single
endpoint focus reduction neutralization test (FRNT) using neat antibody supernatant (~10
mg/ml) and identified 13 MAbs that inhibited infection by 40% or greater (Fig 1B).
Candidate neutralizing MAbs were purified by immunoaffinity chromatography and
tested for inhibitory activity with a more complete dose-response curve (Fig 1C). We
confirmed that five MAbs (H77.16, H77.28, H77.31, H77.39 and H77.56) had
reproducible neutralizing activity, and determined the concentration of MAb at which
50% of foci were inhibited (EC50 value) (Fig 1C). Of these MAbs, H77.16 and H77.39
showed the greatest inhibitory activity, with EC50 values of ~3.4 µg/ml and ~1.1 µg/ml,
respectively.
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To evaluate the neutralizing activity of MAbs generated against E2 derived from
the genotype 2a HCV strain, we utilized a genotype 2a J6/JFH1/JC1 infectious chimera
of HCV that contains a Renilla-luciferase reporter gene inserted immediately upstream of
NS2A cleavage site22. All 41 MAbs that bound the genotype 2a E2 protein were purified
and assessed for inhibitory activity over a broad range of concentrations to determine the
concentration of antibody that reduced luciferase expression by 50% (EC50 value) (data
not shown). We identified two antibodies, J6.36 and J6.103 that efficiently neutralized
infection, (Fig 1D) with J6.36 having an EC50 value below 2 mg/ml. Notably, no
significant difference in inhibitory potency of a given neutralizing MAb was observed
when the luciferase and FRNT assays were directly compared (data not shown).
Cross-reactivity of anti-E2 MAbs. HCV is comprised of six epidemiological
important genotypes with ~70% nucleotide identity2. A better understanding of the
specific epitopes that are conserved and recognized by inhibitory antibodies may
facilitate the design of future vaccines. To begin to address this, we assessed how
genotype variation affected MAb reactivity using recombinant E2 proteins displayed on
yeast (1a, H77; 2a, J6; 3a, UKN3a; 4a, UKN4a; 5a, SA13; and 6a, UKN6) and
neutralization capacity with chimeric HCV strains (1a, H77; 2a, J6; 3a, S52; 4a, ED43;
5a, SA13; and 6a, HK6a) containing the non-structural proteins (NS3-NS5B) of the
genotype 2a JFH1 strain and structural proteins, p7, and NS2 from strains representative
of HCV genotypes 1-6.
(a) Binding to different HCV genotypes. The ectodomain of E2 from individual
strains corresponding to HCV genotypes 1-6 was expressed on the surface of yeast,
incubated with MAbs, and analyzed for binding by flow cytometry. Four of the eight
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neutralizing MAbs were broadly cross-reactive and recognized all five (H77.16, H77.36,
and H77.39) or four of the five (H77.56) heterologous genotypes (Fig 2 and Table 1).
Three of the neutralizing MAbs (H77.31, J6.36, and J6.103) bound to yeast expressing
only the homologous E2.
(b) Cross-neutralizing potential of MAbs. As MAb binding capacity to
recombinant viral structural proteins does not always directly correlate with neutralizing
potential40, we evaluated the inhibitory activity of several of the cross-reactive MAbs
against HCV virus of other genotypes. Initially, single endpoint focus reduction assays
were performed with high concentrations (50 mg/ml) of purified MAbs generated against
genotype 1a or genotype 2a that cross-reacted with genotype 2a or genotype 1a E2,
respectively (Fig 3A and 3B). Of the cross-reactive MAbs generated against genotype 1a
E2, only H77.39 neutralized the genotype 2a virus. Of the cross-reactive MAbs generated
against genotype 2a E2, only J6.27 inhibited genotype 1a HCV infection (Fig 3B and
3C). This was surprising because J6.27 lacked neutralizing activity against the genotype
2a strain against which it was generated (Fig 3C); this pattern of enhanced neutralizing
activity of cross-reactive antibodies against the heterologous virus also has been observed
with MAbs against distantly related flaviviruses41,42. H77.39 inhibited the genotype 2a
virus with an EC50 value of ~5 mg/ml (Fig 3D), which was comparable to that observed
with the genotype 1a virus (see Fig 1C). We subsequently tested whether H77.39
neutralized infection of a panel of chimeric viruses that expressed structural proteins from
the remaining heterologous HCV genotypes. H77.39 dose-dependently inhibited HCV
infection of genotypes 3a, 4a, and 5a but showed reduced activity against a virus
containing structural proteins of genotype 6a (Fig 3E).
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Mechanism of MAb neutralization. Antibody neutralization may involve
different stages of viral infection including attachment, internalization, or fusion43. To
begin to understand how our inhibitory MAbs blocked infection, we performed pre- and
post-attachment neutralization assays and binding studies to the CD81 and SR-B1
receptors.
(a) Pre- and post-attachment assays. To identify the stage of infection at which
MAbs neutralize infection, we adapted a pre- and post-attachment inhibition assay
originally developed for flaviviruses44–46. Purified anti-E2 MAb was incubated with virus
before or after attachment at 4°C to Huh-7.5 cells, and infection was measured by a
single endpoint focus reduction assay. Of the nine neutralizing MAbs tested, two
(H77.39, and J6.36) significantly reduced infection compared to the negative control
MAb (WNV E16) when added after viral absorption to a cell monolayer, suggesting
blockade of a post-attachment step (Fig 4A-D). Interestingly, both anti-CD81 and antiSR-B1 MAbs also inhibited infection after viral adsorption, confirming previous results
in Huh-7.5 cells which suggested that HCV binds to CD81 and SR-B1 after initial
attachment47,48. Inhibition of infection at a post-attachment step by H77.39 was
confirmed by performing more complete dose-response curve analysis (Fig 4E).
(b) MAb inhibition of sE2 binding to receptors. Given that anti-CD81, anti-SRB1, and several anti-E2 MAbs all blocked after HCV attached to Huh-7.5 cells, it was
difficult to discern whether some antibodies blocked binding to individual HCV
receptors. To address this, we developed a binding assay for soluble E2 (sE2) to CHO
cells that ectopically expressed human CD81 or SR-B1. CHO cells were transduced with
a lentiviral vector encoding CD81 or SR-B1 fused to GFP. Surface staining of intact cells
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with anti-CD81 and anti-SR-B1 MAbs confirmed high-level receptor expression (Fig
5A), as did analysis of cells for GFP fluorescence (data not shown). Binding of genotype
1a (Fig 5B) and genotype 2a (Fig 5C) sE2 to CD81 and SR-B1 expressing CHO cells
(solid histograms), but not control CHO cells (outlined histograms) was confirmed by
flow cytometry. To determine whether sE2-CD81/SR-B1 receptor interactions could be
disrupted by anti-E2 MAbs, neutralizing or control (anti-WNV E16) MAbs were preincubated with sE2, added to wells containing CHO cells expressing CD81 or SR-B1,
and loss of binding was assessed by flow cytometry (Fig 5D). The neutralizing MAb
H77.39 significantly blocked (>70%, P < 0.01) sE2 binding to both CD81 and SR-B1. In
comparison, H77.31 also reduced binding of sE2 to both receptors, although inhibition of
SR-B1 binding was more modest (~40%, P = 0.04) compared to that seen with CD81
(>80%, P = 0.003). Conversely, J6.36 efficiently inhibited sE2-SR-B1 binding (>80%, P
= 0.0002) yet only modestly (~50%, P < 0.05) diminished sE2-CD81 binding. H77.16
and J6.103 blocked sE2 binding to only a single receptor, with both efficiently reducing
(>75%, P = 0.0005) binding to SR-B1 (Fig 5D). Three neutralizing MAbs, H77.28,
H77.56, and J6.27, did not inhibit significantly sE2 attachment to either CD81 or SR-B1,
suggesting that these may block an alternate attachment or entry step (Fig 5E).
Epitope localization of MAbs. To correlate the function of the anti-E2 MAbs with
structure of the HCV E2 protein, we localized their epitopes using a previously validated
yeast surface display mapping assay31,41,45. Initially, COOH-terminal truncated versions
of E2, based on those described previously34, were displayed on the surface of yeast and
MAbs were tested for immunoreactivity by flow cytometry (Fig 6 and Table S1).
Neutralizing MAbs showed different requirements for binding. H77.16, H77.39, J6.36,
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and J6.103 bound to a region bracketed by amino acids 384-520 of genotype 1a and 384518 of genotype 2a E2 (designated “region I”), whereas H77.28, H77.31, and J6.27
required amino acids 521-605 of genotype 1a or 519-603 of genotype 2a E2 (designated
“region II”) for binding. In contrast, MAb H77.56 required the full E2 ectodomain (1664), suggesting that it interacts with amino acids 606-664 alone or requires a
conformation of E2 that this region stabilizes. MAbs that neutralized efficiently at a postattachment step, H77.39 and J6.36, both bound to region I of E2.
To localize MAb epitopes more clearly, we used error-prone PCR mutagenesis
and yeast surface display to create a library of H77 and J6 E2 variants to define
individual amino acid binding residues of neutralizing and non-neutralizing MAbs. Yeast
that lost expression of individual MAb epitopes were sorted by flow cytometry and
plasmids were recovered, sequenced, and tested for reactivity against a select panel of
MAbs (Fig 7 and Tables 2 and 3).
H77.39, the most potent and highly cross-neutralizing MAb, showed markedly
reduced binding when residues N415 and N417 of E2 were changed (Fig 7A and Table
2). Two neutralizing MAbs (J6.36, and J6.103) required a pair of mutations for
significant loss of binding. J6.36 and J6.103 lost binding with changes in HVR1 and a
more distal region of E2; mutation of residues G406, F403, or a combined mutation at
residues G397 and R572 abrogated MAb binding. Single mutations of G397 and R572,
however, did not affect binding (Fig 7B and Table 3). Similarly, H77.16 showed weakly
reduced binding when a serine was introduced at residue G406 (Fig 7A), but complete
loss of binding when residue G530 was altered in combination with G406S. However,
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complete loss of H77.16 binding also was observed when residue G406 was mutated to
an aspartic acid residue.
The neutralizing MAbs that were quantitatively weaker in our neutralization
assays, H77.31 and J6.27, showed decreased binding when residues in the putative CD81
binding region (amino acids 523-53549) were changed. H77.31 binding to E2 on yeast
was lost when residues W529, G530, and D533 were mutated, whereas J6.27 binding was
abolished when amino acids A524 and W529 were altered. The remaining two weakly
neutralizing MAbs (H77.28 and H77.56) showed reduced binding with changes at
residues R543 and C552, respectively (Fig 7A and Tables 2 and 3).
Some non-neutralizing MAbs also were mapped. Several non-neutralizing MAbs
(H77.27, H77.36, J6.2, J6.6, J6.15, J6.39, and J6.85) shared residues that impacted
binding of H77.31 or J6.27 (Tables 2 and 3), and a few (J6.2, J6.6, J6.40, and J6.101)
had total or partial loss of binding to residue G406, which was identified as an important
recognition residue for the neutralizing MAbs H77.16, J6.36 and J6.103. In addition to
G406, J6.2, J6.40 and J6.101 recognition was also affected by mutation of residue H617,
thus defining another discontinuous epitope, albeit one that is not apparently involved in
neutralization (Fig 7 and Tables 2 and 3). Additional residues that uniquely affected
binding by non-neutralizing MAbs included G470 (H77.14 and H77.23), Y443 (J6.60),
and H617 (J6.30).
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A1.5 Discussion
In this study, we generated a novel panel of 78 MAbs against the E2 proteins of
HCV genotypes 1a and 2a, analyzed them functionally for inhibition of HCV infection,
and localized epitopes using yeast surface display of truncated and substituted forms of
the E2 protein. We defined MAbs that mapped to distinct regions of E2, neutralized
infection at different stages, and differentially affected CD81 and SR-B1 engagement.
Our mapping data also suggests a tertiary interaction between the HVR1 and the COOHterminal membrane proximal regions of E2, which provides new insight into the
quaternary structural aspects of neutralization by functionally relevant antibodies.
Prior mapping studies of anti-E2 MAbs have utilized peptide binding10,50, phage
display51, alanine scanning mutagenesis of recombinant E1-E2

18,37,39,52

or E253, or

generation of neutralization escape mutants54 to localize antibody binding sites. In
comparison, we used a forward genetic mutational approach coupled with yeast surface
display to identify mutants in the context of the entire ectodomain of E2 protein in an
unbiased manner. Three of our nine neutralizing MAbs required amino acid mutations
greater than 100 amino acids apart in the linear sequence for loss of binding, suggesting
that discontinuous regions of E2 come together to create functionally important antibody
epitopes. H77.16 showed a loss-of-binding phenotype when mutations in the HVR1
(G406S) and the more COOH-terminal residue (G530A) were paired, suggesting that
H77.16 binds a conformational epitope. Although complete loss of binding could be
achieved with a single less conserved mutation (G406D), the more conserved G406S
change required a second mutation at a discontinuous site (G530) for loss-of-binding.
This finding, which suggests that the HVR1 interacts with more COOH-terminal
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residues, is consistent with MAb competition studies with recombinant proteins that
suggested that amino acids 396-424, 436-447, and 523-540 comprise an antigenic region
(designated “antigenic region-3”) within E218, and with sequencing results of MAb AP33
escape variants, which identified non-contiguous amino acid residues (N415 and E655)
as factors in the loss of neutralization phenotype54. Additionally, these data support the
recently described model of HCV E2 based on the three domain structure of class II E
proteins in Flaviviridae and Togaviridae, which predicts that the HVR1 proximally
apposes the proposed HCV Domain I (D1)55 (Fig 8B).
Two other neutralizing MAbs, H77.31 and J6.27, also recognized residues within the
third segment of antigenic region-3 (A524, W529, G530 and D533) but did not show a
loss-of-binding phenotype when amino acids within segment 1 (396-424) were changed.
These two MAbs less potently neutralized infection and were less cross-reactive. In
comparison, human anti-HCV MAbs (A8, 1:7, and CBH5) that share epitopes in this
region37,56 have been characterized as inhibitory and cross-reactive (Table 4). Although
further analysis is required, the differences in function of the mouse and human MAbs
could be related to affinity or possibly, that the human MAbs bind additional sites and do
not exclusively recognize the linear epitope centered at residues G523-D535, as was
suggested in previous studies15,56.
The neutralizing MAbs J6.36 and J6.103 also mapped to a discontinuous epitope,
requiring residues within the HVR1 (G397, F403, and G406) and the more COOHterminal residue R572. Although neutralizing MAbs (9/2710,57 and AP21351) have been
mapped to the HVR1, to our knowledge, MAbs that bind residues at or near R572 have
not been identified. The MAb 9/27 does not block binding of sE2 to CD8110,57 although it
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did inhibit HCV VLPs interaction with CD8116, suggesting that it also may recognize a
conformational or possibly oligomeric epitope.
The MAb in our study with the greatest inhibitory activity, H77.39, localized to two
amino acids, N415 and N417, that are highly conserved among all HCV genotypes58,59.
N415 and N417 were defined previously as possible binding residues for MAbs AP33
and 3/1139,54,58 (Table 4). Residue N417 comprises part of a highly conserved N-linked
glycosylation site60,61 that is implicated in obscuring antibody-mediated neutralization59.
H77.39, as well as AP33 and 3/11, are thus unique in mapping to an N-linked glycan that
is paradoxically hypothesized to impair antibody recognition.
To relate binding epitopes to function, MAbs were tested for their ability to inhibit
sE2 engagement with the HCV cognate receptors CD81 and SR-B1. The MAbs J6.36,
J6.103, and H77.16, which recognized residues within the HVR1 as well as the more
COOH-terminal region, blocked sE2-SR-B1 binding6,13,14. These results are consistent
with data suggesting the HVR1 participates in SR-B1 binding, and that the HVR1specific MAb 9/27 inhibits sE2-SR-B1 interactions6,14. Although J6.36 did not map to
any of the predicted CD81 binding residues49, it partially inhibited binding to CD81.
J6.36 could map to additional amino acid residues (within the CD81 binding site) not
identified in our study or steric hindrance could mediate this partial inhibition. In the
recently modeled E2 structure55, the J6.36 interaction residues lie in proximity to the
HCV D1, which is predicted to contain key CD81 binding residues49,55 (Fig 8B).
Conversely, H77.31, which potently inhibited CD81 binding and maps to residues
(W529, G530) involved in CD81 binding49 partially inhibited SR-B1 engagement despite
a lack of contact residues in the HVR1. The inability of J6.103 to inhibit binding to CD81

195	
  

despite localizing to the same residues as J6.36 could be explained by overlapping but not
identical MAb footprints or perhaps differences in affinity of interaction.
Only one MAb, H77.39, potently inhibited sE2 binding to both CD81 and SR-B1.
Interestingly, H77.39 did not map to residues within known SR-B1 or CD81 binding
regions, suggesting that it may recognize a site that once occupied, can sterically prevent
receptor engagement. This concept is supported by studies showing that N415 and N417
can obscure the CD81 and SR-B1 binding sites58,59. Finally, the E2 model recently
proposed by Krey et al predicts that residues N415-N417 lie at the junction of the HVR1
and D1 (Fig 8B), in proximity to both HVR1 and the CD81 binding residues located
within C and D loops of D149,55.
Pre- and post-attachment neutralization studies provided additional insight into
the relative potency of MAbs. Studies with distantly related Flaviviruses have shown that
MAbs inhibiting at a post-attachment step tend to have greater inhibitory activity in vitro
and in vivo because they require reduced virion occupancy for neutralization31,45,46,62,63.
Indeed, our two most potent MAbs, H77.39 and J6.36, neutralized infection in the postattachment assay. Nevertheless, J6.103 shared apparent binding epitopes with J6.36, yet
did not neutralize efficiently when added after attachment. This discrepancy may be
explained by J6.36 having additional amino acid contacts not identified in our study.
MAb binding to conserved residues may not directly predict cross-binding or
cross-neutralizing capabilities36,40. Despite mapping to highly conserved residues, MAbs
H77.31, J.36 and J6.103 failed to cross-react with any other strains tested, and J6.27 was
cross-reactive with only two of the strains tested. In comparison, MAb H77.16 was
highly cross-reactive, but still did not neutralize heterologous strains. In contrast, H77.39
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cross-reacted with genotypes 1-6 and neutralized chimeric virus representative of all
strains except genotype 6. The inability of H77.39 to neutralize the genotype 6 chimeric
virus may be explained by the presence of a mutation in one of the recognition residues,
N417T64. This mutation is rare in natural HCV isolates49,58, but was required for
adaptation of the HK6a/JFH1 chimera in vitro64. Mutations at N415 are rare49,58 and
attenuating in the context of HCV infection54.
Generation of an HCV vaccine has been impeded by the lack of a structural
understanding of the epitopes on E2 that should be targeted by inhibitory antibodies.
Although direct structural confirmation is necessary, our data suggests the existence of
discontinuous epitopes that are recognized by antibodies that inhibit CD81 and SR-B1
binding. The yeast surface display antibody mapping data also provides support for a
recently proposed structural model of E2 in which the residues comprising the CD81
binding region lie within a single domain of b-pleated sheets that contains the HVR1 as
an N-terminal extension55. The epitopes defined by the MAbs H77.16, J6.36, and J6.103
suggest that the HVR1 might lie in proximity to this domain, creating an conformational
epitope (Fig 8B), which could be a useful target for vaccines and therapeutic antibodies.

A1.6 Materials and methods
Cells and viruses. Huh-7.5 cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Equitech), nonessential amino acids (Gibco), and antibiotics (penicillin G and streptomycin) at 37°C in
a 5% CO2 incubator. SF9 cells were cultured in Grace’s Insect cell medium (Gibco)
supplemented with 10% FBS at 28oC. HI-5 cells were cultured in Ex-cell media (Gibco)
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at 27oC. CHO cells were grown in Ham’s F12 medium (Gibco) supplemented with 10%
FBS (HyClone) at 37°C.
The genotype 2 J6/JFH1/JC1 HCV chimera that expresses luciferase22 was a
generous gift from Apath Inc. The HJ3-5 H77/JFH1 chimera, which expresses the coreNS2 segment of the genotype 1a polyprotein within a genotype 2a background has been
described23,24. The genotype 1a H77/JFH125, genotype 2a J6/JFH126, genotype 3a
S52/JFH127, genotype 4a ED43/JFH125, genotype 5a SA13/JFH128, and genotype 6a
HK6a/JFH127 infectious HCV recombinants used in cross-neutralization studies also have
been described.
To generate virus stocks from infectious cDNA clones, plasmids were linearized
and RNA transcription was performed using the T7 DNA-dependent RNA polymerase
(MEGAscript Kit, Ambion). Infectious HCV RNA (2 mg) was electroporated as
described26, and virus was harvested at 48, 72, and 96 hours, sterile filtered (0.2 mm
filter, Corning Inc), and buffered with 10mM HEPES pH 7.2 (Mediatech, Inc.). Virus
was stored at 4°C for up to 6 weeks protected from light or aliquotted at -80°C. Virus
titration on Huh-7.5 cells was performed by TCID50 assay as previously described26.
Generation of CHO cells stably expressing HCV cell entry factors. Human SRBI and CD81 genes were expressed in CHO cells via lentivirus transduction in the
context of pTRIP, a self-inactivating lentiviral provirus that expresses no HIV proteins
but instead employs an internal cytomegalovirus (CMV) promoter to express cloned
genes. An intermediate plasmid, called TRIP-GFP-linker, was generated as a backbone
into which SR-BI and CD81 were cloned (all entry factor templates were kindly provided
by C. Rice, Rockefeller University, NY). TRIP-GFP-linker was generated by amplifying
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the GFP sequence with the forward oligonucleotide 5’-CGC AAA TGG GCG GTA GGC
GTG and reverse oligonucleotide 5’-CTC GAG CTA GTC GAC TTC GAA ACT AGT
GCT AGC CCG CGG CTT GTA CAG CTC GTC CAT GCC. This PCR product was
digested with restriction enzymes BamHI and XhoI and ligated into the TRIP-GFP
plasmid digested with the same enzymes. The human SR-BI sequence was amplified with
forward oligonucleotide 5’-CCG CGG ATG GGC TGC TCC GCC AAA GCG and
reverse oligonucleotide 5’-GCT AGC CAG TTT TGC TTC CTG CAG CAC from the
previously described TRIP-hu-SR-BI plasmid8, to generate TRIP-GFP-hu-SR-BI-linker.
This PCR product was digested with SacII and NheI and ligated into similarly digested
TRIP-GFP-linker. The human CD81 sequence was amplified from an expression
construct, TRIP-GFP-hu-CD816, with forward oligonucleotide 5’-GCT AGC ATG GGA
GTG GAG GGC TGC ACC and reverse oligonucleotide 5’-ACT AGT GTA CAC GGA
GCT GTT CCG GAT. This PCR product was digested with NheI and SpeI and ligated
into similarly digested TRIP-GFP-linker, to generate TRIP-GFP-hu-CD81-linker.
Pseudoparticle production was performed as previously described

by co-

transfection of three plasmids encoding a TRIP provirus containing a transgene, HIV
Gag-Pol, and the VSV-G glycoprotein. 293-T cells were seeded at 1.8 x 106 cells/well
into a poly-L-lysine (Sigma)-coated six-well plate. Transfection was performed the next
day using a total of 1.5 mg of DNA plasmid, with 6 ml of TransIT-LT1 transfection
reagent (Mirus). Supernatants were collected 24, 48, and 72 h post-transfection, filtered
(0.45-mm pore size), and mixed with 100 ml of 1 M HEPES buffer. All transductions
were performed in the presence of 4 mg/ml Polybrene (Sigma). Receptor expression was
verified by flow cytometry using the following protocol: cells were lifted using PBS
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supplemented with 4 mM EDTA and 10% FBS, washed, and pelleted in a V-bottom
plate. Cells (105) were incubated with either 20 mg/ml of mouse anti-hu-CD81 (BD
Biosciences) or rabbit anti-hu-SR-B1 (Ab-Cam) for 30 minutes on ice, washed, and then
incubated with goat anti-mouse IgG or goat anti-rabbit IgG secondary antibody
conjugated to Alexa Fluor 647 (Molecular Probes). Cells were washed twice and receptor
expression was analyzed on a FACSArray flow cytometer (Becton-Dickinson) using
FloJo software (Tree Star).
Cloning, expression, and purification of recombinant HCV E2. The E2 protein
ectodomain of strains H77 (aa 384-661)29 or J6 (aa 385-661) was cloned into a
baculovirus expression vector (pFastBac derivative) from plasmids containing the
structural proteins of H77 (gift of M. Gale, Jr., University of Washington) or the
infectious J6/JFH1/JC122 viral genome (gift of Apath, Inc). The baculovirus expression
vector adds a honeybee melittin signal peptide at the NH2 terminus and a thrombincleavable His6 tag and stop codon at the COOH-terminus. Recombinant baculoviruses
expressing HCV E2 ectodomains were generated as described previously30, amplified in
SF9 cells, and used for large scale infection of Hi-5 cells under serum-free conditions.
Supernatant was concentrated and buffer exchanged into binding buffer (300 mM sodium
citrate, 150 mM sodium chloride, 50 mM sodium phosphate pH 8.0) using a Centramate
tangential flow concentrator. E2 was purified by sequential nickel-affinity and sizeexclusion chromatography and monodispersed fractions of monomeric protein were
collected and used for subsequent studies.
Generation, purification, and labeling of anti-HCV MAbs. MAbs were
generated by five independent splenocyte-myeloma fusions as described31. Mice were
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immunized via an intraperitoneal route with sE2 produced from either genotype 1a (H77)
or 2a (J6) HCV strains after complexing with RIBI Adjuvant System (Corixa Corp) or
complete Freund’s adjuvant (Sigma Chemical). Mice were boosted between two and five
times with homologous HCV sE2 protein complexed with either incomplete Freund’s
adjuvant (Sigma), RIBI Adjuvant System (Corixa), or Sigma Adjuvant system (Sigma),
depending on commercial availability, until adequate titers (>1:2500 by ELISA) were
achieved. Mice with the highest serum titers were boosted intravenously with purified
sE2 (50 mg) three days prior to fusion of splenocytes with P3X63Ag8.53 myeloma
cells32. Hybridomas producing anti-HCV E2 antibodies were identified after binding to
Saccharomyces cerevesiae yeast expressing sE2 on their surface by flow cytometry,
subcloned by limiting dilution, and isotyped by ELISA. For large-scale production,
MAbs were generated from ascites or adapted to growth in Hybridoma Serum Free
Media (Gibco) and purified using protein A or G affinity chromatography (Pierce). In
some experiments, MAbs were labeled with Alexa Fluor 647 (Molecular Probes) or
NHS-FITC (Pierce) MAb labeling kits according to the manufacturer’s instructions.
Virus neutralization assays. Neutralization of HCV infection by viruses
containing genotype 1a structural proteins (H77/JFH1) was assessed by a focus forming
unit (FFU) assay. Serial dilutions of HCV-specific MAb, control MAb (WNV E1631),
anti-human CD81 (clone JS81, BD Biosciences), or anti-human SR-B1 (clone 396, AbCam) were pre-incubated with 2.4 x 102 FFU of virus for one hour at 37°C. Virus-MAb
mixtures were added to Huh-7.5 cells (1.2 x 104 cells per well) in a 48-well tissue culture
plate pre-coated with poly-L lysine (Sigma). After 72 hours, cells were fixed with
methanol (0oC), and incubated sequentially with a mouse anti-NS5A (APA-1, 40 ng/ml)26
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(a generous gift of Apath, Inc.) and secondary goat anti-mouse HRP diluted 1:3000
(Sigma). FFU were visualized using the True Blue Peroxidase Reagent (KPL) and
quantitated using an S5 Biospot Macroanalyzer (Cellular Technologies Ltd). EC50 values
were determined using non-linear regression analysis (Graph Pad Prism 4).
Neutralization of the genotype 2a (J6/JFH1/JC1) HCV was assessed by luciferase
assay. Serial dilutions of HCV-specific or control MAbs were pre-incubated with the
J6/JFH1/JC1 virus that expresses luciferase (102 FFU) for one hour at 37°C and then
added to Huh-7.5 cells (104 cells per well) in a 96-well black flat bottom polystyrenetreated microplate (Corning). After 48 hours, cells were lysed and luciferase was detected
using the Renilla Luciferase Assay System (Promega) according to the manufacturer’s
instructions. EC50 values were determined using non-linear regression analysis (Graph
Pad Prism 4).
Neutralization of chimeric viruses with genotype 1a-6a specific core-NS2
sequences was assessed by FFU assay with the following modifications: 50 to 400
TCID50 of HCV were incubated 1 hour at 37°C with MAb H77.39 or an isotype control
and then incubated with cells for 3 hours. After 48 hours, cells were immunostained for
NS5A as previously described33. FFU counting was automated using ImmunoSpot Series
5 UV Analyzer27. Percent neutralization was calculated by relating FFU counts to mean
of six-replicates incubated in the absence of antibody (virus only). Neutralization data
were analyzed as variable slope dose-response curves using GraphPad Prism 4.0 and
EC50 values were interpolated by the software.
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Pre-and post virus attachment assays. To assess the ability of MAbs to inhibit
H77/JFH1 virus at pre- and post-attachment steps, FFU assays were modified as follows.
For the post-attachment assay, pre-chilled cells were incubated with 4.8 x 102 FFU of
virus for one hour at 4°C. Cells were washed thrice with cold DMEM to remove unbound
virus and MAbs (diluted to 50 mg/ml in media and pre-warmed at 37°C) were added and
the cells shifted to 37°C. After one hour, a 1:1 MEM-methylcellulose overlay with 4%
FBS was added to prevent viral spread. For the pre-attachment assay, 4.8 x 102 FFU of
virus were pre-incubated with 50 mg/ml of media for one hour at 37°C and then added to
pre-seeded Huh-7.5 cells.
To assess the ability of MAbs to inhibit J6/JFH1/JC1 at pre- and post-attachment
steps, the luciferase assay was modified in the following manner. 48-well tissue culture
plates were pre-coated with poly-L lysine (Sigma) and seeded with 1.2 x 104 cells per
well. For the post-attachment assay, 4.8 x 102 FFU of virus was added to pre-chilled
cells and “spinoculated” for 45 minutes at 400 x g at 4°C, followed by a 15 minute
incubation at 4°C. Cells were washed and pre-warmed MAbs and methylcellulose were
added as described above. For the pre-attachment assay, 4.8 x 102 FFU of virus were preincubated with 50 mg/ml of MAb for one hour at 37°C and then added to pre-seeded
Huh-7.5 cells. Cells from both the pre-and post-attachment assay were lysed after 48
hours and transferred to a 96-well black-bottom plate and luciferase was detected using
the Renilla Luciferase Assay System (Promega) according to the manufacturer’s
instructions.
Cross-reactivity and mapping analysis of MAbs using yeast surface display. To
assess MAb cross-reactivity with other HCV genotypes, the ectodomain of the E2 genes
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from genotype 1a (H77, amino acids 384 to 660), genotype 2a (J6, amino acids 385 to
664), genotype 3a (UKN 3A13.6, amino acids 385 to 667), genotype 4a (UKN 4.21.16,
amino acids 392 to 663), genotype 5a (SA13 NIH, amino acids 384 to 663) and genotype
6a (UKN 6, amino acids 385 to 668) was amplified by PCR with BamH1 and XhoI sites
for cloning added at the 5’ and 3’ ends, respectively. The PCR products were cloned as
downstream fusion proteins to the Aga2 gene in the pYD1 vector (Invitrogen) for
expression on the surface of yeast. To determine the relative binding regions on E2 of
specific MAbs, COOH-terminal truncation constructs, based on previous studies34 were
generated for genotypes 1a and 2a corresponding to regions I (amino acids 384 to 520 in
genotype 1a and 384 to 518 in genotype 2a) or I and II (amino acids 384 to 605 in
genotype 1a and 384 to 603 in genotype 2a) and displayed on the surface of yeast.
Expression constructs were transformed into Saccharomyces cerevisiae strain
EBY10035 using the S.c. EasyComp transformation Kit (Invitrogen). Individual yeast
colonies were grown to logarithmic phase at 30°C in tryptophan-free yeast selection
media containing 2% glucose. Protein expression was induced by cultivating yeast for an
additional 48 to 72 hrs in tryptophan-free media supplemented with 2% galactose at
20°C. Yeast cells were washed with PBS containing 1 mg/ml BSA (PBS/BSA) and
incubated with 40 ml of MAb (neat supernatant or 20 mg/ml purified diluted in PBS) for
30 minutes on ice. Yeast were washed in PBS/BSA, incubated with goat anti-mouse IgG
secondary antibody conjugated to Alexa Fluor 647 (Molecular Probes) for 30 minutes on
ice, washed, and analyzed on a FACSArray flow cytometer (Becton-Dickinson) using
FloJo software (Tree Star).
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Random mutant libraries of E2 were generated from genotype 1a (H77 strain) and
genotype 2a (J6 strain) genes by error-prone PCR using a GeneMorph II random
mutagenesis kit (Stratagene). Libraries were ligated into the pYD1 vector and
transformed into XL2-Blue ultracompetent cells (Stratagene) with ~5.7 x 105 and 5.5 x
105 transformants for genotypes 1a and 2a, respectively. Screening of the libraries for
loss of binding variants was performed as described31,36. In brief, yeast expressing E2
variants that lost specific binding to individual MAbs were sorted using two-color flow
cytometry. To eliminate mutations that abolished surface expression of E2, yeast were
stained sequentially with the Alexa Fluor 647-conjugated individual MAb, followed by a
FITC-conjugated oligoclonal pool of the cross-reactive MAbs J6.1, J6.2, J6.16, J6.39,
J6.51, and J6.101 for the genotype 1a library and J6.2, J6.14, J6.15, J6.39, J6.51, and
J6.99 for the genotype 2a library on ice for 30 minutes. Yeast that stained positively for
the oligoclonal pool but negatively for the MAb of interest were collected, cultivated, and
iteratively sorted. In some cases, sorting was performed using MACS LS magnetic
columns (Miltenyi Biotech). In brief, ~107 yeast cells were pelleted and resuspended in
MACS buffer (PBS + 0.5% BSA+ 2mM EDTA) containing a 1:50 dilution of a FITClabeled MAb of interest for 30 minutes, washed, and then incubated with 10 ml of antiFITC microbeads (Miltenyi Biotech) on ice for 15 minutes. Yeast were washed and
passed over a MACS LS column and the flow-through collected. After four to five
rounds, yeast were plated and individual colonies were tested for binding to individual
MAbs by flow cytometery. For clones that lost binding to the desired MAb of interest,
the plasmid was recovered using a Zymoprep yeast minipreop kit (Zymo Research),
transformed into XL1-Blue competent E. coli, purified using a QIAprep spin miniprep kit
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(Qiagen) and sequenced. In cases where more than one mutation was detected, sitespecific mutagenesis using the Quick Change II Mutagenesis kit (Stratagene) was used to
generate individual mutations within the E2 protein to define the mutant of interest. 	
  
Inhibition of CD81 and SR-B1 binding. To assess the ability of neutralizing
MAbs to inhibit binding of sE2 to CD81 and SR-B1, 50 mg/ml of purified MAb was preincubated with 20 mg/ml H77 E2 or J6 sE2 for 30 minutes at 37C. CHO cells expressing
HCV receptors were detached with PBS supplemented with 4 mM EDTA and 10% FBS,
and washed three times in medium. Cells (105) were pelleted in a V-bottom plate,
resuspended with MAb-protein mixture, and incubated on ice for 30 minutes. Cells were
washed and then incubated with a pool of Alexa Flour 647 labeled anti-E2 MAbs (J6.1,
J6.2, J6.39, J6.51, H77.30, and H77.34 for the detection of H77 E2; and J6.2, J6.39,
J6.51, J6.60, and J6.101 for the detection of J6 E2) for 20 minutes on ice. Cells were
washed twice and sE2 binding was analyzed on a FACSArray flow cytometer (BectonDickinson) using FloJo software (Tree Star).
Statistical analysis. All data was analyzed using Graphpad Prism software
(version 4.0). For neutralization assays and receptor-binding assays, an unpaired t-test
was used to determine statistical significance.

206	
  

Table 1: Binding of MAbs to HCV E2 from different HCV genotypes
MAb

Binding to genotypea:
1a(H77) 2a(J6) 3a(UKN 3) 4a(UKN4) 5a(SA13) 6a(UKN6)

J6.1

+++

+++

+++

+++

+++

+++

J6.2

+

+++

+++

+++

−

−

J6.6

+

+++

+

−

−

−

J6.7

+++

+++

+++

+

+++

+++

J6.8

+

+++

−

−

−

−

J6.9

+++

+++

−

−

+++

−

J6.12

+++

+++

+++

+++

−

−

J6.13

−

+++

−

−

−

−

J6.14

+++

+++

+++

+

+

+++

J6.15

−

+++

+++

+++

+++

+++

J6.16

+++

+++

+++

−

+++

−

J6.21

+++

+++

−

−

−

−

J6.23

+

+++

−

−

−

−

J6.25

−

+++

−

−

−

−

J6.27

+++

+++

+++

−

−

−

J6.30

+++

+++

+++

+++

+++

+++

J6.33

+++

+++

+++

+++

+++

+++

J6.34

+++

+++

+

+

+++

+

J6.36

−

+++

−

−

−

−

J6.39

+++

+++

+++

−

−

−

J6.40

−

+++

+

−

−

−

J6.42

+

+++

+++

+++

−

−

J6.48

−

+++

−

−

−

−

J6.49

−

+++

−

−

−

−

J6.51

+

+++

+

+++

−

−

J6.56

+++

+++

+++

+

+++

+++

J6.58

+++

+++

+++

+/−

+++

−

J6.60

−

+++

−

−

−

+++

J6.62

+++

+++

+++

+

+++

+

J6.67

+++

+++

+

−

+++

−

J6.68

+

+++

−

−

−

−

J6.75

+++

+++

+++

+++

+++

+++

J6.76

−

+++

−

−

−

−

J6.81

+++

+++

+++

−

+++

−

J6.85

−

+++

+++

+++

+++

+++

J6.86

+

+++

+++

+++

−

−

J6.91

+

+++

−

−

−

−

J6.98

−

+++

+

+++

−

−

J6.99

−

+++

−

−

−

+

+++

+

+++

−

+++

J6.101 +++
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MAb

Binding to genotypea:
1a(H77) 2a(J6) 3a(UKN 3) 4a(UKN4) 5a(SA13) 6a(UKN6)

J6.103 −

+++

−

−

−

−

H77.1

+++

−

−

−

−

−

H77.7

+++

+++

+++

+++

+++

+++

H77.8

+++

−

−

−

−

−

H77.9

+++

−

−

−

−

−

H77.11 +++

−

−

−

−

−

H77.12 +++

+++

−

−

+++

−

H77.13 +++

−

−

−

−

−

H77.14 +++

−

−

−

−

−

H77.16 +++

+++

+++

+++

+++

+++

H77.17 +++

−

−

−

−

−

H77.18 +++

−

−

−

+

−

H77.19 +++

−

−

−

−

−

H77.22 +++

−

−

−

−

−

H77.23 +++

−

−

−

−

−

H77.27 +++

+++

−

−

+

−

H77.28 +++

+++

−

−

+

−

H77.29 +++

+++

−

−

+

−

H77.30 +++

−

−

−

−

−

H77.31 +++

−

−

−

−

−

H77.32 +++

+

+++

−

+++

−

H77.33 +++

−

−

+++

−

−

H77.34 +++

−

−

−

−

−

H77.35 +++

−

−

−

−

−

H77.36 +++

+++

+++

+++

+++

+++

H77.37 +++

−

−

−

+++

−

H77.38 +++

−

−

−

−

−

H77.39 +++

+++

+++

+++

+++

+++

H77.42 +++

−

−

−

+

−

H77.43 +++

−

−

−

−

−

H77.44 +++

−

−

−

+++

−

H77.45 +++

−

−

−

−

−

H77.46 +++

−

−

−

+++

−

H77.47 +++

+++

−

−

−

−

H77.50 +++

−

−

−

−

−

H77.53 +++

−

−

−

+++

−

H77.55 +++

−

−

−

+++

−

H77.56 +++

+++

+++

+++

−

+++

↵a +++, strong binding (40 to 100%) to yeast expressing E2; +, weak binding (15 to
40%) to yeast expressing E2; −, no appreciable binding detected. The data are a summary
of 3 to 5 independent experiments.
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Table 2. Summary of MAb binding to genotype 1 mutants expressed on the surface
of yeast

Values shown were obtained by dividing the total fluorescence product (percent positive
population x mean fluorescence intensity) of a mutant for a given MAb by the total
fluorescence product of the wild type E2 for a given MAb. This value was then divided
by the total fluorescence product of a mutant for an oligoclonal pool of MAbs by the total
fluorescence product of WT E2 for the olicoglonal pool (to control for E2 binding) and
multiplied by 100. Values in bold indicate complete loss of binding, with reductions in
MAb binding greater than or equal to 80% for a given mutation. Underlined values show
partial loss of binding, with a reduction between 50 and 79%. The results are the average
of three independent experiments for each mutant and each antibody. Poly-protein amino
acid numbering was determined by alignment with the H77 strain using Sequence
Location tool on the Los Alamos HCV database
(http://hcv.lanl.gov/cgibin/LOCATE/locate.cgi)
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Table 3: Summary of MAb binding to genotype 2 mutants expressed on yeast

Values shown were obtained by dividing the total fluorescence product (percent positive
population x mean fluorescence intensity) of a mutant for a given MAb by the total
fluorescence product of the wild type E2 for a given MAb. This value was then divided
by the total fluorescence product of a mutant for an oligoclonal pool of MAbs by the total
fluorescence product of WT E2 for the olicoglonal pool (to control for E2 binding) and
multiplied by 100. Values in bold indicate complete loss of binding, with reductions in
MAb binding greater than or equal to 80% for a given mutation. Underlined values show
partial loss of binding, with a reduction between 50 and 79%. The results are the average
of three independent experiments for each mutant and each antibody. Poly-protein amino
acid numbering was determined by alignment with the H77 strain using Sequence
Location tool on the Los Alamos HCV database
(http://hcv.lanl.gov/cgibin/LOCATE/locate.cgi)
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Table 4: Previously characterized anti-E2 MAbs with available mapping
information
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Figure 1: Identification of neutralizing anti-E2 antibodies against HCV.
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Figure 1 legend: Identification of neutralizing anti-E2 antibodies against HCV. A.
Examples of MAb neutralization as judged by a reduction in the number of FFU using
the Biospot Macroanalyzer. Spot counts are labeled below each well and well numbers
are labeled above. Wells 1 through 8 represent decreasing (3-fold) concentrations of the
neutralizing MAb H77.39 (starting concentration of 50 mg/ml). Well 9 shows infection in
the absence of MAb, and well 10 is an uninfected well. Data are representative of three
independent experiments performed in duplicate. B. MAb supernatant was mixed with
the H77-JFH1 chimeric HCV for one 1 hour at 37°C and Huh-7.5 cells were infected.
Three days later, neutralization was determined by FFU assay. MAb supernatants that
decreased the number of FFU to 40% or less (below the solid black line) than the
negative control MAb (anti-WNV E122) were purified for testing in full dose-response
analysis. Data is pooled from three independent experiments performed in duplicate. C.
Serial dilutions of genotype 1a specific purified MAbs were mixed with H77-JFH1
chimeric virus and neutralization was assessed. Efficient neutralization was observed for
five (H77.16, H77.28, H77.31, H77.39 and H77.56) genotype 1a specific MAbs but not
for the negative control MAb (data not shown). EC50 values were calculated after nonlinear regression analysis. Data is pooled from of at least three independent experiments
performed in duplicate. D. Increasing concentrations of purified genotype 2a specific
MAbs (J6.36 and J6.103) were mixed with J6-JFH1-JC1-luciferase-expressing virus. At
48 hours, neutralization was assessed in Huh-7.5 cells by monitoring luciferase
expression. EC50 values were calculated after non-linear regression analysis. Data is
pooled from at least three independent experiments performed in duplicate. In this Figure,
all error bars represent the standard error of the mean.
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Figure 2: Identification of MAbs that bind heterologous HCV genotypes using yeast
display of E2 protein.
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Figure 2 legend: Identification of MAbs that bind heterologous HCV genotypes
using yeast display of E2 protein. The E2 ectodomain gene from six strains
corresponding to HCV genotypes 1-6 was cloned into the PYD1 vector and expressed on
the surface of yeast (see Materials and Methods). Yeast expressing HCV E2 were
incubated with MAb supernatants and binding was assessed by flow cytometry.
Representative histograms from all neutralizing MAbs (H77.16, H77.28, H77.31,
H77.39, H77.56, J6.27, J6.36 and J6.103; solid black histograms) and negative control
MAb (WNV E16; unfilled gray histograms) are depicted. Data is representative of three
independent experiments.
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Figure 3: MAb neutralization of heterologous HCV genotypes. MAbs that were
generated against (A) genotype 1a or (B) genotype 2a E2 proteins were tested for their
ability to neutralize infection of virus from the heterologous genotype. Purified J6 or H77
MAbs (50 mg/ml) were pre-incubated at 37°C with H77-JFH1 (genotype 1a) or J6-JFH1JC1 (genotype 2a) virus, respectively, and neutralization was assessed as described in
Figure 1. C-E. EC50 analysis was performed with (C) J6.27 MAb and H77-JFH1 virus
(■) or J6-JFH1-JC1 virus (○) or (D) H77.39 MAb and J6-JFH1-JC1 virus (○) or (E)
H77.39 MAb and H77/JFH1 (■), J6/JFH1(▲), S52/JFH1(▼), ED43/JFH1(♦),
SA13/JFH1(●) and HK6a/JFH1(□) chimeric viruses. Graphs represent pooled data from
at least three independent experiments performed in duplicate (A-D) or two independent
experiments performed in triplicate (E), and error bars represent the standard error of the
mean.
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Figure 4: Pre- or post-attachment neutralization.
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Figure 4 legend: Pre- or post-attachment neutralization. A-D. To determine whether
MAbs neutralize HCV infection at a post-attachment step, Huh-7.5 cells were pre-chilled
at 4°C and 480 FFU of (A) genotype 1a (H77-JFH1) or (B) genotype 2a (J6-JFH1-JC1)
virus was added to each well for 1 hour at 4°C. After three washes with 4°C DMEM,
saturating concentrations of MAbs (50 mg/ml) were added for 1 hour at 37°C and the
neutralization assay completed. In comparison, a standard pre-incubation neutralization
test was performed at 37°C, in which (C) genotype 1a virus or (D) genotype 2a virus and
MAb were pre-incubated at 37°C prior to addition to cells. Data shown are the average of
three independent experiments, with error bars representing standard error of the mean.
Statistically significant difference in neutralization are compared to infection in the
presence of a negative control MAb (WNV E16): *, p < 0.05; **, p < 0.01; and ***, p <
0.001. E-F. To confirm the ability of (E) H77.39 to neutralize infection at both pre-and
post-attachment steps, a dose response curve was performed under both pre-and postattachment conditions as described above using H77/JFH1 virus. Solid squares (■)
represent pre-attachment data and clear squares (□) represent post-attachment data.
Graphs represent pooled data from at least three independent experiments performed in
duplicate, and error bars represent the standard error of the mean.
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Figure 5: Inhibition of sE2 binding to CD81 and SR-B1 by neutralizing MAbs. A.
Verification of ectopic CD81 and SR-B1 receptor expression on CHO cells. CHO-CD81
or CHO-SR-B1 cells were incubated with either mouse anti-hCD81 or rabbit-anti-hSRB1 (black histograms) or an irrelevant MAb (unfilled gray histograms) for 30 minutes on
ice. Cells were washed, incubated with the appropriate secondary antibodies, and
processed by flow cytometry. B-C. Binding of (B) genotype 1a (H77) E2 or (C)
genotype 2a (J6) E2 to CHO-CD81 and CHO-SR-B1 but not WT CHO cells. CHO-CD81
or CHO-SR-B1 (solid black histograms) or WT CHO (unfilled gray histograms) cells
were incubated with sE2 and binding was assayed by flow cytometry. Data are
representative of at least three independent experiments. D. Assessment of inhibition of
sE2 binding to CHO-CD81 or CHO-SR-B1 cells by neutralizing MAbs. sE2 was preincubated with neutralizing MAbs, added to CHO cells, and binding detected by flow
cytometry. Examples of MAbs that inhibit sE2 binding only to CD81 (H77.31), to both
CD81 and SR-B1 (H77.39), or only to SR-B1 (J6.103), as well as a negative control
MAb (WNV E16) are shown. Histograms are representative of three individual
experiments. Solid black histograms represent sE2 binding in the presence of MAb, red
histograms represent sE2 binding in the absence of MAb, and shaded gray histograms
represent sE2 binding to CHO WT cells. E. Graphical representation of sE2 binding to
CHO-CD81 and CHO-SR-B1 cells in the presence of neutralizing MAbs. Values were
determined by dividing the fluorescence quotient (mean fluorescence intensity x percent
positive cells) for E2 binding in the presence of a neutralizing MAb by the fluorescence
quotient of sE2 binding to either CHO-CD81 or CHO-SR-B1 cells alone. Asterisks
represent statistically significant difference in sE2 binding compared to the negative
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control MAb, WNV E16: *, p < 0.05; **, p < 0.01; and ***, p < 0.001. Error bars
represent the standard error of the mean. Data are pooled from three independent
experiments.

220	
  

Figure 6: Mapping of anti-E2 antibodies
using COOH-terminal truncation mutants.
A.
Scheme of E2 truncations used for
mapping. cDNA containing region I (aa 384520 and aa 384-518 in E2 of genotypes 1a and
2a, respectively) I and II (aa 384-605 and 384603 in E2 of genotypes 1a and 2a,
respectively), and the full length ectodomain
(aa 384-664) were displayed on the surface of
yeast. B. MAb supernatants were incubated
with yeast and assessed for binding by flow
cytometry. Neutralizing MAbs binding to
regions I (H77.16, H77.39, J6.36, and J6.103),
II (H77.28, H77.31, and J6.27), and III
(H77.56) are shown. Solid black histograms
depict binding of HCV-specific MAbs and
gray, unfilled histograms represent binding of a
negative control MAb (WNV E16).
Histograms are representative of three
independent experiments.
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Figure 7: Epitope localization of anti-HCV MAbs.
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Figure 7 legend: Epitope localization of anti-HCV MAbs. Binding of neutralizing
MAbs to yeast expressing E2 protein variants. A. Flow cytometry histograms of wild
type and loss-of-binding genotype 1a E2 variants (G406D, G406S, N410Y, I411N,
N415Y, N417T, W529R, G530A, D533N, R543G, C552S, and G406S + G530A).
Representative histograms are shown for the MAbs H77.14, H77.16, H77.28, H77.31,
H77.39, H77.56 xand WNV E16 (negative control) with WT H77 E2 and each of the
variants. Data shown are representative of three independent experiments. Red arrows
indicate >80% loss-of-binding of a specific MAb for a given variant. B. Flow cytometry
histograms of wild type and loss-of-function genotype 2a E2 variants (G397E, F403L,
G406C, A524V, W529C, R572S, H621L and G397E+R572S) with individual
neutralizing MAbs. Representative histograms are shown for the MAbs J6.27, J6.36,
J6.101, J6.103 and WNV E16 (negative control) with the wild type E2 and each of the
variants. Data shown are representative of three independent experiments. Arrows
indicate >80% loss-of-binding of a specific MAb for a given variant.
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Figure 8: Localization of MAb binding residues on E2.
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Figure 8 legend: Localization of MAb binding residues on E2. A. Alignment of E2
sequences from HCV genotypes 1-6 with superimposed mapping of MAb binding
residues. The sequences of E2 from strains representative of the different genotypes
(genotype 1a, H77; genotype 2a; J6, genotype 3a, UKN 3; genotype 4a, UKN4a;
genotype 5a, SA513; genotype 6a, UKN 6) were aligned and colored boxes and symbols
were used to highlight neutralizing MAb binding residues as follows: red boxes, J6.36
and J6.103; purple boxes, H77.39; blue underscoring, H77.16; green boxes, J6.27; pink
circles, H77.31; orange box, H77.28; yellow box, H77.56. B. Putative model of structure
of the E2 protein with MAb binding regions highlighted. A scheme depicting a possible
E2 structure was adapted from Krey et al. (36) to highlight regions involved in MAb
recognition. N-linked glycosylation residues are labeled in green and amino acids
numbered in black at intervals. b-sheets in D1 are labeled as previously described (36).
MAb binding regions are highlighted by colored circles as follows: red circles, J6.36 and
J6.103; purple circle, H77.39; light blue circles, H77.16; green circle, J6.27; pink circle,
H77.31; orange circle, H77.28; yellow circle, H77.56. C. Summary of neutralizing MAbs
described in this study. EC50 values (neutralization against homologous virus), crossreactivity to E2 from different genotypes, inhibition of binding to CD81 and SR-B1,
reactivity with different regions of E2, and loss of binding residues are listed. MAb
names are color-coded to correspond to panels A and B.
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Appendix Table 1: HCV E1&E2 constructs, purification and crystallization
attempts.
Construct and
polyprotein residues
H77E2 384-660

Vector

Results and
purification
HTPbac-GFP Secreted, nickel,
SEC

H77E2 384-660 C652S

HTPbac-GFP Secreted, nickel,
SEC

J6E2 385-660

HTPbac-GFP Secreted, nickel,
SEC

ΔHVR1 H77E2 384-386,
410-660
ΔHVR1 J6E2 384-386,
410-660
ΔHVR1 J6E2-cys 384386, 410-652
H77E2 short 384-520
H77E2 med 384-605
J6E2 short 385-518
J6E2 med 385-603
H77E2 8cys 384-563
H77E2 10cys 384-580
ΔHVR1 H77E2 8cys
384-386, 410-580
ΔHVR1 H77E2 10cys
384-386, 410-563
H77E2 384-660
J6E2 8cys 384-563

HTPbac-GFP Secreted, nickel,
SEC
HTPbac-GFP Secreted, nickel,
SEC
HTPbac-GFP Secreted, nickel,
SEC
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
HTPbac-GFP Secreted, misfolded
Pet21a(+)
Pet21a(+)

Did not refold
Did not refold
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Crystallization
trials
alone
+CD81-LEL
+H77.16
+H77.34
+H77.16&H77.34
+H77.16, H77.34,
chymo
+H77.46
+H77.55
+deglyc
+deglyc, chymo
+deglyc, thrombin,
H77.55, CD81
+H77.39
+ deglyc, thrombin
H77.55, H77.39
alone
+E1frag
+E1frag, CD81LEL
+CD81-LEL
+J6.36

+deglyc,
+deglyc+J6.36
-

J6E2 10cys 384-580
J6E2 12cys 384-596
J6E2 385-660
J6E2 short 385-518
J6E2 med 385-603
J6E2 8cys 384-563
J6E2 10cys 384-580
J6E2 12cys 384-596
J6E2 cys14-16 590-655
J6E1 frag 191-262
J6E1 short 191-269
J6E1 long 191-334
Yeast constructs
H77 E2
H77 E2 region 1
H77 E2 region 2
J6 E2
J6 E2 region 1
J6 E2 region 2
J6 E1 short 191-262
UKN 3a13.6 E2 385-667
UKN 4.21.16 E2 392-663
SA13 (5a) E2 384-663
UKN 6 E2 385-668

Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
Pet21a(+)
HTPbac-GFP
HTPbac-GFP
PYD1
PYD1
PYD1
PYD1
PYD1
PYD1
PYD1
PYD1
PYD1
PYD1
PYD1

Did not refold
Did not refold
Did not refold
Did not refold
Did not refold
Did not refold
Did not refold
Did not refold
Did not refold
Refolded, disordered
Secreted, misfolded
Not secreted

-

Displayed
Displayed
Displayed
Displayed
Displayed
Displayed
Displayed
Displayed
Displayed
Displayed
Displayed

-

If a crystallization attempt is listed, this indicates the automated or manual setup of at
least 192 sparse matrix conditions.
Legend:
+ thrombin: sE2 was incubated with 50U/mg thrombin overnight at 4 degrees
+ chmyo: 0.1% w/w chymotrypsin was added to the stock prior to screening
+ CD81-LEL: equimolar CD81-LEL was added to the stock prior to screening
+ E1 frag: equilmolar refolded E1 192-262 peptide was added to the stock
+ deglyc: E2 was pre-treated with Endo F1, Endo F3 and PngaseF as described in 4.6.3
+ H77.XX or +J6.XX: E2 was complexed with sE2 prior to screening
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